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ABSTRACT 
 
 
Introduction: The brain-gut axis may influence disease outcomes in inflammatory 
bowel disease (IBD). Evidence supporting brain-gut axis activity would highlight a 
need for novel management strategies targeting this pathophysiological mechanism in 
IBD. The aim of this thesis was to examine these issues directly. 
 
Methods: In simultaneous cross-sectional studies, the relationship between symptom-
reporting, psychological co-morbidity, and disease activity, and the prevalence of 
irritable bowel syndrome (IBS)-type symptoms, as well as their association with 
impaired mood and quality of life, was assessed. In longitudinal follow-up, the temporal 
relationship between disease activity and psychological co-morbidity was examined to 
assess for the presence of brain-gut axis activity. The relationship between the reporting 
of IBS-type symptoms and the natural history of IBD was also assessed. A systematic 
review and meta-analysis of randomised controlled trials was conducted to investigate 
the efficacy of psychological therapies in IBD. 
 
Results: The correlation between symptom-reporting and mucosal inflammation was 
poor. Symptom-reporting, but not mucosal inflammation, was associated with 
psychological co-morbidity. Baseline disease activity was associated with new-onset 
anxiety (odds ratio = 5.17; 95% confidence interval (CI) 1.35-19.8), and baseline 
anxiety was associated with new-onset disease flare (hazard ratio = 2.08; 95% CI 1.31-
3.30), suggesting possible bi-directional brain-gut axis activity in IBD. IBS-type 
symptom-reporting was associated with psychological co-morbidity and poor quality of 
life, but reporting these symptoms was not associated with adverse longitudinal disease 
9 
 
 
 
activity outcomes. Psychological therapies were associated with short-term beneficial 
effects on depression and quality of life, but had no effect on disease activity.  
 
Conclusions: Bi-directional brain-gut axis activity may influence the natural history of 
disease activity, and psychological wellbeing, in IBD. Patients reporting IBS-type 
symptoms exhibit psychological co-morbidity and reduced quality of life. Evidence 
supporting the use of psychological therapies in IBD is poor, but trials of these 
treatments in patients at risk of mood disorders may still prove beneficial. 
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FGID  functional gastrointestinal disorder 
FODMAP fermentable oligosaccharides, disaccharides, monosaccharides, and 
polyols 
FMT  faecal microbiota transplantation 
GI  gastrointestinal 
GWAS genome wide association study 
HADS  hospital anxiety and depression scale 
HBI  Harvey-Bradshaw index 
HR  hazard ratio 
IBD  inflammatory bowel disease 
IBS  irritable bowel syndrome 
IL  interleukin 
LPS  lipopolysaccharide 
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IQR  interquartile range 
mRNA  messenger ribonucleic acid 
NOD  nucleotide-binding oligomerisation domain-containing protein 
NF-κB  nuclear factor kappa B 
OR  odds ratio 
PHQ  patient health questionnaire 
PROM  patient-reported outcome measure 
RNA  ribonucleic acid 
RR  relative risk 
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SF-36  short-form 36 
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SMD  standardised mean difference 
TGF-β  transforming growth factor beta 
Th  T helper cell 
TNFα  tumour necrosis factor alpha 
UC  ulcerative colitis 
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CHAPTER 1: Introduction 
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This chapter provides an overview of the medical history, epidemiology, 
pathophysiology, natural history, and conventional management of inflammatory bowel 
disease (IBD). A description of the current understanding of the relationship between 
gastrointestinal (GI) symptom-reporting, psychological co-morbidity, quality of life, 
and inflammatory activity in IBD, as well as a review of the current evidence base for 
alternative management strategies targeting mood disorders and irritable bowel 
syndrome (IBS)-type symptom-reporting in IBD will then be discussed. Deficits in the 
current understanding in these areas will be highlighted, which in turn will provide the 
rationale for conducting the work described within the latter chapters of this thesis. 
 
1.1 Introduction to IBD 
 
1.1.1 History of IBD 
IBD, comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a 
collective term used to describe chronic inflammatory disorders of the GI tract. IBD 
presents with symptoms including diarrhoea, haematochezia, weight loss, and 
abdominal pain. The first description of chronic diarrhoeal illness dates as far back as 
ancient times, the aetiology of which was uncertain. Diarrhoea attributable to GI tract 
inflammation was first described in the 18
th
 century, but the distinction between 
inflammatory and infective causes of diarrhoea remained uncertain due to the 
overwhelming incidence of cholera infection that was observed in Western populations 
during this time.  
Sir Samuel Wilks authored a case report in 1859 in which the pathological 
findings of a case of acute dysentery were discussed. Here, a differential diagnosis of 
infective diarrhoea, poisoning, or an alternative non-infective inflammatory pathology, 
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akin to what may be considered IBD today, was discussed (Wilks, 1859). Subsequent to 
this, several additional cases were described in the latter half of the 19
th
 century, after 
which time the term “ulcerative colitis” became integrated into common medical 
parlance (Hale-White, 1888). In 1909, during a symposium in which a selected sample 
of 177 cases of UC were discussed, pre-eminent medical professionals of the time 
discussed proposed risk factors, presenting symptoms, and potential treatments for UC 
(Allchin, 1909). 
The recognition of a non-infective inflammatory pathology affecting the GI tract 
did not, however, provide a distinction between the two common forms of IBD that are 
recognised today. Despite previous medical practitioners noting pathology in the 
terminal ileum preceding this date (Wilks, 1859; Dalziel, 1913), a positive description 
of a GI disorder associated with pan-enteric inflammation, initially termed “regional 
enteritis”, but later taking the eponymous title used today, was not formally described 
until 1932 (Crohn et al., 1932). Here, the authors described a case series of patients with 
inflammatory ileitis affecting the terminal ileum, with evidence of the stricturing and 
fistulising/penetrating phenotypes that are recognised in CD today (Silverberg et al., 
2005). 
 
1.1.2 Pathophysiology of IBD 
 The aetiology of IBD is not fully understood. No unique pathophysiological 
mechanism has been identified that accounts for the development and propagation of 
either UC or CD. Instead, it is considered that a plethora of interacting factors combine 
to give rise to the typical phenotypic characteristics of IBD. These factors are likely to 
include, but are not limited to, dysregulation of enteric immunity, susceptible host 
genetics, alterations in the intestinal microbiome, and environmental factors. More 
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recently, in addition to this, psychological co-morbidity and stress have been recognised 
as potential additional contributory factors that may also be implicated in the 
pathogenesis of these diseases. 
 
1.1.2.1 Dysregulation of enteric immunity 
 It is hypothesised that an abnormal immune response to the presence of pro-
inflammatory gut microorganisms may be pivotal to the development of IBD. 
Traditionally, IBD has been considered a disorder characterised by dysregulation of 
adaptive immunity, with CD and UC considered T helper (Th) 1 and Th2-mediated 
disorders, respectively (Fuss et al., 1996). Despite this, disordered innate immune 
function is also likely to contribute to the development of these diseases. The innate 
immune system is the first line of defence against luminal pathogens, and comprises the 
intestinal barrier, and non-specific immune cells such as macrophages and dendritic 
cells. The function of each of these facets of innate immunity may be defective in IBD. 
Intestinal barrier dysfunction is characterised by increased paracellular permeability and 
reduced expression of tight junction proteins (Vivinus-Nebot et al., 2014). This, in turn, 
increases exposure to luminal pathogens, which is likely to contribute to the immune 
activation observed in IBD, via recognition of bacterial lipopolysaccharides (LPS).   
 The innate immune system is involved in the recognition of pathogenic antigens 
by immune cells including macrophages and dendritic cells, mediated by pattern 
recognition receptors such as trans-membrane Toll-like receptors and cytoplasmic 
nucleotide-binding oligomerisation domain-containing protein (NOD) like receptors, 
including NOD1 and NOD2. Innate immune cell activation results in an inflammatory 
cascade, mediated by nuclear factor kappa B (NF-ĸB), resulting in the production of 
pro-inflammatory cytokines and a disordered immune response including excessive Th1 
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responses (Watanabe et al., 2004), and inhibition of anti-inflammatory cytokines 
including interleukin (IL)-10 (Noguchi et al., 2009).  
 Adaptive immunity, involving both humoral and cell-mediated responses, differs 
from innate immunity, and is mediated via T cells. T cells interact with the innate 
immune system to produce an effective, long-lasting, individualised response to specific 
pathogens. Dysregulation of adaptive immunity in IBD results in an excessive immune 
response involving the inappropriate secretion of cytokines, leading to a pro-
inflammatory state, which results in GI tract inflammation and ulceration. The role of T 
cells in the pathogenesis of IBD may differ between CD and UC. Th1-mediated 
interferon-γ  expression in the mucosa of patients with CD is higher than that observed 
in patients with UC (Camoglio et al., 1998). In contrast, excessive Th2-mediated IL-5 
and IL-13 release observed in UC is not typically seen in patients with CD (Heller et al., 
2005). These findings have led to the assumption that CD and UC are Th1 and Th2-
mediated diseases, respectively (Fuss et al., 1996).  
 Despite this, more recent opinion casts doubt on the simplicity of these binary 
associations. In addition to Th1 and Th2 activity, Th17 cells are also implicated in the 
pathogenesis of IBD. Their production is facilitated by IL-6 and transforming growth 
factor beta (TGF-β), and is enhanced by IL-23 (Zhou et al., 2007). Th17 cells are 
associated with the release of IL-17 and IL-21, which in turn results in the up regulation 
of IL-23 receptor expression, resulting in a positive feedback loop of pro-inflammatory 
cytokine release (McGovern and Powrie, 2007). The relative abundance of Th17 cells in 
the lamina propria of patients with IBD (Rovedatti et al., 2009), and the increased 
presence of IL-17 in the mucosa of patients with CD and UC when compared with 
healthy controls (Sugihara et al., 2010), supports the role of Th17 cells in the 
pathogenesis of IBD. IL-23 plays a key role in the crosstalk between innate and 
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adaptive immune responses in IBD. It is produced by activated dendritic cells of the 
innate immune system and, in addition to its role in the Th17 response described above, 
is responsible for the stimulation of innate immune cells to produce inflammatory 
cytokines, including IL-6 and tumour necrosis factor alpha (TNFα), which drive 
intestinal inflammation (McGovern and Powrie, 2007).  
 In addition to the propagation of pro-inflammatory immune pathways in IBD, 
dysfunction of anti-inflammatory homeostatic mechanisms is also likely to contribute to 
the development of active inflammation. Regulatory T cells are able to suppress the 
proliferation of naïve T helper cells, and produce anti-inflammatory cytokines including 
IL-10 and TGF-β (O'Garra and Vieira, 2004). However, defective TGF-β signalling, 
due to the up regulation of Smad7, inhibits regulatory T cell function, resulting in 
defective anti-inflammatory cytokine production in patients with IBD (Sedda et al., 
2015). Inhibition of Smad7 has been the focus of clinical trials in IBD (Feagan et al., 
2018), although its role in treatment algorithms is yet to be defined. 
 The combination of inappropriate immune activation, resulting in the production 
of pro-inflammatory cytokines including interferon-γ, IL-23, IL-17, and TNFα, and 
defective host anti-inflammatory mechanisms, results in the development of intestinal 
inflammation and the typical phenotypic characteristics observed in patients with active 
IBD.  
 
1.1.2.2 Host genetics 
 Familial susceptibility to the development of IBD, particularly in twin studies, 
has led to the assumption that host genetics plays a role in the development of both CD 
and UC (Bengtson et al., 2010; Spehlmann et al., 2008). Despite this, the lack of an 
absolute association in the incidence of IBD between monozygotic twins confirms that 
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susceptible host genetics is only one contributory factor in the aetiology of IBD. 
Observational studies have described a greater association between the incidence of CD 
than UC within families (Spehlmann et al., 2008), and that the relative risk of 
developing IBD, when compared with the background population, is highest in 
monozygotic twins, followed by  dizygotic twins, and then first-degree siblings 
(Bengtson et al., 2010). 
Unlike disorders with classical Mendelian inheritance, no single gene has been 
identified that accounts for the development of either CD or UC. Instead, over 200 
single nucleotide polymorphisms have been identified since the advent of genome wide 
association studies (GWAS) investigating genetics and IBD (Ye and McGovern, 2016). 
To date, the strongest genetic association is between CD and the presence of the caspase 
recruitment domain-containing protein 15 (CARD15)/NOD2 mutation on chromosome 
16 (Hugot et al., 2001; Ogura et al., 2001). Other IBD risk variants have been identified 
including those involving the IL-23 receptor gene (Duerr et al., 2006). GWAS meta-
analyses have identified at least 163 IBD risk loci, with significant cross over between 
CD and UC phenotypes (Jostins et al., 2012). A detailed description of the plethora of 
studies detailing the individual risk loci associated with IBD is beyond the scope of this 
thesis.  
 
1.1.2.3 The intestinal microbiome 
 Typical microbiome changes in IBD include an increase in the relative 
abundance of pro-inflammatory species, a reduction in anti-inflammatory bacterial 
species such as Faecalibacterium prausnitzii, and a reduction in overall alpha bacterial 
diversity, when compared with healthy controls without IBD (Gevers et al., 2014). 
Notwithstanding the differences observed between IBD populations and healthy 
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controls, alterations in the microbiome have been observed between those with active 
and quiescent disease (Sepehri et al., 2007). Reduced abundance of F. prausnitzii has 
been observed in the mucosa-associated microbiome of some patients with CD 
following surgical resection for active disease, with these changes associated with 
higher rates of endoscopic recurrence at 6 months (Sokol et al., 2008). Furthermore, 
alterations in the mucosa-associated microbiome between inflamed and healthy areas of 
the GI tract in patients with an established diagnosis of CD have also been observed, 
thus supporting the association between alterations in the microbiome and disease 
activity in IBD (Gevers et al., 2014). Although the exact role of the microbiome in the 
development of intestinal inflammation in IBD is unknown, recognition of bacterial 
LPS, resulting in the aberrant immune activation that is described in more detail below, 
is thought to contribute. Whether susceptible host genetics has any influence on the 
microbiome profile in patients with IBD is uncertain, but individuals with an IBD-
related genotype are more likely to display associated microbiome alterations, despite 
not displaying phenotypic characteristics of IBD (Imhann et al., 2018).  
 
1.1.2.4 Environmental factors 
 Although the relationship between host genetics, enteric immunity, and the 
microbiome is likely to play a pivotal role in the aetiology of IBD, other environmental 
factors may also impact on the natural history of the disease. Tobacco smoking has a 
detrimental effect on the natural history of CD, with a significant increase in the odds of 
flare of disease activity, first surgery, flare of disease activity after first surgery, and the 
requirement for a second surgical resection observed in smokers when compared with 
non-smokers and ex-smokers (To et al., 2016b). In UC, tobacco smoking has 
traditionally been considered to impart beneficial effects on disease course, with the 
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onset of disease and flares of disease activity associated with smoking cessation 
(Harries et al., 1982; Calkins, 1989). However, trials of nicotine containing therapies 
have proved largely unsuccessful in UC (McGrath et al., 2004; Nikfar et al., 2010; 
Thomas et al., 1995; Thomas et al., 1996), and in meta-analyses of observational studies 
assessing the effect of tobacco smoking on the natural history of UC, results have been 
conflicting (Kuenzig et al., 2016; To et al., 2016a), thus casting doubt on the role of 
smoking in UC. 
In addition to tobacco smoking, other environmental factors including urban 
dwelling (Soon et al., 2012), antibiotic use (Ungaro et al., 2014), lack of exercise 
(Sonnenberg, 1990; Khalili et al., 2013), and previous appendicectomy (Kaplan et al., 
2008; Andersson et al., 2001; Myrelid et al., 2017) may also be implicated in the 
development of IBD.  
 
1.1.2.5 Psychological factors 
Psychological disorders, including anxiety, depression, and stress affect up to 
one-third of patients with IBD (Neuendorf et al., 2016). The mechanism by which these 
factors influence the development and natural history of IBD is uncertain, and forms a 
large part of the rationale for conducting the work which is described in this thesis. 
Studies conducted in functional gastrointestinal disorders (FGIDs) suggest that the 
relationship between GI symptom-reporting and mood disorders may be bi-directional 
(Koloski et al., 2012; Koloski et al., 2016), implicating brain-gut axis activity as a 
potential mediator of these relationships. Whether the same temporal relationship 
between disease activity and psychological co-morbidity exists in IBD is uncertain. A 
more detailed review of the proposed mechanisms by which psychological co-morbidity 
may negatively impact disease outcomes in IBD is provided later on. 
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1.1.3 Epidemiology of IBD 
The global incidence and prevalence of IBD varies according to geographical 
locale and disease subtype. In a systematic review of 260 epidemiological studies 
conducted between 1920 and 2008 (Molodecky et al., 2012), the incidence and 
prevalence of UC and CD were reported separately for regions including Europe, Asia 
and the Middle East, and North America. In UC, the annual incidence was reported to 
range from 0.6 to 24.3 per 100,000 person-years in Europe, with a corresponding figure 
of 0 to 19.2 per 100,000 person-years in North America and 0.1 to 6.3 per 100,000 
person years in Asia and the Middle East. In CD, the annual incidence was reported to 
range from 0.0 to 20.2 per 100,000 person-years in North America, with a 
corresponding figure for Europe, and Asia and the Middle East of 0.3 to 12.7 per 
100,000 person-years, and 0.04 to 5.0 per 100,000 person-years, respectively. Data 
reported in the same study suggested that the overall prevalence of UC varied from 4.9 
to 505 per 100,000 in Europe, 0.6 to 322 per 100,000 in North America and 4.9 to 168.3 
per 100,000 in Asia and the Middle East. In CD, the overall prevalence was reported to 
vary from 0.6 to 322 per 100,000 in Europe, 16.7 to 318.5 per 100,000 in North 
America and 0.88 to 67.9 per 100,000 in Asia and the Middle East. There appeared to 
be no difference in the incidence or prevalence of IBD between male and female sex, 
and a peak age of onset occurred in the third decade of life. Overall, in studies that 
reported data over a minimum 10-year period, a temporal rise in the incidence of UC 
(annual percentage change (APC) 2.4% to 18.1%) and CD was observed (APC 1.2% to 
23.3%), possibly due to an increase in urban dwelling (Soon et al., 2012), increased 
awareness of IBD, or greater use of colonoscopic and radiological investigations.  
An update to this study, conducted by the same authors, including an additional 
52 studies, demonstrated similar findings in Western populations (Ng et al., 2018b). 
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However, the inclusion of new epidemiological studies from the developing world 
provided a novel estimate of the prevalence of IBD in regions including Eastern Asia, 
South-eastern Asia, Western Asia, South America, and Africa where the reported 
prevalence (UC: 106.2 per 100,000; CD: 53.1 per 100,000) and incidence (UC: 6.76 per 
100,000 person-years; CD: 8.40 per 100,000 person-years) of IBD was universally low. 
In keeping with the previous systematic review (Molodecky et al., 2012), the incidence 
of IBD was also noted to be increasing in developing countries, including Brazil (APC 
for CD 11.1% (95% confidence interval (CI) 4.8-17.8) and UC 14.9% (95% CI 10.4-
19.6)) and Taiwan (APC for CD 4.0% (95% CI 1.0-7.1) and UC 4.8% (95% CI 1.8-
8.0)). 
 
1.1.4 The natural history of IBD 
CD and UC are chronic GI disorders without cure. As a consequence, patients 
with IBD face a lifetime of disease with the need for long-term medical and surgical 
interventions, with the ultimate goal of minimising digestive damage. The natural 
history of IBD is that of quiescence interspersed with episodic flare-ups of disease 
activity. Such flare-ups may present with the development of new GI symptoms and/or 
new-onset inflammatory activity. Medical management of IBD has advanced in recent 
decades, such that the requirement for surgical intervention in both UC and CD has 
declined, particularly since the introduction of biological therapies. Current estimates 
suggest that the cumulative 5 year risk of surgery in CD is between 19.6% and 33.3%, 
with a corresponding figure of between 7.5% and 11.6% in UC (Rungoe et al., 2014; 
Frolkis et al., 2013). Furthermore, the risk of first surgery in CD may be reducing by up 
to 3.5% per year (Ma et al., 2017), and the risk of second surgery in CD is also reducing 
over time (Frolkis et al., 2014). Given the chronic nature of these diseases, there 
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remains a need for effective medical interventions that induce remission of active IBD, 
and effectively maintain remission in patients with quiescent disease. 
 
1.1.5 Contemporary medical management of IBD 
 A combination of medical and surgical interventions form the basis of the 
management of patients with IBD. The aim of medical management is the maintenance 
of quiescent disease activity, the avoidance of glucorticosteroid therapy, and the 
avoidance of surgery. Pharmacological interventions in IBD target the putative 
pathophysiological mechanisms that contribute to the development and propagation of 
inflammatory activity. As described previously, a disordered immune response to a pro-
inflammatory microbiome in genetically susceptible individuals may lead to the 
development of the phenotypic characteristics of IBD. The mainstay of contemporary 
pharmacological interventions in IBD, including glucocorticosteroid, 5-aminosalicylic 
acid (5-ASA), immunomodulators, and biological therapies, target the dysregulation of 
enteric immunity in order to impart their beneficial effects. Other interventions, 
including those seeking to modulate the pro-inflammatory microbiome in patients with 
IBD, such as probiotics, antibiotics, and faecal microbiota transplantation (FMT) have 
also been tested in IBD. A summary of the evidence base for these interventions is 
provided below.  
 
1.1.5.1 Glucocorticosteroids 
 Glucocorticosteroids have formed the cornerstone of management of active IBD 
since the 1950s (Truelove and Witts, 1955; Lennard-Jones et al., 1960). The mechanism 
of action by which these drugs impart their anti-inflammatory effect is via cytoplasmic 
glucocorticoid receptor-mediated down regulation of NF-κB and activator protein-1, 
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both of which are potent transcription factors for many pro-inflammatory cytokines 
(Farrell and Kelleher, 2003). Since the publication of initial case series and uncontrolled 
trials of glucocorticosteroid therapy, conducted predominantly in patients with UC, 
several randomised controlled trials (RCT) assessing the effect of these drugs in IBD 
have been conducted. A systematic review and meta-analysis of RCTs seeking to clarify 
the evidence base for the use of glucocorticosteroids in IBD investigated the effect of 
glucocorticosteroids on the maintenance of disease remission and the induction of 
remission in active IBD (Ford et al., 2011b). The authors reported that there was likely 
to be a beneficial effect of glucocorticosteroid therapy over placebo for the induction of 
remission of active UC (relative risk (RR) of failure to achieve remission = 0.65; 95% 
CI 0.45-0.93) although the benefit was less clear in CD (RR of failure to achieve 
remission = 0.46; 95% CI 0.17-1.28), probably due to heterogeneity between the 
included studies. Adverse events were more common in patients receiving active 
treatment. Maintenance therapy with glucocorticosteroids is not recommended due to 
the well-documented systemic side effects of long-term treatment.  
 Due to its relatively favourable side-effect profile, budesonide is considered an 
alternative to standard glucocorticosteroid therapy in some instances in IBD. Several 
Cochrane reviews have sought to better elucidate its role in the management of IBD. 
These have reported that budesonide was inferior to standard glucocorticosteroids, but 
superior to placebo in the treatment of active CD (RR of achieving remission = 0.85, 
95% CI 0.75-0.97 and RR of achieving remission = 1.93, 95% CI 1.37-2.73, 
respectively) (Rezaie et al., 2015), that budesonide-MMX® was superior to placebo in 
inducing clinical and endoscopic remission in patients with active UC (RR of achieving 
remission = 2.25; 95% CI 1.50-3.39), particularly in those with left sided disease 
(Sherlock et al., 2015), and that budesonide was not superior to placebo in the 
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maintenance of remission in quiescent CD at 3 months (RR of maintaining remission = 
1.25; 95% CI 1.00-1.58) (Kuenzig et al., 2014). 
 
1.1.5.2 5-aminosalicylic acids 
Via their interaction with peroxisome proliferator-activated receptor gamma, 5-
ASAs effectively reduce the expression of pro-inflammatory cytokines in UC, in part by 
the suppression of NF-κB, but potentially also by their interaction with lipoxygenase, 
cyclo-oxygenase, IL-1, IL-2, and TNFα (Iacucci et al., 2010). In a systematic review 
and meta-analysis of RCTs, these drugs were shown to be effective at maintaining 
remission in UC (RR of relapse versus placebo = 0.65; 95% CI 0.55-0.76), and for the 
treatment of mild-to-moderate active inflammation using oral preparations (RR of 
failure to achieve remission versus placebo = 0.79; 95% CI 0.73-0.85) (Ford et al., 
2011a). In a further systematic review and meta-analysis, topical 5-ASAs were superior 
to placebo at maintaining remission in quiescent UC (RR of relapse = 0.60; 95% CI 
0.49-0.73) (Ford et al., 2012b). Finally, combined topical and oral 5-ASA have been 
shown to be superior to oral 5-ASA monotherapy for the treatment of active UC (RR of 
failure to achieve remission = 0.65; 95% CI 0.47-0.91) (Ford et al., 2012a). 5-ASA use 
may also be associated with some chemoprotective effect against the onset of colitis-
associated colorectal cancer (van Staa et al., 2005), although this assertion is disputed 
by others (Bernstein et al., 2011; Nguyen et al., 2012).  
In contrast to UC, the evidence base for the use of 5-ASAs in the treatment of 
CD is less convincing. In a systematic review and meta-analysis of 22 RCTs, 5-ASAs 
were superior to placebo for the induction of remission of active CD (RR of failure to 
achieve remission = 0.89; 95% CI 0.80-0.99), but there was no benefit of 5-ASA over 
placebo for maintenance of remission in quiescent CD (RR of relapse versus placebo = 
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0.97; 95% CI 0.90-1.05) (Ford et al., 2011c). Despite this, the same authors did suggest 
there may be a role for mesalazine in the prevention of relapse of CD after surgically 
induced remission (RR of relapse versus placebo = 0.80; 95% CI 0.70-0.92) (Ford et al., 
2011d).  
 
1.1.5.3 Immunomodulators  
Immunomodulators including thiopurines, methotrexate, and calcineurin 
inhibitors, such as tacrolimus and ciclosporin, have been trialled in patients with IBD. 
Their mechanisms of action are distinct, but focus on the inhibition of production of 
lymphocytes, or the inhibition of pro-inflammatory cytokine production. 
Thiopurines are the most commonly prescribed immunomodulators in IBD. The 
efficacy of mercaptopurine, and its pro-drug azathioprine, has been investigated in 
several RCTs in both UC and CD. A systematic review and meta-analysis of RCTs 
investigating the efficacy of these drugs in IBD reported that their use as an intervention 
for the treatment of active disease was no better than placebo in CD (RR of induction of 
remission = 0.87; 95% CI 0.71-1.06) or UC (RR of remission = 0.85; 95% CI 0.71-1.01) 
(Khan et al., 2011a). In the same meta-analysis, the authors described a significant 
benefit of azathioprine therapy in the maintenance of remission of quiescent UC when 
data were pooled from three RCTs (RR of relapse versus placebo = 0.60; 95% CI 0.37-
0.95). In CD, there appeared to be no overall benefit of thiopurines over placebo for the 
maintenance of remission in quiescent disease when data were pooled from two RCTs 
(RR of relapse = 0.64; 95% CI 0.43-1.23). However, when data from three withdrawal 
studies were assessed, there was an overall benefit (RR of relapse = 0.39; 95% CI 0.21-
0.74) (Khan et al., 2011a). In the TOPPIC trial (Mowat et al., 2016), where the efficacy 
of mercaptopurine in the maintenance of remission in post-operative CD was compared 
41 
 
 
 
with placebo, there was no benefit of routine post-operative prophylaxis (HR for clinical 
recurrence = 0.54; 95% CI 0.27-1.06), other than in active smokers (HR for clinical 
recurrence = 0.13; 95% CI 0.04-0.46), where the deleterious effects of smoking (To et 
al., 2016b)  appeared to be ameliorated.  
A recent Cochrane review of RCTs investigating the effect of methotrexate as a 
therapeutic intervention in the treatment of refractory CD suggested that there may be a 
benefit of intramuscular methotrexate over placebo (McDonald et al., 2014), on the 
basis of the results from a single RCT (RR of failure to achieve remission = 0.75; 95% 
CI 0.61-0.93) (Feagan et al., 1995). Oral preparations were no more beneficial than 
placebo (RR of failure to achieve remission = 3.00; 95% CI 0.68-13.31). In the same 
meta-analysis, the combination of methotrexate and biological therapy was not found to 
be superior to biological therapy alone (McDonald et al., 2014). Two subsequent studies 
have been conducted that have advocated the use of methotrexate in refractory CD, but 
these studies had significant limitations, including a retrospective study design (Huang 
et al., 2017; Kopylov et al., 2016). A further Cochrane review of RCTs has reported on 
the efficacy of methotrexate as a maintenance treatment in CD (Patel et al., 2014). Here, 
intramuscular methotrexate was superior to placebo over 36 to 40 weeks of follow-up 
(RR of relapse = 1.67; 95% CI 1.05-2.67). The evidence base for the efficacy of 
methotrexate in UC is poorly quantified (Chande et al., 2014), and its use is not 
advocated by international consensus (Harbord et al., 2017). 
The efficacy of calcineurin inhibitors, including tacrolimus and ciclosporin, has 
also been investigated in IBD. When compared with placebo, ciclosporin is an 
evidence-based treatment for glucocorticosteroid-refractory acute severe UC (Lichtiger 
et al., 1994), and its efficacy is equivalent to that of infliximab (Williams et al., 2016). 
However, there is a lack of evidence to support its use in the maintenance of remission 
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of quiescent UC, or in the treatment of CD. Topical tacrolimus has been shown to be 
effective in achieving clinical remission in patients with difficult-to-treat ulcerative 
proctitis (Lawrance et al., 2017), but its role as an oral treatment in both UC and CD is 
poorly defined (Gerich et al., 2013; Thin et al., 2013).  
 
1.1.5.4 Biological therapies 
 Biological therapies form the mainstay of escalated medical treatment in IBD. 
Their use is advocated by international consensus for the management of both CD and 
UC (Gomollon et al., 2017; Harbord et al., 2017). At present, in the United Kingdom, 
the National Institute of Health and Care Excellence has approved the use of biological 
therapies including the anti-TNFα drugs infliximab, adalimumab, and golimumab 
(NICE, 2010; NICE, 2015a), the anti-integrin vedolizumab (NICE, 2015b; NICE, 
2015c), and the IL-12/23p40 antagonist ustekinumab (NICE, 2017). Each of these drug 
classes has a distinct mechanism of action, but with the collective aim of modulating the 
disordered immune response that is observed in patients with IBD. 
Infliximab has been shown to be an effective rescue therapy for active UC 
refractory to intravenous glucocorticosteroid therapy in a RCT including 45 patients 
(Jarnerot et al., 2005). Here, colectomy rates at 3 months were significantly lower in 
patients randomised to receive infliximab compared with placebo (7 (29%) of 24 versus 
14 (66.7%) of 21; P = 0.017). The ACT 1 and ACT 2 RCTs of infliximab as a treatment 
for glucocorticosteroid-refractory active UC demonstrated improved clinical response 
when compared with placebo after 8 weeks (69% versus 37%; P <0.001), which was 
sustained after 30 weeks of follow-up (Rutgeerts et al., 2005). In addition, the 
combination of azathioprine with infliximab has been shown to be superior to 
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infliximab monotherapy at achieving glucocorticosteroid-free remission after 16 weeks 
(31 (39.7%) of 78 versus 17 (22.1%) of 77; P = 0.017) (Panaccione et al., 2014).  
The efficacy of adalimumab, an alternative anti-TNFα preparation administered 
subcutaneously, has been studied in the treatment of active UC, refractory to 
glucocorticosteroids and/or immunosuppressants. In the ULTRA 1 RCT, patients 
randomised to adalimumab therapy received induction doses of 160mg followed by 
80mg at week 2, and 40mg every other week thereafter. These patients were more likely 
to achieve clinical remission at week 8 than those receiving placebo (18.5% versus 
9.2%; P = 0.03) (Reinisch et al., 2011). In longitudinal follow-up over 52 weeks 
(ULTRA 2), adalimumab was also superior to placebo at maintaining clinical remission 
in UC (17.3% versus 8.5%; P = 0.004), with anti-TNFα naive patients more likely to 
respond than those with prior exposure (Sandborn et al., 2012b).  
Golimumab, an alternative subcutaneously administered anti-TNFα drug, has 
also been trialled in patients with objectively confirmed glucocorticosteroid-refractory 
UC. The PURSUIT trial demonstrated that patients with moderate-to-severely active 
UC treated with golimumab had higher rates of clinical remission and mucosal healing 
following 6-week induction therapy than patients randomised to placebo (P ≤0.0001) 
(Sandborn et al., 2014a). The sustained response of 464 patients who responded to 
golimumab induction therapy at 6 weeks was evaluated after 54 weeks. Patients were 
randomised to 100mg every 4 weeks or placebo maintenance therapy. Here, the 
proportion of patients in clinical remission, and the proportion who had mucosal healing 
at week 54, was higher in patients randomised to receive active treatment than those 
receiving placebo (27.8% versus 15.6%; P = 0.004 and 42.4% and 26.6%; P = 0.002, 
respectively) (Sandborn et al., 2014b).  
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GEMINI 1 was a RCT of vedolizumab in endoscopically confirmed moderate-
to-severe UC. Patients were randomised to receive vedolizumab 300mg or placebo at 
weeks 0 and 2, and were assessed for response at week 6. In terms of clinical response 
rate, defined as a reduction in Mayo score of three points and a decrease in score of 30% 
from baseline, a significant beneficial effect of vedolizumab therapy over placebo was 
identified at week 6 (47.1% versus 25.5%; P <0.001). Clinical remission rates at week 
52, defined as a Mayo score ≤2 and no subscore >1, were also higher in patients 
randomised to receive vedolizumab maintenance therapy, either every 8 weeks or every 
4 weeks, than placebo (41.8% versus 15.9%; P <0.001 and 44.8% versus 15.9%; P 
<0.001, respectively) (Feagan et al., 2013). This effect was greater in patients who were 
naïve to anti-TNFα therapy (Feagan et al., 2017). 
As was the case in UC, infliximab was the first anti-TNFα therapy to be trialled 
in CD. In a RCT of infliximab as induction therapy in moderate-to-severe CD, a single 
infusion of 5mg per kilogram was superior to placebo in achieving a clinical response at 
4 weeks (22 (81%) of 27 versus 4 (17%) of 24; P <0.001), which persisted at 12 weeks 
(Targan et al., 1997). The efficacy of maintenance infliximab therapy was assessed in 
the ACCENT 1 RCT (Hanauer et al., 2002). In this study, patients with active CD, who 
responded to an initial infusion of infliximab, were randomised to receive maintenance 
infliximab 5mg/kg or placebo at week 2, week 6, and at 8-weekly intervals thereafter. 
At week 30, clinical remission was maintained in a significantly greater proportion of 
patients treated with infliximab, when compared with placebo (44 (39%) of 113 vs. 23 
(21%) of 110; P = 0.003). Investigators from the same study group also demonstrated a 
benefit of both induction and maintenance infliximab therapy over placebo in the 
management of fistulising CD (Present et al., 1999; Sands et al., 2004) The benefit of 
combined anti-TNFα and thiopurine therapy  was assessed in the SONIC study 
45 
 
 
 
(Colombel et al., 2010). Here, the efficacy of infliximab, azathioprine, or combined 
infliximab and azathioprine was assessed. Glucocorticosteroid-free remission rates at 26 
weeks were statistically significantly higher with combination therapy than with 
infliximab monotherapy (96 (56.8%) of 169 versus 75 (44.4%) of 169; P = 0.02), which 
in turn was more effective than azathioprine monotherapy (75 (44.4%) of 169 versus 51 
(30.0%) of 170; P = 0.02).  
In the CLASSIC-I trial, adalimumab monotherapy was trialled as a treatment for 
active CD. Patients included were anti-TNFα naïve. Clinical remission rates were 
significantly higher in those receiving adalimumab induction therapy (160mg week 0 
and 80 mg week 2) when compared with placebo at 4 weeks (36% versus 12%; P = 
0.001) (Hanauer et al., 2006). This effect appeared to be attenuated in patients 
previously exposed to anti-TNFα therapy (Sandborn et al., 2007). In the EXTEND 
study, the use of adalimumab maintenance treatment in CD over 12 months follow-up 
was assessed. All patients received 160mg/80mg induction therapy and then were 
randomised to either 40mg every other week, or placebo. Rates of mucosal healing and 
clinical remission were significantly higher in those treated with adalimumab, when 
compared with placebo at 52 weeks (24% versus 0%; P <0.001 and 33% versus 9%; P = 
0.001, respectively) (Rutgeerts et al., 2012). Although not licensed for use in the UK, 
certolizumab pegol is an alternative anti-TNFα preparation that appears to be of benefit 
in both the induction and maintenance of remission in CD (Schreiber et al., 2005; 
Schreiber et al., 2007), particularly in those with objective inflammatory disease activity 
at randomisation.  
In the GEMINI 2 RCT, the efficacy of the anti-integrin vedolizumab for the 
treatment of active CD, defined using clinical parameters and objective measures of 
inflammatory activity, was assessed (Sandborn et al., 2013). Here, vedolizumab therapy 
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was superior to placebo at achieving clinical remission at 6 weeks, although overall 
rates of remission were low (14.5% versus 6.8%; P = 0.02). Those who responded to 
induction therapy were then re-randomised to receive either placebo, vedolizumab 
300mg every 4 weeks, or vedolizumab every 8 weeks. A greater proportion of patients 
receiving either vedolizumab every 4 weeks or every 8 weeks achieved clinical 
remission at 52 weeks when compared with placebo (39.0% versus 21.6%; P <0.001 
and 36.4% versus 21.6%; P = 0.004, respectively) (Sandborn et al., 2013).  
Ustekinumab an anti-IL-12/23p40 monoclonal antibody has also been trialled 
for the treatment of active CD that is refractory to anti-TNFα therapy (Sandborn et al., 
2012a; Feagan et al., 2016). Two parallel RCTs (UNITI-1 and UNITI-2) were 
conducted to assess clinical response rates following induction therapy at week 6, and 
maintenance therapy at week 44. Clinical response rates at week 6 were significantly 
higher in patients receiving intravenous induction therapy with ustekinumab when 
compared with those receiving placebo (UNITI-1; P ≤0.003 and UNITI-2; P <0.001). 
Of those that responded to initial induction therapy who were then re-randomised to 
receive either ustekinumab every 8 weeks, ustekinumab every 12 weeks, or placebo 
remission rates at week 44 were higher in those receiving ustekinumab 8-weekly when 
compared with placebo (53.1% versus 35.9%; P = 0.005), and ustekinumab 12-weekly 
when compared with placebo (48.8% versus 35.9%; P = 0.04). 
  
1.1.5.5 Faecal microbiota transplantation 
 Modification of the pro-inflammatory intestinal microbiota that is observed in 
patients with active IBD is the mechanism by which FMT is supposed to impart its 
beneficial effect on disease activity in IBD. Indeed, post-FMT faecal microbiome 
profiling in IBD populations has demonstrated that the microbiome post-transplant 
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mirrors that of the donor, rather than the host (Jacob et al., 2017). In a recent systematic 
review and meta-analysis of case reports, case series, cohort studies and RCTs, the 
efficacy of FMT in active UC and CD was reported (Paramsothy et al., 2017b). The 
majority of studies in UC, and all the studies in CD, were observational in nature. There 
were only four RCTs in patients with UC, which recruited a total of 277 patients 
(Moayyedi et al., 2015; Rossen et al., 2015; Paramsothy et al., 2017a; Costello et al., 
2017). Formal meta-analysis of these studies revealed a potential benefit of FMT in UC 
(pooled OR of achieving clinical remission with FMT versus control = 2.89; 95% CI 
1.36-6.13). Despite this, there was evidence of heterogeneity, and significant 
methodological differences in the study protocols, including different routes of faecal 
donor administration. Thus, at present, FMT remains an experimental intervention. 
 
1.1.5.6 Probiotics and antibiotics 
 Probiotics are live microorganisms that confer a health benefit on the host. Their 
potential benefit in IBD is thought to arise via manipulation of the intestinal 
microbiome. Several RCTs have described the effect of probiotics, either as a single 
strain or as combined preparations, on disease activity in CD and UC, as well as for the 
maintenance of remission in patients with quiescent disease. Most recently, a systematic 
review and meta-analysis of RCTs reported that there was no effect of probiotics for the 
induction of remission of active CD, the maintenance of remission in quiescent CD, or 
the prevention of disease recurrence in post-operative CD (Derwa et al., 2017). The 
authors also noted that there was no overall benefit of probiotics in the treatment of 
active UC, but that when only RCTs of the combination probiotic VSL#3 were 
included, their appeared to be a benefit over placebo (RR of failure to achieve remission 
= 0.74; 95% CI 0.63-0.87). Furthermore, probiotics appeared to be of equivalent 
48 
 
 
 
efficacy to 5-ASA preparations for the maintenance of disease remission in quiescent 
UC (Derwa et al., 2017). 
 A systematic review and meta-analysis of RCTs investigating the use of 
antibiotics in the treatment of IBD reported that antibiotics may be of benefit in the 
treatment of both active UC and CD, but that significant heterogeneity was observed in 
these analyses (Khan et al., 2011b). Fewer studies have reported on the effect of 
antibiotic therapy on the maintenance of remission in quiescent IBD. Current 
international guidance does not support the use of antibiotics in IBD, apart from in the 
management of perianal CD, septic complication of penetrating CD, or in the treatment 
of small intestinal bacterial overgrowth (SIBO) (Gomollon et al., 2017; Harbord et al., 
2017). 
 
1.2  Symptom reporting in IBD 
Traditional assessment of disease activity in IBD is centred upon the 
interpretation of patient-reported symptoms that are deemed likely to be attributable to 
active GI inflammation. Clinical decision-making is often made on these grounds, with 
recourse to ‘gold-standard’ investigations, including ileocolonoscopy and radiological 
investigations, reserved for patients who are deemed to have active disease on the basis 
of these symptoms. In clinical practice, as well as in clinical trials of novel therapies in 
IBD, clinical disease activity indices are routinely used to estimate disease activity. The 
use of the Crohn’s disease activity index (CDAI) and Harvey-Bradshaw index (HBI) are 
commonplace in CD, with equivalent indices including the Powell-Tuck index, 
Rachmilewitz clinical activity index, Mayo score, and simple clinical colitis index 
(SCCAI) adopted in UC.  
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The relationship between GI symptom-reporting and the presence of objectively 
quantified active mucosal inflammation has been previously investigated. Several 
authors have demonstrated that the correlation between GI symptom-reporting, captured 
using clinical disease activity indices, is suboptimal, particularly in CD. These indices, 
when compared with gold-standard investigations, perform inferiorly to objective 
markers of inflammation, including C-reactive protein (CRP) and faecal calprotectin 
(FC) (Falvey et al., 2015; af Bjorkesten et al., 2012; Sipponen et al., 2008; Jones et al., 
2008; Schoepfer et al., 2009; Schoepfer et al., 2010; Targownik et al., 2015).  
Accordingly, reliance on subjective measures of disease activity assessment, 
based on patient-reported symptoms, may have implications for the long-term 
management of patients with IBD. In a cross-sectional study of 150 patients with CD 
and 126 patients with UC, where the attending physician was blinded to FC results, 
physician decision-making made on the basis of clinical parameters alone, was 
recorded. Here, 31% of patients who underwent escalation of medical therapy and 60% 
of patients who were referred for endoscopic or radiological investigations, did not have 
a FC >250µg/g (Derwa et al., 2018). The authors also reported that more than one-in-
three patients with a FC >250µg/g received neither escalation of medical therapy nor 
referral for investigations to objectively determine inflammatory activity (Derwa et al., 
2018). Although, in the latter instance, the benefit of a treat-to-target approach towards 
the management of patients with IBD has yet to be determined (Sandborn et al., 2014c; 
Bryant et al., 2014; D'Haens et al., 2014), these data highlight the inherent 
inconsistencies associated with clinical decision-making in IBD, when made on the 
basis of patient-reported symptoms alone. This is of particular relevance at the current 
time as the US Food and Drug Administration have recently advocated the use of 
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patient-reported outcome measures (PROMs) as end points in trials of novel therapeutic 
interventions in IBD (Williet et al., 2014). 
 
1.2.1  Symptom reporting in the absence of inflammation in IBD 
Given that the correlation between symptom-reporting and objectively 
confirmed mucosal inflammation is poor, factors other than inflammatory activity are 
likely to contribute to the generation of GI symptoms in IBD. The presence of 
symptoms in the absence of inflammation has often been attributed to co-existent 
irritable bowel syndrome (IBS), which is reported to affect up to 35% of patients with 
clinically quiescent IBD (Halpin and Ford, 2012). In contrast to IBD, IBS is a highly 
prevalent condition, with a worldwide population prevalence of between 10% and 20% 
(Lovell and Ford, 2012). The cardinal features of IBS are those of a change in bowel 
habit in the presence of abdominal pain or discomfort. Patients are subtyped according 
to the predominant stool pattern they report: IBS with diarrhoea, IBS with constipation, 
or mixed IBS, if stool pattern fluctuates between the two. IBS is a FGID, without any 
known organic explanation. The condition is diagnosed using symptom-based 
diagnostic criteria, with the current gold-standard being either the Rome III (Longstreth 
et al., 2006) or Rome IV criteria (Mearin et al., 2016). Recent evidence suggests that the 
accuracy of these in predicting the presence of IBS is only modest (Ford et al., 2013), 
but may be improved with additional history and simple laboratory investigations (Sood 
et al., 2016). 
 
1.2.2 The overlap between IBS and IBD 
Symptoms associated with a flare of disease activity in IBD may include 
abdominal discomfort, alteration in bowel habit towards looser stools, and rectal 
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bleeding. Traditional management dictates that a change in symptoms in individuals 
with IBD should prompt an assessment of disease activity, via clinical disease activity 
scoring systems such as the SCCAI in UC (Walmsley et al., 1998) or HBI in CD 
(Harvey and Bradshaw, 1980).  The results of these clinical disease activity indices are 
then combined with serum and/or faecal biomarkers of disease activity, including CRP 
and FC, as well as endoscopic visualisation of the colonic mucosa, with 
histopathological interpretation of biopsy specimens, or appropriate radiological 
investigations.  
These investigations may aid the decision-making process, in terms of the need 
to modify or escalate pharmacotherapy. However, when patients present with lower GI 
symptoms in the absence of biochemical, radiological, endoscopic, and 
histopathological evidence of disease activity, the clinician is faced with a dilemma 
regarding further management, as this then raises the possibility of either subclinical 
inflammatory activity, or co-existent IBS in a patient with known IBD. Escalation of 
therapy in this situation may be advocated by some experts, but the use of 
immunomodulator therapies or biological agents is not without the risk of adverse 
events (Williams et al., 2014; Ford and Peyrin-Biroulet, 2013; Beaugerie et al., 2009; 
Peyrin-Biroulet et al., 2011) and, in the case of biological therapies, carries with it 
significant financial implications. In addition, in clinical trials, patients with IBD 
without objective evidence of disease activity often do not respond to these agents as 
well as those with definitive evidence of active inflammation (Reinisch et al., 2012; 
Colombel et al., 2010; Schreiber et al., 2005). 
Given that both IBS and IBD are chronic diseases, which may present with 
similar symptoms, and that individuals with IBS are often diagnosed on symptom 
grounds alone using an imperfect gold-standard (Ford et al., 2013), there is the potential 
52 
 
 
 
for a missed diagnosis of IBD in patients thought to have IBS. Indeed, the rate of 
incident IBD diagnoses in patients with an existing diagnosis of IBS is over five times 
that of the background non-IBS population (Canavan et al., 2014).  It is also possible 
that alternative organic, non-inflammatory pathology such as bile acid malabsorption 
(BAM), or SIBO could also affect patients with quiescent IBD, leading to a mis-
diagnosis of lower GI symptoms as co-existent IBS. This is particularly relevant to 
patients with CD with a stenosing phenotype, or those having undergone prior intestinal 
resection (Gracie et al., 2012; Aziz et al., 2015; Ford et al., 2009a; Chachu and 
Osterman, 2016; Rana et al., 2013). Furthermore, some individuals with IBS, 
particularly those with a post-infectious aetiology, have been shown to display evidence 
of low-grade mucosal inflammation (Sundin et al., 2014; Chadwick et al., 2002; 
Barbara et al., 2004; Barbara et al., 2007), suggesting that this may be a contributing 
factor in the development of these symptoms in patients with IBD. This has led to some 
experts proposing that the classical view that IBS and IBD are mutually exclusive 
conditions, falling either side of a functional-organic divide, is too simplistic. Instead a 
biopsychosocial model of ‘IBD-IBS’ has been put forward (Long and Drossman, 2010), 
although this approach remains controversial.  
 
1.2.3 Proposed aetiology of IBS-type symptoms in IBD 
Given that there is a several-fold increase in the prevalence of IBS-type 
symptoms in IBD compared with the background population (Halpin and Ford, 2012; 
Lovell and Ford, 2012), it follows that patients with IBD who display these symptoms 
may share common risk factors for their development with the IBS population. To date, 
the aetiology of IBS is unclear, but is thought to arise from a combination of 
psychological, as well as organic pathologies. An increasing body of evidence 
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suggesting that the cause of IBS is multifactorial has superseded the classical view of 
IBS as a centrally driven condition. There is now a realisation that low-grade mucosal 
inflammation (Ford and Talley, 2011), an altered microbiome (Kassinen et al., 2007), 
increased intestinal permeability (Marshall et al., 2004), and genetic factors contribute 
to its development (Ek et al., 2015), all of which are common to IBD, as described 
above.  
 
1.2.3.1 Mucosal inflammation, dysbiosis, intestinal permeability, and visceral 
hypersensitivity  
Mucosal inflammation is the hallmark of IBD. However, recent advances in the 
understanding of the aetiology of IBS suggest subclinical mucosal inflammation and 
increased mucosal barrier permeability may play a role in the development of 
symptoms. Studies have demonstrated increased levels of circulating pro-inflammatory 
cytokines in the peripheral blood (McKernan et al., 2011; Keohane et al., 2010), and 
intestinal mucosa of patients with IBS (Chadwick et al., 2002; Ford and Talley, 2011), 
when compared with controls. The exact cause of this inflammation is uncertain, but 
may be related to an alteration in the gut microbiome, with evidence of a dysbiosis in 
IBS, and a relative abundance of pro-inflammatory species compared with healthy 
individuals without IBS (Lee and Lee, 2014). 
The advent of 16s ribosomal ribonucleic acid (RNA) gene sequencing has 
provided a specific and relatively inexpensive method of studying microbial diversity in 
the gut, and with it further investigation of the association of altered gut microbial 
composition in various GI diseases including IBS (Hong and Rhee, 2014), IBD 
(Walujkar et al., 2014), and colorectal cancer (Akin and Tozun, 2014). The mechanism 
by which gut microbes may be able to affect intestinal permeability, thus propagating 
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symptoms compatible with IBS, is complex but dysregulation of the enteric nervous 
system in response to an altered microbiome, as is observed in IBD, has been proposed 
as a cause (Zhou et al., 2009; Camilleri et al., 2012). 
It is suggested that dysbiosis is associated with an increase in the expression of 
Toll-like receptors in the intestinal epithelium, which are responsible for the recognition 
of bacterial LPS (Brint et al., 2011). This, in combination with the presence of pro-
inflammatory bacterial species, induces activation of the enteric nervous system, 
resulting in mucosal inflammation, altered expression of tight junction proteins (Piche 
et al., 2009), epithelial barrier dysfunction, increased mucosal permeability, and 
consequent visceral hypersensitivity and stimulation of the brain-gut axis. Moreover, 
the complex interactions between gut microbes, the enteric nervous system, and the 
brain-gut axis has also been implicated in the development of stress, anxiety, and 
depression in patients with IBS (Mayer et al., 2014), with some evidence to suggest this 
interplay may also affect the prevalence of psychological illness, even in individuals 
without any evidence of GI disease (Vitetta et al., 2014).  
One could assume, therefore, that distinct alterations in the microbiome would 
be observed in patients with IBD with quiescent inflammatory activity who report IBS-
type symptoms. This topic is poorly described, yet in one study attempting to 
investigate this matter, there was no significant difference in the differential abundance 
of bacterial taxa or alpha diversity, and little difference in beta diversity, between 
patients with asymptomatic quiescent IBD and those who reported IBS-type symptoms 
(Shutkever et al., 2018). Despite this, the authors conceded that the lack of observable 
difference in the faecal microbiota between these groups could have been secondary to 
unmeasured confounding, which may have resulted from the concomitant use of 
medications, including proton pump inhibitors and antibiotics. The study also failed to 
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address the potential impact of the mucosa-associated microbiome, and any role that the 
proteome or metabolome may have had on the development of these symptoms. 
The potential role of subclinical inflammatory activity in the aetiology of IBS-
type symptoms in IBD has been investigated in a prospective case-control study of 
patients with IBS or quiescent IBD, including 31 patients with CD and 18 patients with 
UC, and healthy controls undergoing ileocolonoscopy. Biopsy specimens were taken 
and questionnaires completed to assess the severity of IBS-type symptoms in all 
participants (Vivinus-Nebot et al., 2014). These biopsies were assessed for pro-
inflammatory cell infiltrates, including mast cells, intraepithelial lymphocytes, and 
eosinophils, as well as immunohistochemistry for CD-117 and CD-3. Colonic 
paracellular permeability and TNFα levels were quantitatively assessed. Messenger 
RNA (mRNA) expression of tight junction proteins ZO-1, a-catenin, and occludin were 
also measured. The authors demonstrated an increase in paracellular permeability in 
patients with IBD with IBS-type symptoms, compared with those without, and reported 
that paracellular permeability in patients with IBS was comparable to those with 
quiescent IBD with IBS-type symptoms, whereas paracellular permeability in patients 
with quiescent IBD without IBS-type symptoms was similar to that of controls. The 
presence of IBS-type symptoms was associated with increased paracellular permeability 
and reduced tight junction protein mRNA expression universally. Mast cell infiltrates 
were higher in patients with IBS, CD, and UC versus controls, but intraepithelial 
lymphocytes were demonstrated in higher numbers in all IBD groups, including those 
reporting IBS-type symptoms, versus IBS and controls. This suggests that subclinical 
inflammation is implicated in the aetiology of these symptoms, especially as TNFα 
mRNA expression were higher in the subgroup of IBD patients who reported IBS-type 
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symptoms compared to those who did not, albeit that no associated increase in TNFα 
protein expression was identified.  
The chronic recurrent mucosal inflammation characteristic of IBD may also lead 
to visceral afferent hypersensitivity. This could, in turn, lead to symptoms compatible 
with IBS via abnormal neuronal responses causing hyperalgesia and allodynia, together 
with abnormal local reflexes, resulting in altered GI motility and secretion. Evidence to 
support this comes from a rat model of colitis (La et al., 2003) and, more recently, a 
barostat study conducted among patients with UC in remission (van Hoboken et al., 
2011). Here, a positive correlation between rectal perception thresholds and IBS-type 
symptoms was observed when compared with healthy controls. Furthermore, in patients 
reporting IBS-type symptoms, an increased number of mast cells were observed in the 
colonic mucosa, with a higher percentage of these mast cells in close proximity to nerve 
fibres, a finding previously described in patients with IBS (Barbara et al., 2004).  
 
1.2.3.2 Psychological co-morbidity and the brain-gut axis 
Several observational studies have highlighted an association between the 
reporting of IBS-type symptoms and psychological co-morbidity and poor quality of life 
in patients with IBD (Simren et al., 2002; Ansari et al., 2008; Barratt et al., 2011; 
Bryant et al., 2011; Farrokhyar et al., 2006; Minderhoud et al., 2004; Piche et al., 2010). 
Stress, anxiety, and depression are common in both IBS and IBD (Whitehead et al., 
2002; Graff et al., 2009; Henningsen et al., 2003; Panara et al., 2014; Neuendorf et al., 
2016). However, the effect of psychological co-morbidity on the natural history of these 
conditions remains controversial. Prior understanding of the cause of these conditions 
led healthcare professionals to assume that IBS was a centrally-mediated process, and 
IBD a condition largely restricted to the GI tract. However, evidence now exists to 
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suggest that the relationship between stress and flares of disease activity in the two 
conditions may be more complex, and that the presence of psychological co-morbidity 
is associated with increased symptom severity or flares of disease activity in both 
(Lackner et al., 2013; Shah et al., 2014; Mittermaier et al., 2004). 
A proposed explanation is that psychological co-morbidity results in a 'stress 
response’, which may contribute to worse outcomes in these conditions. This stress 
response results from a complex interaction between different interconnected parts of 
the brain including the hypothalamus, amygdala, and hippocampus. Communication 
between these areas results in activation of the hypothalamus-pituitary axis. In response 
to stressful stimuli, adrenocorticotropic-releasing hormone is secreted from the 
hypothalamus. This stimulates the production of adrenocorticotropic hormone from the 
anterior pituitary gland, resulting in increased secretion of glucocorticosteroids from the 
zona fasciculata of the adrenal cortex. The impact of hypothalamus-pituitary activity 
may include direct effects of adrenocorticotropic hormone on the GI tract, such as 
increased intestinal permeability, which has been observed in murine models of stress 
(Santos et al., 1999). In addition, increased sympathetic autonomic activity associated 
with stressful stimuli is associated with enhanced secretion of catecholamines, including 
adrenaline and noradrenaline, from the adrenal medulla. The combination of increased 
catecholamine secretion, and increased sympathetic outflow is postulated to impart pro-
inflammatory effects on the GI tract via stimulation of mast cells and macrophages, 
with inflammatory cytokines mediating these effects (Johnson et al., 2005). In contrast, 
the vagus nerve is thought to have a direct anti-inflammatory role, via cholinergic 
inhibition of pro-inflammatory cytokines (Matteoli and Boeckxstaens, 2013), but these 
parasympathetic responses are diminished during the stress response.  
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In addition to the involvement of neuroendocrine pathways, which may be 
enhanced by stressful stimuli, afferent sensory nerve fibres are involved in the 
propagation of painful stimuli in a gut to brain direction. The aetiology of visceral 
hypersensitivity is uncertain, but may involve abnormal enteric immune system 
activation in response to exposure to luminal bacterial LPS, arising secondary to 
increased colonic permeability, as described previously. In terms of response to visceral 
pain, perception is thought to involve the spinothalamic, spinoreticular and 
spinomesencephalic tracts (Drossman, 2004). Interestingly, the central co-ordinating 
centre for each of these pathways involves the limbic system, which also serves to 
mediate emotional responses, supporting the theory that psychological as well as 
physiological pathology contributes to the development of functional GI symptoms in 
IBS and IBD. This interaction between descending and ascending autonomic nerves, the 
enteric nervous system, neuroendocrine pathways, and the intestinal microbiome is 
referred to as the brain-gut axis (Jones et al., 2006b).  
Figure 1 provides an illustrative description of the proposed neuro-hormonal 
pathways involved in the brain-gut axis. 
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Figure 1: Proposed neurohormonal pathways of the brain-gut axis 
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It follows that psychological health, stress, anxiety and depression symptoms, 
and visceral hypersensitivity are inter-related and, therefore, that mood may influence 
the generation and perception of symptoms. Longitudinal follow-up studies have 
suggested that there is a higher risk of developing anxiety or depression in people 
without mood disorders who report GI symptoms compatible with IBS at baseline, but 
also an increased likelihood of asymptomatic people who demonstrate anxiety or 
depression at baseline developing GI symptoms de novo (Koloski et al., 2012). This bi-
directional effect of the brain-gut pathway seen in FGIDs raises the possibility that the 
relationship between brain and gut may also be bi-directional in IBD, and that co-
existent anxiety or depression, if unrecognised or untreated, may have a role in the 
generation of symptoms compatible with IBS in such patients.   
Evidence to support a bi-directional relationship between the brain and gut in 
IBD comes mainly from animal models. Mice with chronic GI inflammation develop 
behavioural changes akin to mood disorders in humans (Bercik et al., 2010). Studies 
have demonstrated that, in murine models of quiescent colitis, the induction of 
depression can reactivate inflammation of the colonic mucosa (Ghia et al., 2009), which 
can be attenuated by the administration of antidepressant drugs, and that this is 
mediated via interference with the inhibition of pro-inflammatory macrophage activity 
by the vagus nerve (Ghia et al., 2008). In humans, there is some evidence to suggest that 
acute psychological stress induces the production of pro-inflammatory cytokines in the 
serum and mucosa of patients with UC (Mawdsley et al., 2006). Small retrospective 
studies of the effect of psychological counselling or antidepressants have been 
conducted in patients with UC and CD acting as their own controls before and after the 
institution of these interventions, and have demonstrated fewer relapses of disease 
activity, less utilisation of glucocorticosteriods, and requirement for fewer endoscopic 
61 
 
 
 
investigations following their introduction (Goodhand et al., 2012a; Wahed et al., 
2010). In addition, in a recent study patients with IBD demonstrated an improvement in 
overall depression scores following the commencement of anti-TNFα or 
immunomodulator therapy for active disease (Horst et al., 2015). 
Figure 2 provides an illustrative description of the proposed factors that may 
contribute to the development of IBS-type symptoms, and the role of the brain-gut axis, 
in IBD. 
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Figure 2: Proposed aetiology of IBS-type symptoms in patients with IBD 
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1.2.4 Prevalence of IBS-type symptom-reporting in IBD, and deficits in current 
understanding of their aetiology  
A recent systematic review and meta-analysis, which pooled data from 13 cross-
sectional surveys and case-control studies, estimated that around one-in-three patients 
with UC, and almost half of patients with CD reported symptoms compatible with IBS 
(Halpin and Ford, 2012). When compared with healthy controls, the odds for reporting 
IBS-type symptoms in patients with IBD felt to be in clinical remission was 4.39 (95 % 
CI 2.24-8.61). However, 11 of the 13 studies included failed to utilise a quantitative 
measure of mucosal inflammation to define remission of disease activity prior to 
assessing for the presence of IBS-type symptoms. Thus, whether symptom-reporting in 
these studies was secondary to occult inflammatory activity, or the presence of genuine 
IBS-type symptoms is unknown. To complicate matters further, in the two studies that 
did seek to assess for mucosal inflammation (Berrill et al., 2013; Keohane et al., 2010), 
results were conflicting. In one cross-sectional survey of patients with IBD in clinical 
remission, significantly higher levels of FC were observed among those who reported 
symptoms compatible with IBS, compared with those without (Keohane et al., 2010). 
However, in another study of similar design (Berrill et al., 2013), there was no 
difference in median FC levels between those who reported IBS-type symptoms and 
those who did not, suggesting that subclinical inflammation was not the cause of IBS-
types symptoms in this cohort of patients.  
Since the publication of this systematic review and meta-analysis, two further 
studies have also addressed this issue, and reported that IBS-type symptom-reporting 
was not secondary to occult inflammatory activity (Jonefjall et al., 2013; Henriksen et 
al., 2018). However, in the majority of these studies, participant numbers were small, or 
were restricted to patients with UC only, and neither of these studies examined the 
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effect of IBS-type symptom-reporting on the natural history of IBD. Therefore, there 
remains a need for large-scale studies of the prevalence of IBS-type symptom-reporting 
in both UC and CD, where disease activity is assessed objectively, and where 
longitudinal follow-up is performed. These requirements provide the rationale for 
conducting the work that is presented in Chapters 4 and 6 of this thesis.  
 
1.3 The impact of mood in IBD 
 Psychological co-morbidity, including anxiety and depression, is common in 
patients with IBD, with observational studies reporting a prevalence of up to 35% 
(Neuendorf et al., 2016). The impact of these mood disorders in IBD may be several-
fold. Distinct from any potential adverse impact upon disease activity outcomes, it is 
proposed that the presence of psychological disease may affect adherence to medical 
therapy (Goodhand et al., 2013), and also impact the frequency of investigation 
requesting and clinic attendance, which may be ameliorated by the administration of 
antidepressants (Goodhand et al., 2012a). 
 The relationship between mood and disease activity in IBD is uncertain. Cross-
sectional studies alluding to an association between psychological co-morbidity and 
adverse disease activity outcomes fail to address the critical question regarding the 
temporal relationship between the two. As described earlier, interactions between 
psychological wellbeing and disease activity are likely to be mediated by brain-gut 
interactions that have the potential to act in a brain-to-gut direction, a gut-to-brain 
direction, or both. Evidence to support bi-directional relationships between mood and 
GI disorders is based on the findings of studies in patients with FGIDs (Koloski et al., 
2012; Koloski et al., 2016). Here, antecedent mood disorders in asymptomatic 
individuals were  associated with the development of subsequent GI symptoms, and GI 
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symptom-reporting was associated with the development of de novo psychological co-
morbidity over both short-term (Koloski et al., 2012), and long-term follow-up (Koloski 
et al., 2016). However, evidence to support a similar phenomenon in IBD is, to date, 
lacking.  
 
1.3.1 The impact of mood on disease activity in IBD 
 In a systematic review and meta-analysis of observational studies reporting the 
impact of psychological co-morbidity on disease outcomes in IBD, Alexakis et al. 
suggested that, when data were pooled from four longitudinal studies, including a total 
of 314 patients in clinical remission at baseline (Bitton et al., 2008; Bitton et al., 2003; 
Langhorst et al., 2013; Levenstein et al., 2000), depression was not associated with flare 
of disease activity during longitudinal follow-up (hazard ratio (HR) = 1.04, 95% CI 
0.97-1.12) (Alexakis et al., 2017). Although only four studies were included in formal 
meta-analysis, the authors identified an additional seven studies (North et al., 1991; 
Mittermaier et al., 2004; Mardini et al., 2004; Persoons et al., 2005; Mikocka-Walus et 
al., 2008; Camara et al., 2011; Mikocka-Walus et al., 2016), five of which reported a 
significant association between antecedent mood disorders and adverse longitudinal 
disease activity outcomes (Mittermaier et al., 2004; Mikocka-Walus et al., 2016; 
Persoons et al., 2005; Mardini et al., 2004; Camara et al., 2011). In addition to these, a 
large registry-based observational study, not included in the aforementioned systematic 
review, supports the assertion that psychological co-morbidity may negatively impact 
longitudinal disease activity outcomes (Gaines et al., 2016).  
A major limiting factor in the examination of the temporal relationship between 
mood disorders and longitudinal disease activity in all studies conducted to date is the 
lack of objective quantification of inflammatory activity. Of the 12 studies identified 
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above, nine described the impact of pre-existing psychological co-morbidity, including 
depression, anxiety, perceived stress, or a stressful life event on longitudinal disease 
outcomes using clinical disease activity indices as the sole determinant of disease 
activity (Mittermaier et al., 2004; Mikocka-Walus et al., 2016; Persoons et al., 2005; 
Gaines et al., 2016; Mardini et al., 2004; Bitton et al., 2008; Camara et al., 2011; 
Mikocka-Walus et al., 2008; North et al., 1991). The remaining three studies 
(Levenstein et al., 2000; Bitton et al., 2003; Langhorst et al., 2013) used a combination 
of clinical disease activity indices and endoscopic assessment to describe the 
longitudinal association between stress and depression over short-term follow-up in a 
combined study population of only 213 patients with UC.  
The lack of large observational studies where objective measures of 
inflammation are utilised to confirm remission of disease activity, and in which the 
impact of mood disorders on longitudinal disease activity outcomes is assessed, 
particularly in patients with CD, highlights the deficiencies in understanding of the 
temporal relationship between disease activity and psychological co-morbidity in IBD. 
Further longitudinal studies addressing these deficiencies are required to resolve this 
uncertainty.  
 
1.3.2 The impact of disease activity on mood in IBD 
Three longitudinal studies have sought to investigate gut-brain interactions in 
IBD (Panara et al., 2014; Lix et al., 2008; Porcelli et al., 1996). Of these, two (Panara et 
al., 2014; Porcelli et al., 1996) described a detrimental impact of antecedent disease 
activity on subsequent psychological wellbeing, with an increased incidence of new-
onset anxiety and depression during longitudinal follow-up ranging from 6 months to 8 
years. In the third study, the authors described an association between disease activity 
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and subsequent reduced quality of life, but no impact upon development of anxiety or 
depression (Lix et al., 2008). In combination, these data provide some evidence for the 
existence of gut-brain interactions in IBD. However, as previously described, inherent 
limitations in the design of these studies impacts the confidence with which these 
relationships can be accepted. Two of the three studies based their assessment of 
baseline disease activity on clinical measures only (Lix et al., 2008; Porcelli et al., 
1996), and the third used a retrospective case note review in order to determine the 
presence of inflammatory activity, and its impact on longitudinal outcomes (Panara et 
al., 2014). 
 
1.3.3 Bi-directional brain-gut interactions in IBD 
 Sexton et al. conducted a longitudinal follow-up study of 369 patients with IBD 
conducted over a period of 6 months (Sexton et al., 2017). Here, the authors described 
the relationship between perceived stress, symptom-reporting, and longitudinal disease 
activity using baseline and 3-monthly serial FC measurement. Following multivariate 
regression analysis to adjust for confounding variables, their results supported the 
existence of a bi-directional relationship between clinical disease activity and perceived 
stress in CD. However, no temporal relationship between inflammatory activity, as 
defined by FC levels, and perceived stress was identified. 
 
1.3.4 Brain-gut interactions in IBD: more questions than answers? 
 Despite the plethora of observational studies attempting to delineate brain-gut 
interactions in IBD, these relationships remain poorly defined. Flaws in the design of 
several of the previously published works limit the validity of the current evidence in 
this field. Addressing this deficiency in current understanding is important for several 
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reasons. Firstly, any potential association between psychological co-morbidity and 
subsequent adverse disease activity outcomes would prompt a review of the 
management of mood in IBD, particularly as evidence-based management strategies are, 
to date, lacking (Timmer et al., 2011; Mikocka-Walus et al., 2006; Macer et al., 2017; 
Knowles et al., 2013). Secondly, the identification of a bi-directional relationship 
between disease activity and psychological co-morbidity, which is known to adversely 
affect quality of life, would support the need for an integrated model of care combining 
simultaneous management of psychological health and inflammatory activity in patients 
with IBD.  
Thus, studies that deconstruct the mélange of potentially interconnected 
relationships between active mucosal inflammation, GI symptom-reporting, which may 
be secondary to genuine inflammatory activity, a co-existent FGID or somatoform 
behaviour, and psychological co-morbidity are required before the true relationship 
between mood and inflammatory activity in IBD can be confidently described. To 
address these deficiencies, a cross-sectional study independently assessing the 
association between inflammatory activity defined using FC, and clinical/symptomatic 
disease activity defined using clinical disease activity indices, with the presence of 
anxiety, depression, and somatisation was conducted, and is described in Chapter 3.  
Furthermore, a prospective longitudinal study assessing the temporal relationship 
between inflammatory activity, symptom-reporting, psychological co-morbidity, and 
longitudinal disease activity outcomes is required to further delineate potential bi-
directional relationships in IBD. These deficiencies will be addressed in the study 
described in Chapter 5. 
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1.4  Treatment of IBS-type symptoms and psychological co-morbidity in IBD 
In patients without IBD, a confirmed diagnosis of IBS is associated with more 
sickness-related absences from work than those without bowel symptoms (Drossman et 
al., 1993). IBS costs almost $1 billion in direct costs and another $50 million in indirect 
costs per year (Everhart and Ruhl, 2009). Furthermore, patients with IBS consume 
>50% more health care resources than matched controls without IBS (Inadomi et al., 
2003). All of these factors suggest that proactive treatment of IBS-type symptoms in 
IBD may also be required. In IBS, the evidence base for effective therapies has been 
summarised previously (Ford et al., 2014a). Soluble fibre, antispasmodics, 
antidepressants, psychological therapies, and probiotics all appear to be of some benefit 
(Moayyedi et al., 2014; Ford et al., 2014c; Ford et al., 2014b; Ford et al., 2008). As 
described previously, subclinical mucosal inflammation, an abnormal microbiome, and 
disordered brain-gut axis activity may be implicated in the development of IBS-type 
symptoms and psychological co-morbidity in IBD. Thus, the use of immunomodulators, 
probiotics, FMT, antidepressants, and psychological therapies may also be beneficial in 
the treatment of IBS-type symptoms in IBD. A summary of the current evidence base 
for the treatment of IBS-type symptoms and psychological co-morbidity in patients with 
IBD is described below. 
 
1.4.1 Conventional IBD treatment 
As described earlier, several RCTs investigating the effect of various 
medications, including glucocorticosteroids, 5-ASAs, immunomodulators, and 
biological therapies, have been conducted in IBD. However, end-points in these studies 
have focused exclusively on their effect on disease activity, largely using clinical 
disease activity indices. Although none of these studies has reported the efficacy of such 
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treatments on the management of IBS-type symptoms specifically, three RCTs of 
biological therapy have commented on the lack of efficacy of these treatments in 
symptomatic patients with IBD who did not have objective evidence of inflammatory 
activity at randomisation (Reinisch et al., 2012; Colombel et al., 2010; Schreiber et al., 
2005). These findings suggest that conventional medical treatments targeting disordered 
enteric immunity are not effective in the management of symptomatic patients in whom 
the inflammatory burden is limited, akin to the situation seen in patients reporting IBS-
type symptoms.  
The proposed pathophysiological mechanisms by which psychological co-
morbidity and inflammatory activity may be inter-related are discussed above. Mood 
disorders are associated with increased circulating pro-inflammatory cytokines and CRP 
(Howren et al., 2009), suggesting that treatment with immunosuppressants may impart 
beneficial effects on mood, independent of their effects on inflammatory activity. In 
IBD, prior observational studies of patients with CD and UC newly commenced on 
either anti-TNFα therapy or vedolizumab have demonstrated improved depression 
scores and better sleep following treatment (Horst et al., 2015; Stevens et al., 2017). 
Despite these findings being of interest, neither of these studies accounted for the 
potential confounding effect of glucocorticosteroid tapering on mood in their analyses, 
nor were there any data presented to suggest an additional benefit of these drugs on 
mood, other than that associated with an improvement in inflammatory activity. 
 
1.4.2 Manipulation of the intestinal microbiome 
The microbiome-gut-brain axis has been implicated in the development of 
disease activity and psychological co-morbidity. Manipulation of the intestinal 
microbiome is, therefore, an attractive target for therapeutic interventions in IBD.  
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Probiotics may be effective for the treatment of persistent GI symptoms (Ford et 
al., 2014c) and depression (Pinto-Sanchez et al., 2017) in IBS. Their use has also been 
examined in IBD in a recent systematic review and meta-analysis of RCTs (Derwa et 
al., 2017), where their efficacy in the treatment of active disease and maintenance of 
quiescent disease was limited. However, none of the RCTs included in this systematic 
review and meta-analysis sought to determine the effect of probiotics on either mood or 
IBS-type symptom-reporting in patients with IBD. In non-IBD populations, the effect of 
probiotics on mood has been studied in a meta-analysis of 10 RCTs (Ng et al., 2018a). 
Here, the authors concluded that there was a lack of evidence to support the use of 
probiotics in the treatment of depressive symptoms, and that the inclusion of studies of 
depressed and non-depressed populations in the same analyses, as well as the use of 
varying strains and treatment regimens of probiotic, limited the validity of their 
findings.    
FMT is an experimental intervention in IBD. Its use in the treatment of IBS-type 
symptoms in IBD has not been evaluated. However, in an observational study of FMT 
in patients with IBS, active treatment was associated with improved depression scores, 
which were observed in association with an improvement in faecal bacterial diversity, 
measured using the Shannon index (Kurokawa et al., 2018). Overall, there are a lack of 
controlled studies of FMT in both IBS and IBD to support its use outside the setting of 
clinical trials. Despite this, in the only RCT of FMT in IBS (Johnsen et al., 2018), there 
was a significant improvement in IBS symptom severity in patients treated with FMT, 
when compared with a placebo of the patient’s own faeces, at 3-month follow-up 
suggesting that further RCTs may be worthwhile.  
A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and 
polyols (FODMAP) is recommended for the treatment of IBS. FODMAPs are 
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osmotically active fermentable carbohydrates, the ingestion of which results in 
increased luminal water and gas volume (Staudacher et al., 2014), leading to the 
perception of pain, but only in selected patients with visceral hypersensitivity (Major et 
al., 2017). The low FODMAP diet is also associated with alterations in bacterial 
diversity, specifically the abundance of Bifidobacteria (Halmos et al., 2015). In a 
systematic review and meta-analysis of studies assessing the efficacy of a low 
FODMAP diet in the treatment of IBS, significant improvements in symptom severity 
and quality of life were associated with active treatment, when compared with a normal 
diet (Schumann et al., 2018). Only one of these studies assessed the impact of a low 
FODMAP diet on anxiety and depression, with no benefit observed. In three of the nine 
randomised trials included in this meta-analysis, the effect of a low FODMAP diet on 
the intestinal microbiome was assessed (McIntosh et al., 2017; Staudacher et al., 2012; 
Staudacher et al., 2017). A reduction in the abundance of Bifidobacteria was observed 
in association with an improvement in symptom severity after treatment. However, the 
reduction in Bifidobacteria abundance observed in patients on a low FODMAP diet 
appears to be able to be reversed by concomitant probiotic consumption, without 
attenuating the effect of the diet on IBS symptom severity, suggesting its effect may be 
independent of any associated alteration in Bifidobacteria abundance (Staudacher et al., 
2017). Although the effect of the low FODMAP diet on mood in IBS is uncertain, a 
RCT published since the aforementioned systematic review and meta-analysis, 
examined its effect on IBS symptom severity, psychological wellbeing, and quality of 
life. The authors reported a significant improvement in quality of life and anxiety 
scores, in addition to beneficial effects on IBS symptom severity, after 4 weeks of 
treatment (Eswaran et al., 2017).  
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The use of a low FODMAP diet in patients with IBD reporting IBS-type 
symptoms is, to date, poorly described. In a randomised controlled open-label trial of 89 
patients with IBD, who also fulfilled the Rome III criteria for IBS, participants were 
randomised to a low FODMAP or normal diet. The investigators reported higher rates 
of improvement in IBS-type symptom severity and quality of life in patients receiving 
the low FODMAP diet, when compared with those eating a normal diet (P = 0.02 and P 
<0.001, respectively) (Pedersen et al., 2017). In a further randomised, double blind, 
placebo controlled, cross-over, re-challenge trial of patients with IBD with functional 
symptoms who had previously responded to a low FODMAP diet, 32 participants were 
randomly allocated to a series of 3-day fermentable carbohydrate challenges, during 
which time symptom severity and stool output was assessed (Cox et al., 2017). Pain (P 
= 0.004), bloating (P = 0.002), flatulence (P = 0.004), and faecal urgency scores (P = 
0.014) were all significantly higher on day 3 of fructan challenge (FODMAP) compared 
with day 3 of glucose challenge (control). Although these studies, and other 
observational studies, investigating the relationship between FODMAPs and IBS-type 
symptom-reporting in patients with IBD (Maagaard et al., 2016; Gearry et al., 2009; 
Testa et al., 2018; Prince et al., 2016) highlight a potential role for the low FODMAP 
diet in their treatment, the lack of large-scale RCTs limits the applicability of these 
findings to clinical practice. Further RCTs investigating the efficacy of this intervention 
on symptom severity, quality of life, and psychological co-morbidity are required before 
its use can be advocated in IBD. 
 
1.4.3 Antidepressants 
The proposed mechanisms by which these drugs may impart beneficial effects in 
IBD are twofold. These include the induction of vagus nerve-mediated anti-
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inflammatory effects (Ghia et al., 2008), but also a potential direct effect on pro-
inflammatory cytokines that may arise via action of the NF-ĸB and nitric oxide 
pathways, which are both implicated in the aetiology of IBD (Rahimi et al., 2012).  
Tricyclic antidepressants and selective serotonin reuptake inhibitors are more 
effective than placebo in treating IBS (Ford et al., 2014b). However, their efficacy in 
IBD is less well-described. A systematic review of studies reporting the efficacy of 
antidepressant medications in the maintenance and induction of remission of IBD was 
published in 2006 (Mikocka-Walus et al., 2006). The review included six case reports, 
one non-randomised open-label study, and one letter that, collectively, reported 
beneficial effects of bupropion, paroxetine, amitriptyline, and phenelezine. However, 
the studies were small, and all except one was conducted in patients with CD. An 
updated systematic review, including an additional eight studies, has been conducted by 
the same authors (Macer et al., 2017). These studies were again largely retrospective 
and observational in design, with only one RCT involving a total of 35 patients included 
(Daghaghzadeh et al., 2015). Overall, a beneficial effect of antidepressants on disease 
activity was observed in 12 of 15 studies, and an improvement in depression and 
anxiety scores was reported in eight of nine studies reporting these outcomes. Despite 
this, the authors concluded that a lack of RCTs assessing the effect of these drugs on 
longitudinal disease outcomes, mood, and quality of life meant that estimating the 
efficacy of these drugs in IBD was not possible.  
Since the publication of this systematic review, an additional pilot RCT of 
fluoxetine in the treatment of IBD has been conducted (Mikocka-Walus et al., 2017). 
The authors reported that fluoxetine was not superior to placebo in the maintenance of 
disease remission, or treatment of psychological wellbeing, albeit in a small sample of 
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only 26 patients. As a result, the study was unlikely to be sufficiently powered to detect 
a difference in these outcomes.  
 Only one study has reported the efficacy of tricyclic antidepressants in patients 
with IBD reporting ongoing symptoms in the absence of objectively quantified 
inflammatory activity (Iskandar et al., 2014). It is important to point out that patients in 
this retrospective study were not screened formally using validated questionnaires to 
confirm whether or not they met symptom-based criteria for IBS. Despite this, 
outcomes, which were based on self-reported symptom severity using a Likert scale, 
appeared to be good, with at least a moderate improvement in 60% of patients with 
IBD, with a better response observed in patients with UC compared with CD. Symptom 
response in patients with IBD was similar to that observed in a control group of patients 
with IBS. 
 
1.4.4  Psychological therapy 
In addition to antidepressants, psychological therapies have also been shown to 
be beneficial in IBS (Ford et al., 2014c). These include cognitive behavioural therapy 
(CBT) and gut-directed hypnotherapy, both of which are recommended by national 
guidelines for the management of IBS (Ford et al., 2014a; Spiller et al., 2007). 
However, definitive evidence supporting the use of psychological therapies as an 
effective treatment in IBD, particularly in those reporting IBS-type symptoms is 
lacking, with only one study conducted, which recruited just 27 patients with IBS-type 
symptoms among a total study population of 66 (Berrill et al., 2014).  
A Cochrane review has investigated the efficacy of psychotherapy, patient 
education, and relaxation techniques in IBD (Timmer et al., 2011). Outcomes assessed 
included health-related quality of life, coping, emotional status, and disease activity. In 
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total 21 studies were included, but there was no clear benefit identified for any of the 
psychological interventions in adults with IBD, for any of the outcomes of interest. 
Another systematic review of 16 studies of psychological interventions, including stress 
management, psychodynamically informed therapy, CBT, and hypnosis assessed their 
effects on anxiety and depression, quality of life, and IBD activity. CBT and 
psychodynamically informed therapy appeared beneficial for anxiety and depression, 
but had no effect on disease activity, whereas hypnotherapy, used in two studies, 
demonstrated a beneficial effect on disease activity, but not anxiety, depression, or 
quality of life (Knowles et al., 2013). 
Since the publication of the Cochrane review by Timmer et al. in 2011, several 
additional RCTs of psychological therapies in IBD have been conducted (McCombie et 
al., 2016; Mikocka-Walus et al., 2015; Keefer et al., 2012; Schoultz et al., 2015; Jedel et 
al., 2014; Keefer et al., 2013; Berrill et al., 2014; Boye et al., 2011; Mizrahi et al., 2012; 
Vogelaar et al., 2011; Vogelaar et al., 2014). These individual studies have examined 
the effect of CBT, hypnotherapy, solution focussed therapy, and stress management on 
outcomes including disease activity, anxiety, depression, perceived stress, and quality of 
life.   
Five RCTs have studied the effect of CBT on disease activity, psychological 
wellbeing and quality of life  in patients with IBD (Keefer et al., 2012; Berrill et al., 
2014; Mikocka-Walus et al., 2015; Schoultz et al., 2015; McCombie et al., 2016). 
Overall, no beneficial effect on disease activity was observed in any of these studies. 
Positive effects on quality of life were reported in three studies (Keefer et al., 2012; 
McCombie et al., 2016; Mikocka-Walus et al., 2015), but with no effect over treatment 
as usual in the remaining two RCTs (Berrill et al., 2014; Schoultz et al., 2015). 
Similarly, evidence for the impact of these interventions on psychological wellbeing is 
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conflicting, with two studies reporting a benefit (Keefer et al., 2012; Schoultz et al., 
2015), but not the other three (Berrill et al., 2014; McCombie et al., 2016; Mikocka-
Walus et al., 2015).  
Only two RCTs have considered the effect of hypnotherapy on disease outcomes 
in IBD (Mizrahi et al., 2012; Keefer et al., 2013). Results were again conflicting with 
one study reporting a beneficial effect on psychological wellbeing and quality of life, 
but not disease activity (Mizrahi et al., 2012), and the other an increased likelihood of 
remaining in clinical remission, but no effect on quality of life or psychological factors 
(Keefer et al., 2013). Two RCTs, conducted by the same authors, have investigated the 
efficacy of solution focussed therapy in IBD (Vogelaar et al., 2011; Vogelaar et al., 
2014). These studies demonstrated a beneficial effect on fatigue and quality of life, but 
not disease activity or psychological wellbeing. Finally, two RCTs have investigated the 
use of stress management in the treatment of IBD (Boye et al., 2011; Jedel et al., 2014). 
These studies reported a beneficial effect on quality of life, but no effect on disease 
activity or psychological wellbeing.  
As described, a significant number of additional RCTs of psychological 
therapies have been conducted since the Cochrane review was performed in 2011 
(Timmer et al., 2011). In this study, the authors included quasi-randomised and non-
randomised studies in their analysis, thus limiting the quality and reliability of the data 
presented. Furthermore, a prospective study assessing patient attitudes towards 
treatment of mood disorders in IBD reported that psychological therapies were preferred 
to antidepressants, with 60% of patients with IBD receiving psychological therapy 
recommending its use, compared with a corresponding figure of 30% for patients 
treated with antidepressants (Mikocka-Walus and Andrews, 2016). Taken in 
combination, the methodological deficiencies of the previous meta-analysis, the 
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availability of new RCTs of psychological therapies in IBD, and the patient preference 
for psychological intervention ahead of antidepressant therapy in the treatment of mood 
disorders in IBD provides the rationale for conducting a methodologically robust, 
contemporaneous, systematic review and meta-analysis of RCTs of psychological 
therapies in IBD. Such a study would provide a summary of the current evidence base 
of the use of psychological therapies for the treatment of disease activity, psychological 
co-morbidity, and quality of life in IBD. It is for this reason that the systematic review 
and meta-analysis described in Chapter 7 was performed. 
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CHAPTER 2: Aims and objectives 
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The aims of this thesis are to explore the relationship between GI symptom-
reporting, including those symptoms meeting criteria for IBS, inflammatory activity, 
and psychological wellbeing and quality of life in patients with IBD, to describe the 
impact of these relationships on longitudinal disease activity outcomes, and to provide a 
summary of the efficacy of psychological therapies as a therapeutic intervention in IBD. 
These aims are addressed in the following pieces of work: 
 
2.1 Examining the relationship between clinical disease activity and mucosal 
inflammation, and the role of psychological co-morbidity, in IBD 
 The correlation between the presence of mucosal inflammation and GI 
symptom-reporting is poor (Targownik et al., 2015). Despite this, as previously 
described, traditional assessment of IBD activity is centred on the interpretation of 
patient-reported symptoms, with invasive endoscopic and radiological investigations 
performed in those where diagnostic uncertainty persists. Although the relationship 
between symptom-reporting and mucosal inflammation has been investigated 
previously, the association between psychological co-morbidity on symptom-reporting 
has not previously been studied in IBD. This deficiency was addressed by performing a 
cross-sectional study of secondary care patients with confirmed IBD, in which clinical 
disease activity indices, FC and psychological data were collected. The aim of this study 
was to describe the relationship between GI symptom-reporting and the presence of 
mucosal inflammation in IBD, and to assess whether the presence of psychological co-
morbidity including anxiety, depression, or somatisation influenced this relationship. 
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2.2 Assessing the relationship between the reporting of IBS-type symptoms, 
and psychological health and quality of life in patients with IBD 
 The reporting of IBS-type symptoms in patients with clinically quiescent IBD is 
as high as 35% (Halpin and Ford, 2012). The aetiology of these symptoms is uncertain, 
with some authors suggesting they arise secondary to occult inflammatory activity, and 
others disputing this. In IBD, the correlation between GI symptom-reporting and 
mucosal inflammation is poor. Thus, attributing GI symptoms to co-existent IBS is not 
possible without the use of an objective marker of intestinal inflammation. The presence 
of psychological co-morbidity including anxiety, depression, or somatisation, and 
reduced quality of life, is commonly observed in patients with IBS, highlighting the 
potential role of the brain-gut axis in the development of this clinical syndrome. 
Whether a similar association between IBS-type symptom-reporting, and the presence 
of psychological co-morbidity and reduced quality of life exists in IBD populations is 
uncertain. Previous investigators have attempted to describe this relationship. However, 
few of these have sought to quantify inflammatory activity before applying diagnostic 
criteria for IBS, and none have investigated the relationship between IBS-type 
symptom-reporting and somatoform behaviour. The aims of the study described in 
Chapter 4 were to provide an assessment of the prevalence of genuine IBS-type 
symptom-reporting in patients with CD and UC, and to assess the association between 
the presence of genuine IBS-type symptoms and anxiety, depression, somatisation, and 
quality of life. 
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2.3 Assessing the direction of brain-gut interactions in patients with IBD 
 The relationship between GI symptom-reporting and psychological co-morbidity 
in IBS is well-established, and appears to be bi-directional (Koloski et al., 2012; 
Koloski et al., 2016). In keeping with this, therapeutic interventions targeting disordered 
brain-gut activity are evidence based in IBS (Ford et al., 2014b). The prevalence of 
psychological co-morbidity in IBD is high, yet the impact of anxiety and depression on 
longitudinal disease activity outcomes remains uncertain. Previous authors have 
attempted to describe a temporal relationship between psychological factors and disease 
activity in IBD, but many are confounded by limitations including a reliance on 
symptom-reporting as the sole determinant of disease activity, a small sample size, 
exclusion of patients with CD, and a failure to assess whether any potential relationship 
between the brain and the gut in IBD may be bi-directional. Thus, the aim of Chapter 5 
was to simultaneously examine for the presence of both brain-to-gut and gut-to-brain 
interactions in a single study population of patients with IBD. In order to fulfil this aim, 
the association between anxiety or depression at study entry, in patients with quiescent 
disease at baseline, with subsequent disease activity outcomes, including flare of disease 
activity or need for glucocorticosteroid prescription, escalation of medical therapy, 
hospitalisation, and intestinal resection was investigated during longitudinal follow-up. 
Simultaneously, the association between baseline active disease, in patients with normal 
anxiety and depression scores at baseline, and the risk of developing subsequent anxiety 
or depression was also assessed longitudinally.  
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2.4 Describing the association between the reporting of IBS-type symptoms, 
and longitudinal disease activity, healthcare utilisation, psychological health, and 
quality of life in IBD                             
  Although the reporting of IBS-type symptoms occurs in up to 35% of patients 
with clinically quiescent IBD (Halpin and Ford, 2012), the association between the 
reporting of these symptoms and longitudinal disease outcomes has not been studied 
before. The association between IBS-type symptom-reporting, and the presence of 
psychological co-morbidity and poor quality of life is described in Chapter 4. When 
taken in conjunction with the association that psychological co-morbidity may have 
with adverse longitudinal disease activity outcomes described in Chapter 5, it is possible 
that the reporting of IBS-type symptoms in IBD may also be associated with a 
deleterious impact on longitudinal disease outcomes, particularly if these symptoms 
relate to occult disease activity, as some investigators have proposed (Keohane et al., 
2010; Vivinus-Nebot et al., 2014). A longitudinal follow-up study was therefore 
conducted with the aim of assessing disease activity outcomes including flare of disease 
activity or the need for glucorticosteroid prescription, escalation of medical therapy, 
hospitalisation or intestinal resection over a minimum follow-up period of 2 years. An 
additional aim of this study was to assess whether the association between IBS-type 
symptom-reporting and psychological co-morbidity and poor quality of life observed at 
baseline persisted over time, and to determine whether the reporting of these symptoms 
was associated with increased healthcare utilisation.  
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2.5 Summarising the effect of psychological therapies on disease activity, 
psychological co-morbidity, and quality of life in IBD 
 The association between psychological co-morbidity and adverse disease 
activity outcomes in IBD is discussed in Chapter 5. These issues potentially highlight 
the need for an integrated approach to the management of IBD, which incorporates the 
management of inflammatory activity with that of psychological wellbeing. 
Psychological therapy and antidepressants are evidence-based interventions in the 
management of other chronic GI disorders whose pathophysiology may also involve 
brain-gut axis dysregulation (Ford et al., 2014b). It follows that these interventions may 
also have beneficial effects in IBD. Indeed, the use of antidepressants in IBD was the 
subject of a recent systematic review which reported potential benefits for these drugs, 
but also highlighted that a lack of RCTs meant that their use could not be advocated 
strongly (Macer et al., 2017). In addition, the role of psychological therapies in IBD was 
the subject of a Cochrane systematic review and meta-analysis in 2011 (Timmer et al., 
2011). However, methodological weaknesses in this study, as well as the publication of 
several additional RCTs since 2011, means that its findings may be out-dated. An 
updated systematic review and meta-analysis was therefore conducted with the aim of 
providing a thorough and contemporaneous review of the role of psychological 
therapies in IBD, with a focus on their potential effects on disease activity, 
psychological co-morbidity, and quality of life.  
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CHAPTER 3: Examining the relationship between clinical 
disease activity and mucosal inflammation, and the role of 
psychological co-morbidity, in IBD 
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3.1 Introduction 
 Although considered primary GI disorders, CD and UC are associated with 
significant psychological co-morbidity. Anxiety or depression is reported to affect up to 
one-in-three patients with IBD (Tribbick et al., 2015; Walker et al., 2008; Fuller-
Thomson et al., 2015). Furthermore, recent observational data from longitudinal studies 
suggest that mood disorders, including anxiety and depression, may be associated with 
adverse disease outcomes and reduced quality of life (Kappelman et al., 2014). 
However, many studies designed to investigate these issues have used clinical disease 
activity indices to assess disease activity, rather than gold-standard investigations such 
as ileocolonoscopy or small bowel imaging, or faecal biomarkers of intestinal 
inflammation to assess disease activity. As a result, given that the correlation between 
these tools and objective measures of inflammation may be variable, (Falvey et al., 
2015; af Bjorkesten et al., 2012; Sipponen et al., 2008; Jones et al., 2008; Schoepfer et 
al., 2010) the implication of their results is uncertain. 
 Whether psychological co-morbidity affects clinical disease outcomes has 
important implications for clinical practice. A clearer understanding of whether 
psychological health is associated with increasing inflammatory burden, or just the 
reporting of functional symptoms attributable to the GI tract in general, may aid clinical 
decision-making, which is suboptimal when made on the basis of patient-reported 
symptoms alone (Derwa et al., 2018). In the former instance, this may dictate the need 
for escalation of conventional therapies, but in the latter situation where the aetiology of 
these symptoms is unclear, and where evidence suggests that the efficacy of these 
treatments is suboptimal, (Colombel et al., 2010; Schreiber et al., 2005; Reinisch et al., 
2012) other management strategies may be required. This is particularly relevant at the 
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present time, as the US Food and Drug Administration are moving towards PROMs as a 
measure of efficacy in clinical trials of novel therapies for IBD (Williet et al., 2014). 
A large cross-sectional study of patients with IBD was therefore conducted to 
attempt to resolve these uncertainties. Patient-reported clinical disease activity indices 
and FC, as measures of clinically active disease and mucosal inflammation respectively, 
and psychological data regarding anxiety, depression, and somatisation, were recorded. 
The hypothesis was that symptomatic disease activity would be associated with the 
presence of psychological co-morbidity, independent of inflammatory burden.   
 
3.2 Methods 
 
3.2.1 Participants and setting 
 Patients aged 16 and over, with an established radiological, histological, or 
endoscopic diagnosis of CD or UC attending the IBD clinic at St. James's University 
Hospital, Leeds, United Kingdom, a tertiary referral hospital serving a population of 
over 800,000 people were approached about the study. Included participants were both 
consecutive and unselected. Due to difficulty in assessing disease activity indices, 
patients with an end ileostomy or colostomy were excluded, as were those with a 
diagnosis of inflammatory bowel disease unclassified, isolated fistulising peri-anal CD, 
or any individual with an inability to understand written English. Prior to their 
consultation with a gastroenterologist, individuals were provided with an information 
sheet explaining the nature of the study. Those who agreed to take part gave written 
informed consent at this visit. The study received approval from the local research 
ethics committee in November 2012 (REC ref: 12/YH/0443), and data collection ceased 
in June 2015.  
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3.2.2 Data collection and synthesis 
 
3.2.2.1 Demographic data and disease characteristics  
Demographic data including gender, age, ethnicity, marital status, educational 
level, tobacco and alcohol use, weight (in kilograms), and height (in metres), which 
were used to calculate body mass index (BMI), were collected from all participants. 
Medication history, including current use of 5-ASAs, glucocorticosteroids, 
immunosuppressants, or anti-TNFα therapy, disease location or distribution, as defined 
by the Montreal classification (Silverberg et al., 2005), and any previous intestinal 
resection related to CD were also recorded.  
 
3.2.2.2 Assessment of patient-reported IBD activity and mucosal inflammation 
Patient-reported IBD activity was assessed using HBI for CD (Harvey and 
Bradshaw, 1980), and the SCCAI for UC (Walmsley et al., 1998), with a score ≥5 used 
to define clinically active disease for both, as previously recommended (Vermeire et al., 
2010; Jowett et al., 2003).  In addition, participants were asked to report whether, in 
their own opinion, they were attending with a flare of disease activity. Those who 
agreed to participate were asked to provide stool for quantitative FC analysis within 1 
week of inclusion, as an objective marker of mucosal inflammation. This has a reported 
sensitivity and specificity of 93.5% and 79.2% respectively for predicting mucosal 
inflammation identified at ileocolonoscopy (Loitsch et al., 2010). A cut off of ≥250µg/g 
of stool was used to define the presence of active disease, in line with the European 
Crohn’s and Colitis Organisation consensus on the use of FC to measure disease activity 
(Rogler et al., 2013), as other investigators have employed (Targownik et al., 2015; 
D'Haens et al., 2012; Lin et al., 2014). The FC level was measured using an enzyme-
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linked immunosorbent assay (ELISA) (Immundiagnostik AG, Bensheim, Germany), as 
per manufacturer’s instructions. Internal inter-assay coefficient of variation was 8.3% 
(low) to 9.4% (high). 
 
3.2.2.3 Reference standard used to define presence of IBS-type symptoms 
 IBS-type symptoms were assessed via the Rome III criteria (Longstreth et al., 
2006), according to the scoring algorithm incorporated within the Rome III diagnostic 
questionnaire for the adult FGIDs. IBS-type symptoms were defined as present when an 
individual reported abdominal discomfort or pain with a frequency of at least 2 or 3 
days per month over the last 3 months, with the onset of discomfort at least 6 months 
previously, associated with two or more of the following: an improvement of pain or 
discomfort with the passage of stool, more or less frequent bowel movements, or looser 
or firmer stools.  
 
3.2.2.4 Definition of anxiety or depression 
The presence of either anxiety or depression was assessed using the hospital 
anxiety and depression scale (HADS) (Zigmond and Snaith, 1983). This 14-item 
questionnaire consists of seven questions screening for the presence of anxiety 
symptoms, and seven for depression symptoms, with a 4-point response for each item, 
ranging from 0 to 3. The total possible score on the HADS ranges from a minimum of 0 
to a maximum of 21 for both anxiety and depression. Severity was categorised, 
according to total HADS score, into normal (total HADS depression or anxiety score 0-
7), borderline normal (8-10), and abnormal (≥11) (Zigmond and Snaith, 1983). 
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3.2.2.5 Definition of somatisation severity 
Somatisation data were collected using the patient health questionnaire-15 
(PHQ-15), which is derived from the validated full PHQ (Spitzer et al., 1999; Spitzer et 
al., 2000). This questionnaire enquires about the presence of 15 somatic symptoms (or 
symptom clusters) over the last 4 weeks, which are thought to contribute to >90% of 
physical complaints reported in the outpatient environment (Kroenke et al., 1990). Each 
individual was asked to rate the severity of each symptom as “not bothered at all” 
(scored as 0), “bothered a little” (scored as 1), or “bothered a lot” (scored as 2). The 
total PHQ-15 score ranges from a minimum of 0 to a maximum of 30. Somatisation 
severity was categorised, using the total PHQ-15 score, into high (total PHQ-15 ≥15), 
medium (10-14), low (5-9), and minimal (≤4) levels of somatisation severity (Kroenke 
et al., 2002). 
 
3.2.3 Statistical analysis 
 Demographic data, disease characteristics, medication use, presence or absence 
of symptoms meeting the Rome III criteria for IBS, disease activity indices, FC levels, 
and anxiety, depression, and somatisation data were compared between patients with 
CD and UC using a χ2 test for categorical variables and an independent samples t-test 
for continuous data. 
In order to assess the relationship between clinical disease activity indices, 
mucosal inflammation, IBS-type symptoms, and psychological factors, a comparison of 
baseline demographic and disease-related characteristics, the presence of symptoms 
fulfilling the Rome III criteria for IBS, the presence of a self-reported flare of disease 
activity, anxiety, depression, and somatisation scores, and the presence of anxiety, 
depression, or somatisation was conducted between patients with CD and UC 
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separately, and dichotomised into those with or without clinically active symptomatic 
disease, using a total HBI or SCCAI cut off of ≥5 for CD and UC respectively, or those 
with and without active mucosal inflammation, using a FC cut off of ≥250µg/g of stool. 
A χ2 test was used to compare categorical variables and an independent samples t-test 
for continuous data. Independent risk factors for clinically active symptomatic disease 
defined according to HBI or SCCAI, or active mucosal inflammation according to FC, 
were determined for all patients with CD and UC separately by performing multivariate 
logistic regression to control for all other demographic and disease-related 
characteristics, presence of symptoms fulfilling the Rome III criteria for IBS, the 
presence of a self-reported flare of disease activity, and anxiety, depression, and 
somatisation scores.  
The sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) of a total HBI or SCCAI score ≥5, and the individual symptom 
items included within each scoring system, as well as the presence of Rome III IBS-type 
symptoms, a self-reported flare of disease activity, abnormal HADS anxiety or 
depression scores, or high levels of somatisation were calculated in terms of predicting 
mucosal inflammation using a FC of ≥250µg/g, in order to assess the extent to which 
clinical disease activity indices, IBS symptoms, a self-reported flare of disease activity, 
and psychological co-morbidity were indicative of objective evidence of disease 
activity. 
Due to multiple comparisons, a 2-tailed P value of <0.01 was considered to be 
statistically significant for all analyses, and the results of multivariate logistic regression 
were expressed as odds ratios (ORs) with 99% confidence intervals (CIs). All statistical 
analyses were performed using SPSS for Windows version 22.0 (SPSS Inc., Chicago, 
IL, USA). 
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3.3 Results 
 In total, 356 (44.6%) of 799 patients who initially consented to participate had 
complete HBI or SCCAI, Rome III, HADS and PHQ-15 data, and returned a sample for 
FC analysis. Of these, 191 (53.7%) had confirmed CD and 165 (46.3%) UC. In terms of 
baseline demographic characteristics, patients with CD were significantly more likely to 
smoke, less likely to be prescribed 5-ASAs, more likely to be prescribed 
immunomodulator or anti-TNFα therapy, and fulfil Rome III criteria for IBS than 
patients with UC. There were no other statistically significant differences between those 
with CD and UC (Table 1). 
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Table 1: Characteristics of patients with CD and UC 
 Crohn’s disease 
(n = 191) 
Ulcerative colitis 
(n  = 165) 
P value* 
Mean age in years (SD) 46.7 (16.6) 51.2 (16.3) 0.01 
Female gender (%) 119 (62.3) 89 (53.9) 0.11 
Married or co-habiting (%) 118 (61.8) 119 (72.1) 0.04 
University/postgraduate (%) 50 (26.3) 48 (29.4) 0.51 
Mean BMI (SD) 26.3 (5.6) 27.1 (5.7) 0.20 
Tobacco user (%) 40 (20.9) 7 (4.2) <0.001 
Alcohol user (%) 121 (63.4) 110 (66.7) 0.51 
Crohn’s disease location (%) 
Ileal 
Colonic 
Ileocolonic 
 
43 (22.5) 
62 (32.5) 
86 (45.0) 
 
N/A† 
N/A† 
N/A† 
 
 
 
N/A† 
Crohn’s disease behaviour (%) 
Non-stricturing, non-penetrating 
Stricturing 
Penetrating 
 
163 (85.3) 
21 (13.1) 
7 (3.7) 
 
N/A† 
N/A† 
N/A† 
 
 
 
N/A† 
Perianal Crohn’s disease present (%) 16 (8.4) N/A† N/A† 
Ulcerative colitis extent (%) 
Proctitis 
Left sided 
Extensive 
 
N/A† 
N/A† 
N/A† 
 
45 (27.3) 
74 (44.8) 
46 (27.9) 
 
 
 
N/A† 
5-ASA use (%) 53 (27.7) 131 (79.4) <0.001 
Immunomodulator use (%) 88 (46.1) 34 (20.6) <0.001 
Anti-TNFα use (%) 52 (27.2) 4 (2.4) <0.001 
Glucocorticosteroid use (%) 21 (11.0) 17 (10.3) 0.83 
Previous intestinal resection (%) 62 (32.5) N/A† N/A† 
Rome III IBS criteria fulfilled (%) 86 (45.0) 49 (29.7) 0.003 
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Mean HBI/SCCAI (SD) 4.3 (3.5) 4.0 (3.2) N/A† 
HBI/SCCAI ≥5 (%) 69 (36.1) 66 (40.0) 0.45 
Self-reported flare (%) 42 (22.0) 51 (30.9) 0.06 
Mean FC (SD) 468 (777) 541 (922) 0.43 
FC ≥250µg/g (%) 73 (38.2) 65 (39.4) 0.82 
Mean HADS anxiety score (SD) 7.5 (4.6) 7.2 (4.9) 0.49 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
102 (53.4) 
39 (20.4) 
50 (26.2) 
 
93 (56.4) 
32 (19.4) 
40 (24.2) 
 
 
 
0.85 
Mean HADS depression score (SD) 5.0 (4.2) 4.7 (4.3) 0.49 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
139 (72.8) 
32 (16.8) 
20 (10.5) 
 
134 (81.2) 
11 (6.7) 
20 (12.1) 
 
 
 
0.01 
Mean PHQ-15 somatisation score (SD) 10.3 (4.7) 9.0 (5.2) 0.02 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
20 (10.5) 
64 (33.5) 
72 (37.7) 
35 (18.3) 
 
33 (20.0) 
49 (29.7) 
52 (31.5) 
31 (18.8) 
 
 
 
 
0.08 
*Independent samples t-test for continuous data, and χ2 for categorical data. 
†N/A; not applicable. 
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3.3.1 Characteristics of patients with IBD according to the presence or absence of 
clinically active disease 
 Of the 191 patients with CD, 69 (36.1%) had clinically active disease, with an 
HBI ≥5. These patients were more likely to have had a previous intestinal resection, 
fulfil Rome III criteria for IBS, self-report a flare of disease activity, and have higher 
mean HADS anxiety, HADS depression, and PHQ-15 scores, as well as higher anxiety, 
depression, and somatisation severity (Table 2). There was no difference in mean FC, or 
the proportion of patients with an elevated FC, between those with clinically active or 
quiescent disease.  
 Of the 165 patients with UC, 66 (40.0%) had clinically active disease. These 
participants were also more likely to self-report a flare of disease activity, have higher 
mean HADS anxiety, HADS depression, and PHQ-15 scores, and higher anxiety, 
depression, and somatisation severity. In patients with UC mean FC (857µg/g vs. 
333µg/g), and the proportion of patients with an elevated FC, were significantly higher 
in those with clinically active disease (Table 2). 
 After multivariate logistic regression, higher PHQ-15 scores were associated 
with clinically active disease in CD. Self-reported flare was associated with clinically 
active disease in UC (Table 3). 
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Table 2: Relationship between elevated patient-reported disease activity indices (HBI or SCCAI ≥5) and personal and disease 
characteristics in CD and UC 
 Crohn's disease (n = 191) Ulcerative colitis (n = 165) 
HBI <5 
(n = 122) 
HBI ≥5 
(n = 69) 
P value* SCCAI <5 
(n = 99) 
SCCAI ≥5 
(n = 66) 
P value* 
Mean age in years (SD) 46.5 (17.6) 47.1 (14.7) 0.82 53.4 (17.0) 47.9 (14.7) 0.03 
Female gender (%) 68 (55.7) 51 (73.9) 0.01 53 (53.5) 36 (54.5) 0.90 
Married or co-habiting (%) 74 (60.7) 44 (63.8) 0.67 75 (75.8) 44 (66.7) 0.20 
University/postgraduate (%) 36 (29.8) 14 (20.3) 0.15 29 (29.9) 19 (28.8) 0.88 
Mean BMI (SD) 25.8 (5.3) 27.2 (6.0) 0.12 26.5 (5.5) 28.0 (5.8) 0.10 
Tobacco user (%) 22 (18.0) 18 (26.1) 0.19 3 (3.0) 4 (6.1) 0.34 
Alcohol user (%) 79 (64.8) 42 (60.9) 0.59 68 (68.7) 42 (63.6) 0.50 
Crohn’s disease location (%) 
Ileal 
Colonic 
Ileocolonic 
 
20 (16.4) 
46 (37.7) 
56 (45.9) 
 
23 (33.3) 
16 (23.2) 
30 (43.5) 
 
 
 
0.01 
 
N/A† 
N/A† 
N/A† 
 
N/A† 
N/A† 
N/A† 
 
 
 
N/A† 
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Crohn’s disease behaviour (%) 
Non-stricturing, non-penetrating 
Structuring 
Penetrating 
 
110 (90.2) 
9 (7.4) 
3 (2.5) 
 
53 (76.8) 
12 (17.4) 
4 (5.8) 
 
 
 
0.04 
 
N/A† 
N/A† 
N/A† 
 
N/A† 
N/A† 
N/A† 
 
 
 
N/A† 
Perianal Crohn’s disease present (%) 9 (7.4) 7 (10.1) 0.51 N/A† N/A† N/A† 
Ulcerative colitis (%) 
Proctitis 
Left sided 
Extensive 
 
N/A† 
N/A† 
N/A† 
 
N/A† 
N/A† 
N/A† 
 
 
 
N/A† 
 
31 (31.3) 
42 (42.4) 
26 (26.3) 
 
14 (21.2) 
32 (48.5) 
20 (30.3) 
 
 
 
0.36 
5-ASA use (%) 36 (29.5) 17 (24.6) 0.47 79 (79.8) 52 (78.8) 0.88 
Immunomodulator use (%) 54 (44.3) 34 (49.3) 0.50 18 (18.2) 16 (24.2) 0.35 
Anti-TNFα use (%) 35 (28.7) 17 (24.6) 0.55 1 (1.0) 3 (4.5) 0.15 
Glucocorticosteroid use (%) 12 (9.8) 9 (13.0) 0.50 7 (7.1) 10 (15.2) 0.09 
Previous intestinal resection (%) 29 (23.8) 33 (47.8) 0.001 N/A† N/A† N/A† 
Rome III IBS criteria fulfilled (%) 38 (31.1) 48 (69.6) <0.001 22 (22.2) 27 (40.9) 0.01 
Self-reported flare (%) 18 (14.8) 24 (34.8) 0.001 16 (16.2) 35 (53.0) <0.001 
Mean FC (SD) 508 (885) 397 (535) 0.28 333 (556) 857 (1235) 0.002 
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FC ≥250µg/g (%) 45 (36.9) 28 (40.6) 0.61 31 (31.3) 34 (51.5) 0.009 
Mean HADS anxiety score (SD) 6.5 (4.4) 9.2 (4.5) <0.001 5.8 (4.2) 9.2 (5.2) <0.001 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
75 (61.5) 
25 (20.5) 
22 (18.0) 
 
27 (39.1) 
14 (20.3) 
28 (40.6) 
 
 
 
0.002 
 
64 (64.6) 
21 (21.2) 
14 (14.1) 
 
29 (43.9) 
11 (16.7) 
26 (39.4) 
 
 
 
0.001 
Mean HADS depression score (SD) 4.0 (3.7) 6.8 (4.3) <0.001 3.2 (3.0) 7.0 (5.1) <0.001 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
99 (81.1) 
16 (13.1) 
7 (5.7) 
 
40 (58.0) 
16 (23.2) 
13 (18.8) 
 
 
 
0.001 
 
91 (91.9) 
5 (5.1) 
3 (3.0) 
 
43 (65.2) 
6 (9.1) 
17 (25.8) 
 
 
 
<0.001 
Mean PHQ-15 somatisation score (SD) 8.6 (4.3) 13.4 (3.9) <0.001 7.2 (5.0) 11.8 (4.3) <0.001 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
20 (16.4) 
55 (45.1) 
35 (28.7) 
12 (9.8) 
 
0 (0.0) 
9 (13.0) 
37 (53.6) 
23 (33.3) 
 
 
 
 
<0.001 
 
31 (31.3) 
35 (35.4) 
25 (25.3) 
8 (8.1) 
 
2 (3.0) 
14 (21.2) 
27 (40.9) 
23 (34.8) 
 
 
 
 
<0.001 
*Independent samples t-test for continuous data, and χ2 for categorical data. †N/A; not applicable. 
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Table 3: Relationship between elevated patient-reported disease activity indices 
(HBI or SCCAI ≥5) and personal and disease characteristics in CD and UC after 
logistic regression 
 Crohn’s disease 
and HBI ≥5 
OR (99% CI) 
Ulcerative colitis 
and SCCAI ≥5 
OR (99% CI) 
Female gender 1.06 (0.34-3.32) 0.63 (0.17-2.35) 
Age (per year) 1.00 (0.97-1.04) 0.98 (0.95-1.02) 
Married or co-habiting 1.93 (0.64-5.78) 0.35 (0.09-1.28) 
University/postgraduate 1.33 (0.35-5.06) 0.66 (0.17-2.55) 
BMI (per unit) 1.05 (0.96-1.15) 1.04 (0.94-1.16) 
Tobacco use 1.34 (0.34-5.26) 3.95 (0.20-77.9) 
Alcohol use 1.23 (0.40-3.79) 1.70 (0.44-6.61) 
5-ASA use 0.79 (0.21-3.02) 1.13 (0.27-4.81) 
Immunomodulator use 1.35 (0.47-3.81) 1.74 (0.41-7.43) 
Anti-TNFα use 0.92 (0.28-3.04) 1.55 (0.04-66.0) 
Glucocorticosteroid use 1.13 (0.23-5.64) 0.80 (0.13-4.98) 
Previous intestinal resection 2.63 (0.86-8.06) N/A* 
Rome III IBS criteria fulfilled 2.46 (0.86-7.03) 1.25 (0.32-4.85) 
Self-reported flare 1.21 (0.36-4.03) 4.83 (1.37-17.1) 
FC ≥250µg/g 1.77 (0.58-5.39) 3.11 (0.94-10.3) 
Anxiety (per 1-point change on HADS anxiety score) 0.95 (0.81-1.11) 0.94 (0.77-1.13) 
Depression (per 1-point  change on HADS depression score) 1.04 (0.86-1.25) 1.21 (0.97-1.52) 
Somatisation (per 1-point change on PHQ-15 score) 1.31 (1.08-1.60) 1.17 (0.97-1.52) 
*N/A; not applicable 
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3.3.2 Characteristics of patients with IBD according to presence or absence of 
mucosal inflammation 
 In total, 73 (38.2%) patients with CD and 65 (39.4%) with UC were classified as 
having evidence of mucosal inflammation, with an FC ≥250µg/g. Patients with UC with 
mucosal inflammation had higher mean SCCAI scores, and a greater proportion of 
patients had clinically active disease, with an SCCAI ≥5. There were no other 
differences in baseline demographics, disease characteristics, or the prevalence of 
psychological co-morbidity between those with and without mucosal inflammation in 
either CD or UC (Table 4). 
 After multivariate logistic regression, higher somatisation scores (per 1-point 
increase in total PHQ-15 score) were negatively associated with mucosal inflammation 
in CD, and clinically active disease, with an SCCAI ≥5, was positively associated with 
mucosal inflammation in UC (Table 5). 
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Table 4: Relationship between elevated FC ≥250 µg/g and personal and disease characteristics in CD and UC 
 Crohn's disease (n = 191) Ulcerative colitis (n = 165) 
FC <250µg/g 
(n = 118) 
FC ≥250µg/g 
(n = 73) 
P value* FC <250µg/g 
(n = 100) 
FC ≥250µg/g 
(n = 65) 
P value* 
Mean age in years (SD) 45.0 (15.6) 49.5 (17.8) 0.07 51.4 (16.0) 51.0 (17.0) 0.90 
Female gender (%) 70 (59.3) 49 (67.1) 0.28 58 (58.0) 31 (47.7) 0.19 
Married or co-habiting (%) 71 (60.2) 47 (64.4) 0.56 71 (71.0) 48 (73.8) 0.69 
University/postgraduate (%) 33 (28.0) 17 (23.6) 0.51 29 (29.0) 19 (30.2) 0.87 
Mean BMI (SD) 25.9 (5.6) 27.0 (5.5) 0.19 26.4 (5.1) 28.2 (6.4) 0.06 
Tobacco user (%) 25 (21.2) 15 (20.5) 0.92 3 (3.0) 4 (6.2) 0.33 
Alcohol user (%) 77 (65.3) 44 (60.3) 0.49 70 (70.0) 40 (61.5) 0.26 
Crohn's disease location (%) 
Ileal 
Colonic 
Ileocolonic 
 
22 (18.6) 
44 (37.3) 
52 (44.1) 
 
21 (28.8) 
18 (24.7) 
34 (46.6) 
 
 
 
0.12 
 
N/A† 
N/A† 
N/A† 
 
N/A† 
N/A† 
N/A† 
 
 
 
N/A† 
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Crohn’s disease behaviour (%) 
Non-stricturing, non-penetrating 
Stricturing 
Penetrating 
 
103 (87.3) 
9 (7.6) 
6 (5.1) 
 
60 (82.2) 
12 (16.4) 
1 (1.4) 
 
 
 
0.08 
 
N/A† 
N/A† 
N/A† 
 
N/A† 
N/A† 
N/A† 
 
 
 
N/A† 
Perianal Crohn’s disease present (%) 10 (8.5) 6 (8.2) 0.95 N/A† N/A† N/A† 
Ulcerative colitis extent (%) 
Proctitis 
Left sided 
Extensive 
 
N/A† 
N/A† 
N/A† 
 
N/A† 
N/A† 
N/A† 
 
 
 
N/A† 
 
27 (27.0) 
48 (48.0) 
25 (25.0) 
 
18 (27.7) 
26 (40.0) 
21 (32.3) 
 
 
 
0.52 
5-ASA use (%) 37 (31.4) 16 (21.9) 0.16 81 (81.0) 50 (76.9) 0.53 
Immunomodulator use (%) 59 (50.0) 29 (39.7) 0.17 21 (21.0) 13 (20.0) 0.88 
Anti-TNFα use (%) 39 (33.1) 13 (17.8) 0.02 3 (3.0) 1 (1.5) 0.55 
Glucocorticosteroid use (%) 10 (8.5) 11 (15.1) 0.16 9 (9.0) 8 (12.3) 0.50 
Previous intestinal resection (%) 40 (33.9) 22 (30.1) 0.59 N/A† N/A† N/A† 
Rome III IBS criteria fulfilled (%) 54 (45.8) 32 (43.8) 0.80 33 (33.0) 16 (24.6) 0.25 
Mean HBI/SCCAI (SD) 4.1 (3.5) 4.5 (3.6) 0.54 3.3 (2.7) 4.9 (3.6) 0.003 
HBI/SCCAI ≥5 (%) 41 (34.7) 28 (38.4) 0.61 32 (32.0) 34 (52.3) 0.009 
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Self-reported flare (%) 24 (20.3) 18 (24.7) 0.48 25 (25.0) 26 (40.0) 0.04 
Mean HADS anxiety score (SD) 7.5 (4.8) 7.5 (4.4) 0.91 7.5 (5.2) 6.6 (4.5) 0.24 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
62 (52.5) 
24 (20.3) 
32 (27.1) 
 
40 (54.8) 
15 (20.5) 
18 (24.7) 
 
 
 
0.93 
 
54 (54.0) 
19 (19.0) 
27 (27.0) 
 
39 (60.0) 
13 (20.0) 
13 (20.0) 
 
 
 
0.59 
Mean HADS depression score (SD) 4.8 (4.0) 5.4 (4.4) 0.30 4.8 (4.6) 4.6 (3.9) 0.83 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
88 (74.6) 
20 (16.9) 
10 (8.5) 
 
51 (69.9) 
12 (16.4) 
10 (13.7) 
 
 
 
0.52 
 
81 (81.0) 
7 (7.0) 
12 (12.0) 
 
53 (81.5) 
4 (6.2) 
8 (12.3) 
 
 
 
0.98 
Mean PHQ-15 somatisation score (SD) 10.6 (5.0) 10.0 (4.2) 0.40 9.1 (5.4) 8.9 (4.9) 0.78 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
15 (12.7) 
35 (29.7) 
42 (35.6) 
26 (22.0) 
 
5 (6.8) 
29 (39.7) 
30 (41.1) 
9 (12.3) 
 
 
 
 
0.14 
 
20 (20.0) 
29 (29.0) 
30 (30.0) 
21 (21.0) 
 
13 (20.0) 
20 (30.8) 
22 (33.8) 
10 (15.4) 
 
 
 
 
0.83 
*Independent samples t-test for continuous data, and χ2 for categorical data. †N/A; not applicable.
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Table 5: Relationship between FC≥250 µg/g and personal and disease 
characteristics in CD and UC after logistic regression 
 Crohn's disease 
and FC ≥250µg/g 
OR (99%CI) 
Ulcerative colitis 
and FC ≥250µg/g 
OR (99%CI) 
Female gender 1.81 (0.68-4.84) 0.62 (0.21-1.85) 
Age (per year) 1.01 (0.98-1.04) 0.99 (0.95-1.02) 
Married or co-habiting 0.89 (0.35-2.26) 1.34 (0.44-4.06) 
University/postgraduate 0.85 (0.28-2.56) 1.13 (0.35-3.68) 
BMI (per unit) 1.04 (0.96-1.13) 1.05 (0.96-1.15) 
Tobacco use 1.01 (0.29-3.44) 1.63 (0.12-22.4) 
Alcohol use 0.98 (0.37-2.57) 0.43 (0.14-1.30) 
5-ASA use 0.38 (0.12-1.17) 0.67 (0.20-2.23) 
Immunomodulator use 0.49 (0.19-1.26) 0.90 (0.27–2.99) 
Anti-TNFα use 0.56 (0.19-1.67) 0.32 (0.008-12.5) 
Glucocorticosteroid use 2.75 (0.60-12.6) 0.78 (0.15-4.04) 
Previous intestinal resection 0.70 (0.25-1.92) N/A* 
Rome III IBS criteria fulfilled 1.11 (0.42-2.94) 0.69 (0.20-2.38) 
Self-reported flare 1.87 (0.59-5.86) 1.86 (0.57-6.06) 
HBI/SCCAI ≥5 1.69 (0.58-4.95) 3.36 (1.00-11.3) 
Anxiety (per 1-point change on HADS anxiety score) 1.00 (0.87-1.16) 0.95 (0.81-1.12) 
Depression (per 1-point change on HADS depression 
score) 
1.10 (0.94-1.29) 0.97 (0.80-1.18) 
Somatisation (per 1-point change on PHQ-15 score) 0.85 (0.73-0.997) 0.97 (0.84-1.12) 
*N/A; not applicable 
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3.3.3 Performance of HBI, self-reported flare, Rome III criteria, and 
psychological factors in predicting mucosal inflammation in CD 
 The sensitivity, specificity, PPV, and NPV of the individual symptom items of 
the HBI, an HBI ≥5, presence of the Rome III criteria for IBS, self-report of a flare of 
disease activity, and presence of anxiety, depression, or somatisation in predicting 
mucosal inflammation in CD are reported in Table 6. Although the individual HBI 
symptom items demonstrated good specificity generally, ranging between 66.1% for ≥3 
stools per day and 97.5% for the presence of abdominal mass, the corresponding 
sensitivity scores were poor (4.1% to 34.2%). As a result, the PPV of these, and total 
HBI score ≥5, was generally poor, between 35.9% and 50.0%. Reporting symptoms 
compatible with Rome III-defined IBS, a self-reported flare, and the presence of anxiety 
or depression were no worse than either the individual symptoms items of the HBI, or a 
total HBI score ≥5, at predicting mucosal inflammation.  
 
3.3.4 Performance of SCCAI, self-reported flare, Rome III criteria, and 
psychological factors in predicting mucosal inflammation in UC 
 In patients with UC the performance of the SCCAI was broadly similar to self-
reported flare at predicting mucosal inflammation, with increasing daytime or nocturnal 
stool frequency the most specific symptom items, and urgency the most sensitive (Table 
7). In terms of the PPV, the Rome III criteria were inferior to both SCCAI and self-
reported flare at predicting mucosal inflammation, although the 95% CIs overlapped, as 
were the presence of abnormal HADS anxiety, abnormal HADS depression, or high 
somatisation severity.  
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Table 6: Sensitivity, specificity, positive, and negative predictive values of patient-reported clinical disease activity indices, self-reported 
flare of disease activity, Rome III criteria for IBS, and psychological factors in predicting mucosal inflammation in CD 
 FC ≥250 
(n = 73) 
FC <250 
(n = 118) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95%CI) 
NPV 
(95% CI) 
Poor or very poor general health (%) 18 (24.7) 26 (22.0) 24.7 
(15.6-36.4) 
78.0 
(69.2-84.9) 
40.9 
(26.7-56.7) 
62.6 
(54.2-70.3) 
Moderate or severe abdominal pain (%) 15 (20.5) 24 (20.3) 20.5 
(12.3-31.9) 
79.7 
(71.1-86.3) 
38.5 
(23.8-55.3) 
61.8 
(53.6-69.5) 
≥3 stools/day (%) 25 (34.2) 40 (33.9) 34.2 
(23.8-46.4) 
66.1 
(56.7-74.4) 
38.5 
(26.9-51.4) 
61.9 
(52.8-70.3) 
Abdominal mass (%) 3 (4.1) 3 (2.5) 4.1 
(1.1-12.3) 
97.5 
(92.2-99.3) 
50.0 
(14.0-86.1) 
62.2 
(54.7-69.1) 
≥1 associated condition (%) 14 (19.2) 25 (21.2) 19.2 
(11.3-30.4) 
78.8 
(70.1-85.6) 
35.9 
(21.7-52.9) 
61.2 
(52.9-68.9) 
≥2 associated conditions (%) 3 (4.1) 4 (3.4) 4.1 
(1.1-12.3) 
96.6 
(91.0-98.9) 
42.9 
(11.8-79.8) 
62.0 
(54.5-68.9) 
  
 
 
1
0
7
 
HBI ≥5 (%) 28 (38.4) 41 (34.7) 38.4 
(27.4-50.5) 
65.3 
(55.9-73.6) 
40.6 
(29.1-53.1) 
63.1 
(53.9-71.5) 
Rome III IBS criteria fulfilled (%) 
 
32 (43.8) 54 (45.8) 43.8 
(32.4-55.9) 
54.2 
(44.8-63.4) 
37.2 
(27.2-48.4) 
61.0 
(50.9-70.2) 
Self-reported flare (%)  18 (24.7) 24 (20.3) 24.7 
(15.6-36.4) 
79.7 
(71.1-86.3) 
42.9 
(28.1-58.9) 
63.1 
(54.8-70.7) 
Abnormal HADS anxiety score (%) 18 (24.7) 32 (27.1) 24.7 
(15.6-36.4) 
72.9 
(63.8-80.5) 
50.0 
(23.3-50.9) 
61.0 
(52.4-69.0) 
Abnormal HADS depression score (%) 10 (13.7) 10 (8.5) 13.7 
(7.1-24.2) 
91.5 
(84.6-95.6) 
50.0 
(27.9-72.2) 
63.2 
(55.4-70.3) 
High PHQ-15 somatisation severity (%) 9 (12.3) 26 (22.0) 12.3 
(6.1-22.6) 
78.0 
(69.2-84.9) 
25.7 
(13.1-43.6) 
59.0 
(50.8-66.7) 
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Table 7: Sensitivity, specificity, positive, and negative predictive values of patient-reported clinical disease activity indices, self-reported 
flare of disease activity, Rome III criteria for IBS, and psychological factors in predicting mucosal inflammation in UC 
 FC ≥250 
(n = 65) 
FC<250 
(n = 100) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95%CI) 
NPV 
(95% CI) 
≥4 stools/day (%) 31 (47.7) 21 (21.0) 47.7 
(35.3-60.4) 
79.0 
(69.5-86.3) 
59.6 
(45.1-72.7) 
69.9 
(60.5-78.0) 
≥7 stools/day (%) 11 (16.9) 6 (6.0) 16.9 
(9.1-28.7) 
94.0 
(86.9-97.5) 
64.7 
(38.6-84.7) 
63.5 
(55.2-71.2) 
≥1 stool/night (%) 29 (44.6) 22 (22.0) 44.6 
(32.5-57.4) 
78.0 
(68.4-85.4) 
56.9 
(42.3-70.4) 
68.4 
(59.0-76.6) 
≥4 stools/night (%) 2 (3.1) 3 (3.0) 3.1 
(0.5-11.7) 
97.0 
(90.9-99.2) 
40.0 
(7.3-83.0) 
60.6 
(52.6-68.2) 
Any degree of urgency (%) 51 (78.5) 63 (63.0) 78.5 
(66.2-87.3) 
37.0 
(27.7-47.3) 
44.7 
(35.5-54.3) 
72.6 
(58.0-83.7) 
Rectal bleeding (%) 39 (60.0) 52 (52.0) 60.0 
(47.1-71.7) 
48.0 
(38.0-58.2) 
42.9 
(32.7-53.7) 
64.9 
(52.8-75.4) 
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Poor general wellbeing or worse (%) 11 (16.9) 12 (12.0) 16.9 
(9.1-28.7) 
88.0 
(79.6-93.4) 
47.8 
(27.4-68.9) 
62.0 
(53.4-69.9) 
≥1 associated condition (%) 8 (12.3) 13 (13.0) 12.3 
(5.8-23.4) 
87.0 
(78.4-92.6) 
38.1 
(19.0-61.3) 
60.4 
(51.9-68.4) 
≥2 associated conditions (%) 0 (0.0) 3 (3.0) Unable to  
estimate 
97.0 
(90.9-99.2) 
Unable to  
estimate 
59.9 
(51.9-67.4) 
SCCAI ≥5 (%) 34 (52.3) 32 (32.0) 52.3 
(39.7-64.7) 
68.0 
(57.8-76.8) 
51.5 
(39.0-63.9) 
68.7 
(58.5-77.4) 
Rome III IBS criteria fulfilled (%) 16 (24.6) 33 (33.0) 24.6 
(15.1-37.1) 
67.0 
(56.8-75.9) 
32.7 
(20.4-47.7) 
57.8 
(48.2-66.8) 
Self-reported flare (%) 26 (40.0) 25 (25.0) 40.0 
(28.3-52.9) 
75.0 
(65.2-82.9) 
51.0 
(36.8-65.1) 
65.8 
(56.2-74.3) 
Abnormal HADS anxiety score (%) 13 (20.0) 27 (27.0) 20.0 
(11.5-32.1) 
73.0 
(63.0-81.2) 
32.5 
(19.1-49.2) 
58.4 
(49.2-67.0) 
Abnormal HADS depression score (%) 8 (12.3) 12 (12.0) 12.3 
(5.8-23.4) 
88.0 
(79.6-93.4) 
40.0 
(20.0-63.6) 
60.7 
(52.2-68.6) 
High PHQ-15 somatisation severity (%) 10 (15.4) 21 (21.0) 15.4 
(8.0-26.9) 
79.0 
(69.5-86.3) 
32.3 
(17.3-51.5) 
59.0 
(50.1-67.3) 
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3.4  Discussion 
 These results have demonstrated that patient-reported clinical disease activity 
indices are only modest predictors of mucosal inflammation in UC, and do not predict 
mucosal inflammation in CD. In addition, these activity indices were no more accurate 
in predicting mucosal inflammation than patient self-report of a flare of disease activity. 
In univariate analysis, more severe psychological co-morbidity was observed in 
clinically active IBD, but was not significantly associated with the presence of mucosal 
inflammation. The individual symptom items that make up the HBI performed 
suboptimally when used to predict intestinal inflammation, with reasonable specificity, 
but low sensitivity, and poor PPVs. In UC, urgency or rectal bleeding were the most 
sensitive, and high daytime or nocturnal stool frequency the most specific items of the 
SCCAI, although PPVs for predicting mucosal inflammation were still modest.  
 Strengths of this study include the large, well-characterised group of 
consecutive, unselected patients with IBD who provided complete patient-reported 
clinical data, and the use of FC as an objective measure of intestinal inflammation. 
Patients were recruited from a secondary care population, thereby increasing the 
generalisability of these findings to usual clinical practice. The use of validated 
questionnaires for the assessment of symptomatic disease activity in CD and UC 
(Walmsley et al., 1998; Harvey and Bradshaw, 1980), IBS symptoms (Longstreth et al., 
2006; Ford et al., 2013), anxiety and depression (Zigmond and Snaith, 1983), and 
somatisation (Spitzer et al., 1999; Spitzer et al., 2000) is another strength. Specifically, 
the HADS is a measure of anxiety and depression symptoms that is widely used in 
clinical research. Its major strength over other measures of depression including the 
Beck depression inventory is its ease of administration and length, particularly in a 
questionnaire study such as this where responder fatigue may influence the rate of 
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missing data. However, the use of HADS has been criticised by some, as it may fail to 
capture somatic symptoms of depression that could be identified using other measures 
of depression such as the PHQ-9. Accepting this deficiency, a further strength of this 
study was that PHQ-15 somatisation data were collected to address this potential 
shortcoming directly.  
 Although FC was used as an objective measure of mucosal inflammation, a 
weakness is that, due to the observational nature of this study, with recruitment taking 
place alongside usual clinical care, gold-standard investigations for the assessment of 
disease activity, including ileocolonoscopy, histological assessment of ileal and colonic 
mucosal biopsies, and small bowel imaging were not undertaken. The use of a FC cut 
off value of ≥250µg/g of stool to define the presence of active inflammation, although 
supported by previous authors and an international consensus statement (Targownik et 
al., 2015; Rogler et al., 2013; D'Haens et al., 2012; Lin et al., 2014), may be criticised 
by some. In addition, although FC is thought to be representative of endoscopic disease 
activity indices (D'Haens et al., 2012), its utility as a marker of active small bowel 
inflammation in CD is uncertain, with one study assessing its correlation with magnetic 
resonance enterography suggesting equivalence (Cerrillo et al., 2015), another 
supporting its use, but proposing greater accuracy when used to identify colonic over 
small bowel inflammation (Stawczyk-Eder et al., 2015), and a third reporting poor 
correlation with video capsule endoscopy in the identification of significant small bowel 
inflammation (Kopylov et al., 2015). 
Also of note is that a greater proportion of patients with CD with a total HBI 
score ≥5 had isolated small bowel disease than those who did not, suggesting that 
disease location may influence the generation of symptoms or, given that there was no 
association between this variable and biochemical disease activity, that FC 
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underestimates small bowel inflammatory burden. Furthermore, in the absence of 
radiological assessment of the small bowel, it may be that hitherto undiagnosed 
fibrostenotic small bowel disease contributed to the development of symptoms in 
patients with small bowel disease. In clinical practice, this may then be falsely attributed 
to functional disease on the basis of a normal FC. To address these potential 
confounding factors directly, a sensitivity analysis in which the 43 patients isolated ileal 
Crohn’s disease were excluded, was conducted. There remained no significant 
difference in the proportion of patients with, and without clinically active CD with 
evidence of mucosal inflammation defined by FC ≥250µg/g (17 (46%) of 46 vs. 35 
(34.3%) of 102, P = 0.76), and no significant association between those with and 
without clinical disease activity and mean FC (407µg/g vs. 505µg/g, P = 0.51), 
reinforcing the lack of association between total HBI scores and mucosal inflammation 
in ileocolonic and colonic CD.  
 Both IBS-type symptoms and a history of previous intestinal resection were 
associated with symptomatically active CD. Although IBS-type symptoms in patients 
with no evidence of mucosal inflammation could be considered to be due to genuine co-
existent functional symptoms, previous intestinal resection may be associated with 
alternative, non-inflammatory, organic diagnoses such as SIBO or BAM (Gracie et al., 
2012; Greco et al., 2015). This may have led to an overestimate of the prevalence of 
functional symptoms in this subgroup of patients.  
 Several studies have assessed the diagnostic accuracy of patient-reported clinical 
disease activity indices at predicting inflammatory burden in IBD (af Bjorkesten et al., 
2012; Sipponen et al., 2008; Jones et al., 2008; Schoepfer et al., 2010), however few 
have attempted to delineate the relationship between symptoms, inflammation, and their 
relationship with psychological wellbeing. Most recently, Targownik et al. assessed the 
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utility of the HBI, Powell-Tuck Index, and Manitoba IBD Index at predicting active 
IBD using a FC cut off of ≥250 µg/g of stool in 478 patients with IBD, and the 
association between symptoms, inflammatory burden, and perceived stress (Targownik 
et al., 2015). In keeping with the findings described here, there was no association 
between patient-reported clinical disease activity and mucosal inflammation in CD, and 
only a modest relationship between the two in UC. In addition, perceived stress was 
associated with clinically active disease, but not active mucosal inflammation. 
Goodhand et al. described the relationship between disease activity, depression, anxiety, 
and perceived stress in 103 UC and 101 patients with CD, compared with 124 healthy 
volunteers (Goodhand et al., 2012b). In this study, mean anxiety and depression scores 
were higher in both patients with CD and UC, and active inflammation was associated 
with depression, but not anxiety, in UC. Another study conducted among 162 patients 
with IBD examined the association between active disease, the presence of co-existent 
FGIDs, mood disorders, and quality of life using validated questionnaires (Bryant et al., 
2011). The authors reported significantly higher depression scores and lower quality of 
life scores in those with symptoms compatible with a co-existent FGID, regardless of 
the presence of active inflammatory disease. Although these studies reported the 
relationship between psychological health, mucosal inflammation, and IBD-related 
symptoms (Targownik et al., 2015; Goodhand et al., 2012b), or the relationship between 
physician's global assessment of disease activity, functional symptoms, and  
psychological co-morbidity (Bryant et al., 2011), they did not incorporate all of these in 
a large single cohort of patients as has been described here.  
This study has important clinical implications, as the data suggest that patient-
reported symptoms in IBD are associated with significant psychological co-morbidity, 
with abnormal HADS anxiety scores observed in roughly 40% of all patients with IBD 
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with clinical disease activity indices ≥5, and abnormal HADS depression scores in one-
in-four patients with UC with a SCCAI ≥5. The association between somatisation and 
clinically active IBD, but not mucosal inflammation, suggests that the reporting of the 
symptom items that make up these clinical disease activity indices may be due to 
somatoform-type behaviour or co-existent functional disease in a subset of patients, 
rather than being secondary to genuine mucosal inflammation or extra-intestinal 
manifestations of IBD. Furthermore, the lack of any association between psychological 
co-morbidity and inflammatory activity casts doubt on a role of the brain-gut axis in the 
pathogenesis of IBD, which has been championed by some. This emphasises the 
importance of conducting prospective, longitudinal studies examining the temporal 
relationship between inflammatory activity and psychological co-morbidity in IBD, 
such as that described in Chapter 5. 
 These findings highlight the disparity between patient-reported symptoms and 
objective assessments of IBD activity, and reinforce the requirement for careful 
consideration before escalation of conventional IBD therapies, or making judgments 
concerning the effectiveness of novel therapies, on the basis of clinical disease activity 
indices alone. Moreover, the finding that a simple dichotomous patient opinion as to 
whether their disease was active or not was as effective as both the HBI in CD, and the 
SCCAI in UC, at predicting mucosal inflammation in this study further highlights that 
the use of these indices as a sole determinant of disease activity or drug efficacy is not 
desirable. The move toward PROMs, in conjunction with biomarkers of inflammation 
and endoscopic indices, in the assessment of outcomes in IBD clinical trials aims to 
address these inconsistencies (Williet et al., 2014; Peyrin-Biroulet et al., 2015). To date, 
proposed clinical PROMs, include rectal bleeding and alteration in stool frequency in 
UC (Jairath et al., 2015), and abdominal pain, stool frequency, and general well-being 
115 
 
 
 
in CD (Khanna et al., 2015). However, based on these data, these outcomes have only 
modest PPVs when used to assess mucosal inflammation, and have been shown to 
correlate poorly with mucosal healing in UC in other studies (Jharap et al., 2015), 
casting doubt on their utility in this setting.  
 In summary, these findings support the assertions of previous authors in 
suggesting patient-reported clinical disease activity indices are not associated with 
mucosal inflammation in CD, and are only modestly associated with mucosal 
inflammation in UC, suggesting that the move towards PROMs in clinical trials of 
novel IBD therapies may need to be re-examined. Psychological co-morbidity, 
specifically somatisation in CD, was associated with the reporting of the symptoms that 
make up these indices. Although these data suggest that objective biochemical measures 
of inflammatory activity should form the basis of disease activity assessment, ideally as 
a point-of-care test, the association between GI symptoms, in the absence of disease 
activity, and psychological co-morbidity highlights the need for a paradigm shift in the 
management of some patients away from one focused solely on physical well-being. 
This reinforces the requirement for further assessment of psychological therapies or 
antidepressants, and the identification of novel treatments for the significant proportion 
of patients with IBD who suffer from associated psychological co-morbidity. Studies 
assessing such therapies are scarce with disappointing results (Timmer et al., 2011; 
Macer et al., 2017), which supports the requirement for a contemporaneous review of 
the efficacy of these treatments, as is described in Chapter 7.  
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CHAPTER 4: Assessing the relationship between the 
reporting of IBS-type symptoms, and psychological health 
and quality of life in patients with IBD 
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4.1 Introduction 
 Drawing on the conclusions of Chapter 3, there is clear evidence of a disparity 
between inflammatory activity and symptom-reporting in IBD, which may be 
influenced by mood. The explanation for this disparity is uncertain, but co-existent IBS-
type symptom-reporting has been implicated as one potential cause. Pooled data from a 
systematic review and meta-analysis of studies reporting the prevalence of IBS-type 
symptoms in IBD suggested that these symptoms affect between 35% and 44% of 
patients (Halpin and Ford, 2012). However, among the 13 included studies, only two 
assessed for evidence of ongoing disease activity among those who reported these 
symptoms (Keohane et al., 2010; Berrill et al., 2013), using objective measures of 
intestinal inflammation, such as FC. The number of included patients in both studies 
was relatively small, and the results were conflicting.   
 This issue has important implications for clinical practice, as there may be 
considerable difficulty in distinguishing IBS-type symptoms in IBD from those 
secondary to ongoing occult inflammation, due to the lack of immediate access to the 
results of diagnostic tests to differentiate between the two in the outpatient clinic. This 
could result in unnecessary invasive endoscopic investigations or inappropriate 
escalation of therapy to either immunosuppressants or biological therapies in patients 
with functional symptoms, when in fact other management strategies are required 
(Derwa et al., 2018).  
 This issue has therefore been examined in a large cross-sectional study of 
patients with IBD, using FC as an objective measure of disease activity, and the Rome 
III criteria for IBS, in order to assess the true magnitude of this problem. The hypothesis 
was that there is a subset of patients with IBD with genuine IBS-type symptoms, and 
that these symptoms may be associated with poor psychological health and quality of 
118 
 
 
 
life which, if proven, may serve as a mandate for treatment trials in this challenging 
group of patients in order to resolve continuing uncertainty surrounding how best to 
manage them. 
 
4.2  Methods 
 
4.2.1 Participants and setting 
 This was as described in Chapter 3. In brief, unselected and consecutive patients 
aged 16 and over, with an established diagnosis of CD or UC attending the IBD clinic at 
St. James's University Hospital, Leeds, were approached about the study. Patients with 
an end ileostomy or colostomy were excluded, as were those with a diagnosis of 
inflammatory bowel disease unclassified, isolated fistulising peri-anal CD, or any 
individual with an inability to understand written English. Those who agreed to take 
part gave written informed consent at this visit. The study received approval from the 
local research ethics committee in November 2012 (REC ref: 12/YH/0443), and data 
collection ceased in June 2015. 
 
4.2.2 Data collection and synthesis 
  
4.2.2.1 Demographic data and disease characteristics  
This was as described in Chapter 3, with demographic data including gender, 
age, ethnicity, marital status, educational level, tobacco and alcohol use, weight, height 
and BMI collected from all participants. Medication history, including current use of 5-
ASAs, glucocorticosteroids, immunosuppressants, or anti-TNFα therapy, disease 
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location or distribution, and any previous intestinal resection related to CD were also 
recorded.   
 
4.2.2.2 Assessment of IBD activity 
Assessment of IBD activity was performed using the HBI for CD (Harvey and 
Bradshaw, 1980), and the SCCAI for UC (Walmsley et al., 1998), with a score <5 used 
to define clinical remission for both, as previously recommended (Vermeire et al., 2010; 
Jowett et al., 2003). In addition, at their clinic visit participants were asked to provide 
stool for quantitative FC analysis, as an objective marker of mucosal inflammation, 
within 7 days of study entry. A cut off of <250µg/g of stool was used in the primary 
analysis to define no evidence of mucosal inflammation, in line with the European 
Crohn’s and Colitis Organisation consensus on the use of FC to measure disease activity 
(Rogler et al., 2013), as other investigators have employed (Targownik et al., 2015; 
D'Haens et al., 2012; Lin et al., 2014), but using <100µg/g in a secondary analysis 
 
4.2.2.3 Reference standard used to define the presence of IBS-type symptoms 
 This was as described in Chapter 3. IBS-type symptoms were defined as present 
when an individual reported abdominal discomfort or pain with a frequency of at least 2 
or 3 days per month over the last 3 months, with the onset of discomfort at least 6 
months previously, associated with two or more of the following: an improvement of 
pain or discomfort with the passage of stool, more or less frequent bowel movements, or 
looser or firmer stools (Longstreth et al., 2006).  
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4.2.2.4 Definition of disease activity and the presence of IBS-type symptoms 
 Using a combination of disease activity indices, presence or absence of 
symptoms compatible with Rome III-defined IBS, and FC levels, patients with UC or 
CD were categorised into four subgroups. Those who fulfilled the Rome III criteria for 
IBS and had a FC <250µg/g were defined as having IBS-type symptoms, regardless of 
disease activity indices. Those who did not fulfil the Rome III criteria for IBS and had a 
FC <250µg/g were defined as having quiescent disease, regardless of disease activity 
indices. Those with normal disease activity indices and a FC ≥250µg/g were defined as 
having occult inflammation, regardless of IBS symptom status. Finally, those with 
abnormal disease activity indices with a FC ≥250µg/g were defined as having active 
disease, regardless of whether or not they fulfilled the Rome III criteria for IBS. In 
sensitivity analysis, patients were categorised in an identical manner using a FC of 
<100µg/g or ≥100µg/g. 
 
4.2.2.5 Definition of anxiety or depression 
This was as described in Chapter 3, with the presence of either anxiety or 
depression assessed using the HADS (Zigmond and Snaith, 1983). Severity was 
categorised, according to total HADS score, into normal (total HADS depression or 
anxiety score 0-7), borderline normal (8-10), and abnormal (≥11) (Zigmond and Snaith, 
1983). 
  
4.2.2.6 Definition of somatisation severity 
This was as described in Chapter 3. Somatisation data were collected using the 
PHQ-15 (Kroenke et al., 2002), and severity categorised into high (total PHQ-15 ≥15), 
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medium (10-14), low (5-9), and minimal (≤4) levels of somatisation severity (Kroenke 
et al., 2002). 
 
4.2.2.7 Assessment of quality of life 
 The medical outcomes study 36-item short-form (SF-36) health survey, a 
validated questionnaire used to assess physical and mental health status, was used to 
make an assessment of health-related quality of life (McHorney et al., 1993). This 
comprises 36 questions which are grouped into eight health domains (physical 
functioning, role limitations due to physical health, role limitations due to emotional 
health, energy or fatigue, emotional well-being, social functioning, pain, and general 
health). Patients were asked to complete the questionnaire giving responses to each 
question from zero to one hundred, from which a mean score for each health domain 
was calculated, with higher scores indicating more favourable health-related quality of 
life. 
 
4.2.3 Statistical analysis 
 Comparison of baseline demographic characteristics, prevalence of IBS-type 
symptoms, disease activity, HADS scores, PHQ-15 scores, SF-36 scores, and presence 
or absence of anxiety, depression, or somatisation was performed between patients with 
CD and UC using a χ2 test for categorical variables, and an independent samples t-test 
for continuous data. 
After classification of disease activity and IBS-type symptom status using a FC 
<250µg/g of stool to define no evidence of mucosal inflammation, baseline 
demographic characteristics, HADS scores, PHQ-15 scores, SF-36 scores, and presence 
or absence of anxiety, depression, or somatisation were compared between those 
122 
 
 
 
reporting IBS-type symptoms and the other three groups of patients individually 
(quiescent disease, occult inflammation, or active disease) using a χ2 test for categorical 
variables, and an independent samples t-test for continuous data. These comparisons 
were repeated across all four groups using a χ2 test for categorical variables, and a one-
way analysis of variance (ANOVA) for continuous data. Where continuous data were 
not normally distributed, equivalent non-parametric tests including the Mann-Whitney 
U test and Kruskal-Wallis analysis of variance were applied. These analyses were then 
repeated but using an FC of <100µg/g to define no evidence of mucosal inflammation. 
Due to multiple comparisons a 2-tailed P value of <0.01 was considered to be 
statistically significant for all analyses. All statistical analyses were performed using 
SPSS for Windows version 22.0 (SPSS Inc., Chicago, IL, USA). 
  
4.3 Results 
 
4.3.1 Baseline demographics 
 In total, 378 (47.3%) of 799 patients who initially consented to participate in the 
study provided complete Rome III questionnaire and clinical disease activity data, and 
returned a faecal sample for FC analysis. Of these, 206 (54.5%) had confirmed CD and 
172 (45.5%), UC. Characteristics of patients with CD and UC are provided in Table 8. 
There were 144 (38.1%) patients with IBD who reported symptoms compatible with 
IBS, 92 (44.7%) with CD and 52 (30.2%) with UC (P = 0.004). In terms of disease 
activity, 128 (62.1%) of those with CD had an HBI <5, and 103 (59.9%) of those with 
UC had an SCCAI <5. Patients with CD were slightly younger, more likely to smoke, 
less likely to be using 5-ASAs, more likely to be using immunosuppressants or anti-
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TNFα drugs, and scored lower in some domains of the SF-36, such as energy/fatigue, 
pain, and general health than those with UC. 
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Table 8: Characteristics of patients with CD and UC 
 Crohn’s disease 
(n = 206) 
Ulcerative colitis 
(n = 172) 
P value* 
Mean age in years (SD) 47.1 (16.6) 51.9 (16.4) 0.005 
Female gender (%) 126 (61.2) 93 (54.1) 0.16 
Married or co-habiting (%) 127 (61.7) 122 (70.9) 0.07 
University graduate/professional (%) 54 (26.2) 49 (28.5) 0.57 
Mean BMI (SD) 26.4 (5.6) 27.1 (5.7) 0.22 
Tobacco user (%) 43 (20.9) 8 (4.7) <0.001 
Alcohol user (%) 128 (62.1) 115 (66.9) 0.37 
5-ASA use (%) 59 (28.6) 137 (79.7) <0.001 
Immunomodulator use (%) 93 (45.1) 37 (21.5) <0.001 
Anti-TNFα use (%) 57 (27.7) 4 (2.3) <0.001 
Glucocorticosteroid use (%) 21 (10.2) 18 (10.5) 0.93 
Previous intestinal resection (%) 70 (34.0) N/A† N/A† 
Rome III IBS criteria fulfilled (%) 92 (44.7) 52 (30.2) 0.004 
In remission on HBI or SCCAI (%)  128 (62.1) 103 (59.9) 0.66 
Mean HADS anxiety score (SD) 7.7 (4.6) 7.2 (5.0) 0.35 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
106 (51.5) 
42 (20.4) 
58 (28.2) 
 
95 (55.2) 
33 (19.2) 
44 (25.6) 
 
 
 
0.76 
Mean HADS depression score (SD) 5.2 (4.2) 4.7 (4.3) 0.28 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
147 (71.4) 
34 (16.5) 
25 (12.1) 
 
139 (80.8) 
11 (6.4) 
21 (12.2) 
 
 
 
0.01 
Mean PHQ-15 somatisation score (SD) 10.3 (4.7) 9.0 (5.2) 0.012 
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PHQ-15 somatisation categories (%) 
Mild  
Low 
Medium 
High 
 
20 (9.7) 
65 (31.6) 
74 (35.9) 
35 (17.0) 
 
34 (19.8) 
49 (28.5) 
52 (30.2) 
31 (18.0) 
 
 
 
 
0.05 
Median SF-36 quality of life score (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional  problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
85.0 (55.0-95.0) 
50.0 (0.0-100.0) 
100.0 (33.3-100.0) 
40.0 (20.0-60.0) 
68.0 (52.0-84.0) 
75.0 (37.5-87.5) 
67.5 (33.8-80.0) 
40.0 (25.0-60.0) 
 
90.0 (70.0-100.0) 
75.0 (0.0-100.0) 
100.0 (33.3-100.0) 
50.0 (30.0-70.0) 
72.0 (56.0-84.0) 
75.0 (50.0-100.0) 
67.5 (45.0-90.0) 
55.0 (40.0-75.0) 
 
0.13 
0.04 
0.73 
0.006 
0.14 
0.05 
0.002 
<0.001 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-
parametric data, and χ2 for categorical data. 
†N/A; not applicable. 
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4.3.2 Effect of FC analysis using a cut off <250µg/g on disease activity status and 
characteristics of patients with IBD with and without IBS-type symptoms 
 Among the 206 patients with CD, 57 (27.7%) were ultimately classified as 
having IBS-type symptoms based on a cut off <250µg/g, 69 (33.5%) as quiescent CD, 
49 (23.8%) as CD with occult inflammation, and 31 (15.0%) as active CD (Figure 3). 
Therefore, after FC analysis, 57 (62.0%) of 92 patients who met criteria for IBS had no 
evidence of active disease or occult inflammation and were classified as having IBS-
type symptoms. Thirty-one (39.7%) of 78 patients with an HBI ≥5 had genuinely active 
disease, and 32 (41.0%) were reclassified as having IBS-type symptoms.  
There were significantly more females among those with IBS-type symptoms 
and those with active disease, compared with the other two groups, and also more 
tobacco users among those with IBS-type symptoms compared with those with 
quiescent CD, but no other differences in demographic characteristics (Table 9). Of note 
was that mean anxiety, depression, and somatisation scores were all significantly higher 
in patients with CD with IBS-type symptoms compared with patients with either 
quiescent CD, or CD with occult inflammation, but were similar to those in patients 
with active CD. There were also more patients who met criteria for somatisation in the 
CD with IBS-type symptoms group than those with either quiescent CD, or CD with 
occult inflammation, but an almost identical proportion among those with active CD. 
Quality of life scores across all eight domains of the SF-36 were impaired among those 
patients with CD reporting IBS-type symptoms, compared with those with quiescent 
CD, or occult inflammation, and in several instances these differences were statistically 
significant, with scores impaired to a similar degree to that seen in patients with active 
CD.  
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Figure 3: Disease activity and IBS symptom status for patients with CD using a cut off <250µg/g 
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Table 9: Disease activity status and characteristics of patients with CD after FC analysis using a cut off <250µg/g 
 CD with IBS-
type symptoms 
(n = 57) 
Quiescent CD 
(n = 69) 
P 
value* 
CD with occult 
inflammation  
(n = 49) 
P 
value* 
Active CD 
(n = 31) 
P 
value* 
P 
value† 
Mean age in years (SD) 45.5 (15.3) 45.3 (16.2) 0.92 49.3 (19.2) 0.27 50.4 (15.3) 0.16 0.34 
Female gender (%) 44 (77.2) 30 (43.5) <0.001 29 (59.2) 0.05 23 (74.2) 0.75 0.001 
Married or co-habiting (%) 32 (56.1) 45 (65.2) 0.39 28 (57.1) 0.99 22 (71.0) 0.26 0.49 
University graduate/professional (%) 14 (24.6) 21 (30.4) 0.59 11 (22.4) 0.98 8 (25.8) 0.99 0.81 
Mean BMI (SD) 25.6 (5.5) 26.4 (5.6) 0.45 26.6 (5.7) 0.40 27.4 (5.3) 0.15 0.56 
Tobacco user (%) 18 (31.6) 8 (11.6) 0.006 10 (20.4) 0.19 7 (22.6) 0.37 0.06 
Alcohol user (%) 38 (66.7) 42 (60.9) 0.57 28 (57.1) 0.31 20 (64.5) 0.84 0.78 
Crohn’s disease location (%) 
Ileal 
Colonic 
Ileocolonic 
 
13 (22.8) 
21 (36.8) 
23 (40.4) 
 
10 (14.5) 
24 (34.8) 
35 (50.7) 
 
 
 
0.38 
 
13 (26.5) 
14 (28.6) 
22 (44.9) 
 
 
 
0.66 
 
12 (38.7) 
5 (16.1) 
14 (45.2) 
 
 
 
0.09 
 
 
 
0.14 
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Crohn’s disease behaviour (%) 
Non-stricturing, non-penetrating 
Stricturing 
Penetrating 
 
48 (84.2) 
6 (10.5) 
3 (5.3) 
 
61 (88.4) 
4 (5.8) 
4 (5.8) 
 
 
 
0.62 
 
43 (87.8) 
5 (10.2) 
1 (2.0) 
 
 
 
0.68 
 
23 (74.2) 
7 (22.6) 
1 (3.2) 
 
 
 
0.30 
 
 
 
0.29 
Perianal Crohn's disease present (%) 4 (7.0) 6 (8.7) 0.73 3 (6.1) 0.85 3 (9.7) 0.66 0.93 
5-ASA use (%) 20 (35.1) 21 (30.4) 0.58 13 (26.5) 0.34 5 (16.1) 0.06 0.29 
Immunomodulator use (%) 31 (54.4) 30 (43.5) 0.22 18 (36.7) 0.07 14 (45.2) 0.41 0.33 
Anti-TNFα use (%) 18 (31.6) 23 (33.3) 0.83 8 (16.3) 0.07 8 (25.8) 0.57 0.19 
Glucocorticosteroid use (%) 4 (7.0) 6 (8.7) 0.73 8 (16.3) 0.13 3 (9.7) 0.66 0.42 
Previous intestinal resection (%) 24 (42.1) 22 (31.9) 0.24 11 (22.4) 0.03 13 (41.9) 0.99 0.13 
Mean HADS anxiety score (SD)  9.1 (4.4) 6.7 (4.8) 0.004 6.5 (4.0) 0.002 9.3 (4.6) 0.84 0.001 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
21 (36.8) 
15 (26.3) 
21 (36.8) 
 
42 (60.9) 
11 (15.9) 
16 (23.2) 
 
 
 
0.03 
 
31 (63.3) 
10 (20.4) 
8 (16.3) 
 
 
 
0.02 
 
12 (38.7) 
6 (19.4) 
13 (41.9) 
 
 
 
0.76 
 
 
 
0.03 
Mean HADS depression score (SD) 6.3 (3.7) 4.1 (4.3) 0.003 4.4 (3.9) 0.01 7.2 (4.4) 0.33 <0.001 
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HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
37 (64.9) 
11 (19.3) 
9 (15.8) 
 
54 (78.3) 
10 (14.5) 
5 (7.2) 
 
 
 
0.20 
 
39 (79.6) 
6 (12.2) 
4 (8.2) 
 
 
 
0.24 
 
17 (54.8) 
7 (22.6) 
7 (22.6) 
 
 
 
0.62 
 
 
 
0.15 
Mean  PHQ-15 score (SD) 12.7 (4.6) 8.8 (4.6) 0.005 8.2 (3.3) 0.002 12.6 (4.2) 0.92 <0.001 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
1 (1.8) 
12 (21.8) 
25 (45.5) 
17 (30.9) 
 
14 (21.5) 
23 (35.4) 
19 (29.2) 
9 (13.8) 
 
 
 
 
0.001 
 
5 (11.1) 
24 (53.3) 
16 (35.6) 
0 (0.0) 
 
 
 
 
<0.001 
 
0 (0.0) 
6 (20.7) 
14 (48.3) 
9 (31.0) 
 
 
 
 
0.90 
 
 
 
 
<0.001 
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Median SF-36 quality of life score (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional  problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
80.0 (50.0-90.0) 
25.0 (0.0-75.0) 
66.7 (0.0-100.0) 
35.0 (20.0-50.0) 
64.0 (48.0-76.0) 
50.0 (37.5-75.0) 
45.0 (32.5-68.8) 
35.0 (25.0-50.0) 
 
92.5 (66.3-100.0) 
87.5 (25.0-100.0) 
100.0 (33.3-100.0) 
50.0 (22.5-70.0) 
76.0 (60.0-88.0) 
75.0 (50.0-100.0) 
77.5 (50.0-90.0) 
50.0 (35.0-75.0) 
 
0.005 
<0.001 
0.01 
0.01 
<0.001 
0.004 
<0.001 
<0.001 
 
85.0 (55.0-100.0) 
75.0 (25.0-100.0) 
100.0 (41.7-100.0) 
50.0 (30.0-65.0) 
64.0 (52.0-88.0) 
81.3 (56.9-100.0) 
67.5 (45.0-90.0) 
45.0 (25.0-60.0) 
 
0.17 
0.004 
0.05 
0.06 
0.36 
0.001 
<0.001 
0.04 
 
67.5 (27.5-95.0) 
12.5 (0.0-100.0) 
100.0 (0.0-100.0) 
25.0 (10.0-40.0) 
56.0 (44.0-78.0) 
50.0 (37.5-75.0) 
42.5 (22.5-57.5) 
30.0 (15.0-40.0) 
 
0.41 
1.00 
0.41 
0.09 
0.56 
0.83 
0.31 
0.28 
 
0.01 
0.001 
0.06 
0.001 
0.003 
<0.001 
<0.001 
<0.001 
Mean FC (SD) 89.6 (62.7) 88.4 (62.9) 0.91 1200 (1105) <0.001 907 (671) <0.001 <0.001 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-parametric data, and χ2 for comparison of categorical data vs. CD with 
IBS-type symptoms. 
†One way ANOVA for normally distributed continuous data, Kruskal-Wallis analysis of variance for non-parametric data, and χ2 for comparison of categorical data across all 
four groups.  
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Among the 172 patients with UC, 34 (19.8%) were classified as having IBS-type 
symptoms based on a cut off <250µg/g, 68 (39.5%) as quiescent UC, 34 (19.8%) as UC 
with occult inflammation, and 36 (20.9%) as active UC (Figure 4). Therefore, after FC 
analysis, 34 (65.4%) of 52 patients who met criteria for IBS had no evidence of active 
disease or occult inflammation and were classified as having IBS-type symptoms, 
whereas 36 (52.2%) of 69 with an SCCAI ≥5 had genuinely active disease, and 18 
(26.1%) were reclassified as having IBS-type symptoms.  
There were no differences in demographic characteristics between the four 
groups, but mean anxiety, depression, and somatisation scores were all significantly 
higher in those reporting IBS-type symptoms, compared with those with either 
quiescent UC, or occult inflammation, and anxiety scores were also significantly higher 
than in those with active UC (Table 10). There were also significantly more patients 
who met criteria for anxiety, depression, or somatisation in the group with IBS-type 
symptoms than among those with either quiescent UC, or UC with occult inflammation. 
Median quality of life scores were significantly lower in patients with IBS-type 
symptoms compared with patients with quiescent UC for all domains of the SF-36 
except physical functioning, and all domains except physical functioning, role 
limitations due to physical health, and energy/fatigue when compared with UC with 
occult inflammation. As was observed in the analyses for patients with CD, quality of 
life scores in patients with UC reporting IBS-type symptoms were impaired to a similar 
degree to those with active UC.  
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Figure 4: Disease activity and IBS symptom status for patients with UC using a cut off <250µg/g 
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Table 10: Disease activity status and characteristics of patients with UC after FC analysis using a cut off <250µg/g 
 UC with IBS-
type symptoms 
(n = 34) 
Quiescent UC 
(n = 68) 
P 
value* 
UC with occult 
inflammation  
(n = 34 ) 
P 
value* 
Active UC 
(n = 36) 
P 
value* 
P 
value† 
Mean age in years (SD) 48.3 (14.4) 53.6 (16.8) 0.10 54.8 (17.0) 0.09 49.6 (16.8) 0.73 0.25 
Female gender (%) 20 (58.8) 40 (58.8) 1.0 14 (41.2) 0.15 19 (52.8) 0.61 0.36 
Married or co-habiting (%) 25 (73.5) 46 (67.6) 0.70 26 (76.5) 0.99 25 (69.4) 0.91 0.80 
University graduate/professional (%) 10 (29.4) 20 (29.4) 1.0 8 (23.5) 0.78 11 (30.6) 0.99 0.95 
Mean BMI (SD) 26.8 (5.6) 26.1 (4.8) 0.58 28.8 (7.3) 0.21 27.6 (5.4) 0.53 0.15 
Tobacco user (%) 1 (2.9) 2 (2.9) 1.0 3 (8.8) 0.29 2 (5.6) 0.59 0.53 
Alcohol user (%) 22 (64.7) 49 (72.1) 0.45 24 (70.6) 0.604 20 (55.6) 0.44 0.36 
Ulcerative colitis extent (%) 
Proctitis 
Left-sided 
Extensive 
 
11 (32.4) 
15 (44.1) 
8 (23.5) 
 
17 (25.0) 
33 (48.5) 
18 (26.5) 
 
 
 
0.74 
 
11 (32.4) 
13 (38.2) 
10 (29.4) 
 
 
 
0.83 
 
8 (22.2) 
15 (41.7) 
13 (36.1) 
 
 
 
0.45 
 
 
 
0.83 
5-ASA use (%) 30 (88.2) 53 (77.9) 0.21 27 (79.4) 0.32 27 (75.0) 0.16 0.54 
Immunomodulator use (%) 7 (20.6) 16 (23.5) 0.74 6 (17.6) 0.76 8 (22.2) 0.87 0.92 
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Anti-TNFα use (%) 2 (5.9) 1 (1.5) 0.21 0 (0.0) 0.15 1 (2.8) 0.52 0.40 
Glucocorticosteroid use (%) 5 (14.7) 5 (7.4) 0.24 3 (8.8) 0.45 5 (13.9) 0.92 0.59 
Mean HADS anxiety score (SD)  11.2 (5.1) 5.8 (4.3) <0.001 5.8 (4.4) <0.001 7.5 (4.6) 0.003 <0.001 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
9 (26.5) 
7 (20.6) 
18 (52.9) 
 
45 (66.2) 
13 (19.1) 
10 (14.7) 
 
 
 
<0.001 
 
22 (64.7) 
7 (20.6) 
5 (14.7) 
 
 
 
0.002 
 
19 (52.8) 
6 (16.7) 
11 (30.6) 
 
 
 
0.07 
 
 
 
0.001 
Mean HADS depression score (SD) 7.9 (5.1) 3.2 (3.4) <0.001 3.0 (2.5) <0.001 6.2 (4.2) 0.13 <0.001 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
21 (61.8) 
4 (11.8) 
9 (26.5) 
 
62 (91.2) 
3 (4.4) 
3 (4.4) 
 
 
 
0.001 
 
32 (97.0) 
0 (0.0) 
1 (3.0) 
 
 
 
0.002 
 
24 (66.7) 
4 (11.1) 
8 (22.2) 
 
 
 
0.90 
 
 
 
0.001 
Mean  PHQ-15 somatisation score (SD) 12.9 (4.3) 7.3 (5.0) <0.001 6.5 (4.6) <0.001 10.9 (4.4) 0.07 <0.001 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
1 (3.0) 
5 (15.2) 
13 (39.4) 
14 (42.4) 
 
19 (28.4) 
24 (35.8) 
17 (25.4) 
7 (10.4) 
 
 
 
 
<0.001 
 
12 (37.5) 
12 (37.5) 
7 (21.9) 
1 (3.1) 
 
 
 
 
< 0.001 
 
2 (5.9) 
8 (23.5) 
15 (44.1) 
9 (26.5) 
 
 
 
 
0.52 
 
 
 
 
<0.001 
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Median SF-36 quality of life score (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional  problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
80.0 (65.0-95.0) 
25.0 (0.0-96.9) 
50.0 (0.0-100.0) 
40.0 (22.5-50.0) 
58.0 (36.0-75.0) 
62.5 (43.8-87.5) 
45.0 (32.5-73.8) 
45.0 (30.0-57.5) 
 
90.0 (77.5-100.0) 
100.0 (50.0-100.0) 
100.0 (66.7-100.0) 
55.0 (40.0-70.0) 
76.0 (60.0-90.0) 
87.5 (62.5-100.0) 
80.0 (65.6-97.5) 
60.0 (43.8-85.0) 
 
0.05 
<0.001 
<0.001 
0.001 
<0.001 
0.003 
<0.001 
0.003 
 
92.5 (65.0-100.0) 
100.0 (18.8-100.0) 
100.0 (91.7-100.0) 
50.0 (40.0-70.0) 
76.0 (68.0-84.0) 
100.0 (68.8-100.0) 
90.0 (57.5-100.0) 
70.0 (47.5-78.8) 
 
0.33 
0.02 
0.001 
0.02 
0.001 
0.001 
<0.001 
0.001 
 
77.5 (55.0-95.0) 
25.0 (0.0-100.0) 
66.7 (0.0-100.0) 
30.0 (20.0-60.0) 
64.0 (56.0-84.0) 
50.0 (37.5-75.0) 
57.5 (45.0-75.0) 
45.0 (26.3-60.0) 
 
0.69 
0.92 
0.25 
0.83 
0.08 
0.13 
0.13 
0.95 
 
0.06 
<0.001 
<0.001 
0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Mean FC (SD) 93.7 (70.5) 80.0 (59.2) 0.34 854 (714) <0.001 1611 (1340) <0.001 <0.001 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-parametric data, and χ2 for comparison of categorical data vs. UC with 
IBS-type symptoms. 
†One way ANOVA for normally distributed continuous data, Kruskal-Wallis analysis of variance for non-parametric data, and χ2 for comparison of categorical data across all 
four groups.  
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4.3.3 Effect of FC analysis using a cut off <100µg/g on disease activity status and 
characteristics of patients with IBD with and without IBS-type symptoms 
Results of comparisons between the four CD and UC groups using a FC cut off 
<100µg/g to define no evidence of mucosal inflammation were similar in terms of the 
magnitude of the differences in anxiety, depression, somatisation, and quality of life 
scores seen among those with both IBS-type symptoms and active disease, although due 
to a reduction in the size of the group of individuals with IBS-type symptoms there were 
fewer statistically significant differences (Tables 11 and 12). When analyses using this 
cut off were repeated for all patients with IBD combined, the differences in 
psychological co-morbidity and quality of life in those with IBS-type symptoms became 
statistically significant once more (Table 13). 
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Table 11: Disease activity status and characteristics of patients with CD after FC analysis using a cut off <100µg/g 
 CD with IBS-
type symptoms 
(n = 37) 
Quiescent CD 
(n = 49) 
P 
value* 
CD with occult  
inflammation  
(n = 74) 
P 
value* 
Active CD  
(n = 46) 
P 
value* 
P 
value† 
Mean age in years (SD) 48.3 (14.6) 44.8 (17.2) 0.32 47.5 (18.0) 0.81 47.9 (15.6) 0.90 0.75 
Female gender (%) 28 (75.7) 21 (42.9) 0.002 45 (60.8) 0.12 32 (69.6) 0.54 0.009 
Married or co-habiting (%) 21 (58.3) 33 (67.3) 0.39 42 (56.8) 0.88 21 (67.4) 0.40 0.53 
University graduate/professional (%) 9 (24.3) 16 (32.7) 0.40 16 (21.9) 0.78 13 (28.3) 0.69 0.59 
Mean BMI (SD) 25.5 (6.0) 25.7 (4.9) 0.83 26.5 (5.9) 0.39 27.5 (5.2) 0.12 0.35 
Tobacco user (%) 11 (29.7) 5 (10.2) 0.02 16 (21.6) 0.35 11 (23.9) 0.55 0.14 
Alcohol user (%) 26 (70.3) 30 (61.2) 0.38 45 (60.8) 0.33 27 (60.0) 0.33 0.75 
Crohn’s disease location (%) 
Ileal 
Colonic 
Ileocolonic 
 
9 (24.3) 
17 (45.9) 
11 (29.7) 
 
8 (16.3) 
17 (34.7) 
24 (49.0) 
 
 
 
0.19 
 
16 (21.6) 
22 (29.7) 
36 (48.6) 
 
 
 
0.14 
 
15 (32.6) 
8 (17.4) 
23 (50.0) 
 
 
 
0.02 
 
 
 
0.09 
5-ASA use (%) 15 (40.5) 14 (28.6) 0.25 23 (31.1) 0.32 7 (15.2) 0.009 0.08 
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Crohn’s disease behaviour (%) 
Non stricturing, non penetrating 
Stricturing 
Penetrating 
 
33 (89.2) 
3 (8.1) 
1 (2.7) 
 
44 (89.8) 
2 (4.1) 
3 (6.1) 
 
 
 
0.57 
 
64 (86.5) 
8 (10.8) 
2 (2.7) 
 
 
 
0.90 
 
34 (73.9) 
9 (19.6) 
3 (6.5) 
 
 
 
0.22 
 
 
 
0.23 
Perianal Crohn's disease present (%) 2 (5.4) 3 (6.1) 0.89 7 (9.5) 0.46 4 (8.7) 0.57 0.84 
Immunomodulator use (%) 22 (59.5) 20 (40.8) 0.09 31 (41.9) 0.08 20 (43.5) 0.15 0.28 
Anti-TNFα use (%) 9 (24.3) 14 (28.6) 0.66 20 (27.0) 0.76 14 (30.4) 0.54 0.94 
Glucocorticosteroid use (%) 4 (10.8) 3 (6.1) 0.43 10 (13.5) 0.69 4 (8.7) 0.75 0.59 
Previous intestinal resection (%) 13 (35.1) 13 (26.5) 0.39 20 (27.0) 0.38 24 (52.2) 0.12 0.02 
Mean HADS anxiety score (SD)  8.0 (3.9) 6.3 (4.4) 0.06 7.0 (4.7) 0.24 10.0 (4.5) 0.04 <0.001 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
17 (45.9) 
10 (27.0) 
10 (27.0) 
 
31 (63.3) 
8 (16.3) 
10 (20.4) 
 
 
 
0.26 
 
44 (59.5) 
14 (18.9) 
16 (21.6) 
 
 
 
0.39 
 
14 (30.4) 
10 (21.7) 
22 (47.8) 
 
 
 
0.15 
 
 
 
0.01 
Mean HADS depression score (SD) 5.6 (3.9) 3.6 (4.2) 0.03 4.8 (3.9) 0.27 7.3 (4.1) 0.06 <0.001 
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HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
27 (73.0) 
5 (13.5) 
5 (13.5) 
 
40 (81.6) 
6 (12.2) 
3 (6.1) 
 
 
 
0.48 
 
56 (75.7) 
12 (16.2) 
6 (8.1) 
 
 
 
0.65 
 
24 (52.2) 
11 (23.9) 
11 (23.9) 
 
 
 
0.15 
 
 
 
0.04 
Mean  PHQ-15 somatisation score (SD) 11.7 (4.5) 8.8 (4.4) 0.004 8.9 (4.3) 0.003 13.1 (4.3) 0.19 0.001 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
1 (2.9) 
11 (31.4) 
14 (40.0) 
9 (25.7) 
 
11 (23.4) 
15 (31.9) 
15 (31.9) 
6 (12.8) 
 
 
 
 
0.05 
 
8 (11.6) 
32 (46.4) 
22 (31.9) 
7 (10.1) 
 
 
 
 
0.06 
 
0 (0.0) 
7 (16.3) 
23 (53.5) 
13 (30.2) 
 
 
 
 
0.26 
 
 
 
 
<0.001 
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Median SF-36 score quality of life (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional  problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
82.5 (61.3-91.3) 
25.0 (0.0-100.0) 
100.0 (0.0-100.0) 
35.0 (25.0-50.0) 
68.0 (60.0-78.0) 
62.5 (37.5-87.5) 
45.0 (32.5-70.0) 
35.0 (25.0-60.0) 
 
92.5 (66.3-100.0) 
87.5 (6.3-100.0) 
100.0 (75.0-100.0) 
50.0 (31.3-70.0) 
80.0 (60.0-88.0) 
75.0 (50.0-100.0) 
77.5 (50.0-90.0) 
60.0 (35.0-75.0) 
 
0.04 
0.02 
0.05 
0.07 
0.01 
0.14 
0.003 
0.005 
 
85.0 (65.0-100.0) 
75.0 (25.0-100.0) 
100.0 (33.3-100.0) 
50.0 (23.8-65.0) 
66.0 (52.0-88.0) 
75.0 (50.0-100.0) 
70.0 (45.0-90.0) 
50.0 (25.0-60.0) 
 
0.22 
0.02 
0.41 
0.33 
0.71 
0.14 
0.001 
0.15 
 
65.0 (30.0-92.5) 
25.0 (0.0-75.0) 
66.7 (0.0-100.0) 
25.0 (10.0-45.0) 
56.0 (44.0-72.0) 
50.0 (34.4-62.5) 
43.8 (30.0-57.5) 
30.0 (15.0-35.0) 
 
0.10 
0.76 
0.66 
0.009 
0.08 
0.05 
0.35 
0.02 
 
0.003 
0.003 
0.05 
<0.001 
0.003 
0.001 
<0.001 
<0.001 
Mean FC (SD) 50.4 (18.2) 55.3 (25.7) 0.30 849 (1025) <0.001 669 (649) <0.001 <0.001 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-parametric data, and χ2 for comparison of categorical data vs. CD with 
IBS-type symptoms. 
†One way ANOVA for normally distributed continuous data, Kruskal-Wallis analysis of variance for non-parametric data, and χ2 for comparison of categorical data across all 
four groups. 
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Table 12: Disease activity status and characteristics of patients with UC after FC analysis using a cut off <100µg/g 
 UC with IBS-type 
symptoms 
(n = 19) 
Quiescent UC 
(n = 48) 
P 
value* 
UC with occult  
inflammation  
(n = 55) 
P 
value* 
Active UC  
(n = 50) 
P 
value* 
P 
value† 
Mean age in years (SD) 44.5 (14.1) 54.5 (17.4) 0.02 53.3 (16.7) 0.03 50.7 (15.5) 0.12 0.13 
Female gender (%) 10 (52.6) 26 (54.2) 0.91 30 (54.5) 0.89 27 (54.0) 0.92 0.99 
Married or co-habiting (%) 14 (73.7) 29 (60.4) 0.31 44 (80.0) 0.56 35 (70.0) 0.76 0.18 
University graduate/professional (%) 6 (31.6) 13 (27.1) 0.71 16 (30.2) 0.91 14 (28.6) 0.81 0.98 
Mean BMI (SD) 26.7 (5.3) 26.4 (5.0) 0.86 27.1 (6.5) 0.78 27.8 (5.6) 0.44 0.67 
Tobacco user (%) 1 (5.3) 1 (2.1) 0.49 3 (5.6) 0.96 3 (6.0) 0.91 0.79 
Alcohol user (%) 12 (63.2) 34 (70.8) 0.54 39 (70.9) 0.53 30 (60.0) 0.81 0.59 
Ulcerative colitis extent (%) 
Proctitis 
Left-sided 
Extensive 
 
8 (42.1) 
7 (36.8) 
4 (21.1) 
 
11 (22.9) 
25 (52.1) 
12 (25.0) 
 
 
 
0.28 
 
20 (36.4) 
21 (38.2) 
14 (25.5) 
 
 
 
0.89 
 
8 (16.0) 
23 (46.0) 
19 (38.0) 
 
 
 
0.06 
 
 
 
0.14 
5-ASA use (%) 19 (100.0) 36 (75.0) 0.02 45 (81.8) 0.05 37 (74.0) 0.01 0.08 
Immunomodulator use (%) 3 (15.8) 16 (33.3) 0.15 7 (12.7) 0.74 11 (22.0) 0.57 0.08 
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Anti-TNFα use (%) 0 (0.0) 0 (0.0) - 1 (1.8) 0.55 3 (6.0) 0.28 0.20 
Glucocorticosteroid use (%) 2 (10.5) 3 (6.3) 0.55 6 (10.9) 0.96 7 (14.0) 0.70 0.66 
Mean HADS anxiety score (SD)  10.8 (5.5) 6.0 (4.3) 0.002 6.0 (4.8) 0.002 8.5 (4.6) 0.11 <0.001 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
5 (26.3) 
5 (26.3) 
9 (47.4) 
 
31 (64.6) 
12 (25.0) 
5 (10.4) 
 
 
 
0.002 
 
37 (67.3) 
7 (12.7) 
11 (20.0) 
 
 
 
0.008 
 
22 (44.0) 
9 (18.0) 
19 (38.0) 
 
 
 
0.39 
 
 
 
0.002 
Mean HADS depression score (SD) 7.3 (5.5) 3.5 (3.4) 0.01 3.2 (3.2) 0.005 6.6 (4.5) 0.65 <0.001 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
15 (78.9) 
0 (0.0) 
4 (21.1) 
 
43 (89.6) 
3 (6.3) 
2 (4.2) 
 
 
 
0.06 
 
49 (90.7) 
2 (3.7) 
3 (5.6) 
 
 
 
0.11 
 
32 (64.0) 
6 (12.0) 
12 (24.0) 
 
 
 
0.25 
 
 
 
0.005 
Mean  PHQ-15 somatisation score (SD) 11.8 (4.2) 7.3 (4.8) 0.001 7.5 (5.7) 0.001 11.2 (4.3) 0.56 <0.001 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
1 (5.3) 
4 (21.1) 
8 (42.1) 
6 (31.6) 
 
13 (27.7) 
20 (42.6) 
8 (17.0) 
6 (12.8) 
 
 
 
 
0.01 
 
18 (34.0) 
15 (28.3) 
15 (28.3) 
5 (9.4) 
 
 
 
 
0.02 
 
2 (4.3) 
10 (21.3) 
21 (44.7) 
14 (29.8) 
 
 
 
 
1.0 
 
 
 
 
<0.001 
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Median SF-36 quality of life score (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional  problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
85.0 (65.0-100.0) 
50.0 (0.0-100.0) 
66.7 (0.0-100.0) 
50.0 (32.5-57.5) 
68.0 (42.0-78.0) 
75.0 (50.0-100.0) 
62.5 (45.5-80.0) 
52.5 (36.3-66.3) 
 
90.0 (75.0-100.0) 
100.0 (50.0-100.0) 
100.0 (66.7-100.0) 
55.0 (40.0-70.0) 
76.0 (60.0-88.0) 
87.5 (62.5-100.0) 
80.0 (60.0-90.0) 
60.0 (41.3-83.8) 
 
0.48 
0.05 
0.03 
0.09 
0.11 
0.22 
0.03 
0.13 
 
95.0 (70.0-100.0) 
100.0 (50.0-100.0) 
100.0 (66.7-100.0) 
50.0 (40.0-75.0) 
80.0 (60.0-92.0) 
87.5 (62.5-100.0) 
90.0 (57.5-100.0) 
70.0 (45.0-80.0) 
 
0.52 
0.19 
0.06 
0.16 
0.03 
0.17 
0.02 
0.03 
 
75.0 (55.0-95.0) 
25.0 (0.0-100.0) 
66.7 (0.0-100.0) 
30.0 (20.0-60.0) 
64.0 (53.0-80.0) 
50.0 (25.0-75.0) 
56.3 (45.0-70.0) 
45.0 (27.5-57.5) 
 
0.19 
0.24 
0.99 
0.16 
0.71 
0.01 
0.60 
0.28 
 
0.02 
<0.001 
0.005 
<0.001 
0.04 
<0.001 
<0.001 
<0.001 
Mean FC (SD) 40.2 (22.6) 46.4 (19.9) 0.31 589 (654) <0.001 1198 (1307) <0.001 <0.001 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-parametric data, and χ2 for comparison of categorical data vs. UC with 
IBS-type symptoms. 
†One way ANOVA for normally distributed continuous data, Kruskal-Wallis analysis of variance for non-parametric data, and χ2 for comparison of categorical data across all 
four groups. 
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Table 13: Disease activity status and characteristics of all patients with IBD after FC analysis using a cut off <100µg/g 
 IBD with IBS-
type symptoms 
(n = 56) 
Quiescent IBD 
(n = 97) 
P 
value* 
IBD with occult  
inflammation  
(n = 129) 
P 
value* 
Active IBD  
(n = 96) 
P 
value* 
P 
value† 
Mean age in years (SD) 47.0 (14.4) 49.6 (17.9) 0.32 50.0 (17.6) 0.23 49.3 (15.5) 0.35 0.73 
Female gender (%) 38 (67.9) 47 (48.5) 0.02 75 (58.1) 0.21 59 (61.5) 0.43 0.10 
Married or co-habiting (%) 35 (63.6) 62 (63.9) 0.97 86 (66.7) 0.69 66 (68.8) 0.52 0.88 
University graduate/professional (%) 15 (26.8) 29 (29.9) 0.68 32 (25.4) 0.84 27 (28.4) 0.83 0.89 
Mean BMI (SD) 25.9 (5.8) 26.1 (4.9) 0.83 26.8 (6.2) 0.35 27.7 (5.4) 0.07 0.17 
Tobacco user (%) 12 (21.4) 6 (6.2) 0.005 19 (14.8) 0.27 14 (14.6) 0.28 0.05 
Alcohol user (%) 38 (67.9) 64 (66.0) 0.81 84 (65.1) 0.72 57 (60.0) 0.33 0.75 
5-ASA use (%) 34 (60.7) 50 (51.5) 0.27 68 (52.7) 0.32 44 (45.8) 0.08 0.36 
Immunomodulator use (%) 25 (44.6) 36 (37.1) 0.36 38 (29.5) 0.05 31 (32.3) 0.13 0.21 
Anti-TNFα use (%) 9 (16.1) 14 (14.4) 0.79 21 (16.3) 0.97 17 (17.7) 0.80 0.94 
Glucocorticosteroid use (%) 6 (10.7) 6 (6.2) 0.32 16 (12.4) 0.74 11 (11.5) 0.89 0.47 
Mean HADS anxiety score (SD)  9.0 (4.7) 6.1 (4.3) <0.001 6.6 (4.8) 0.002 9.2 (4.6) 0.79 <0.001 
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HADS anxiety categories (%) 
Normal  
Borderline abnormal 
Abnormal 
 
22 (39.3) 
15 (26.8) 
19 (33.9) 
 
62 (63.9) 
20 (20.6) 
15 (15.5) 
 
 
 
0.007 
 
81 (62.8) 
21 (16.3) 
27 (20.9) 
 
 
 
0.01 
 
36 (37.5) 
19 (19.8) 
41 (42.7) 
 
 
 
0.47 
 
 
 
<0.001 
Mean HADS depression score (SD) 6.2 (4.5) 3.6 (3.8) <0.001 4.1 (3.7) 0.003 6.9 (4.3) 0.31 <0.001 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
42 (75.0) 
5 (8.9) 
9 (16.1) 
 
83 (85.6) 
9 (9.3) 
5 (5.2) 
 
 
 
0.08 
 
105 (82.0) 
14 (10.9) 
9 (7.0) 
 
 
 
0.16 
 
56 (58.3) 
17 (17.7) 
23 (24.0) 
 
 
 
0.11 
 
 
 
<0.001 
Mean  PHQ-15 somatisation score (SD) 11.8 (4.4) 8.0 (4.7) <0.001 8.3 (5.0) <0.001 12.1 (4.4) 0.69 <0.001 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
2 (3.7) 
15 (27.8) 
22 (40.7) 
15 (27.8) 
 
24 (25.5) 
35 (37.2) 
23 (24.5) 
12 (12.8) 
 
 
 
 
0.001 
 
26 (21.3) 
47 (38.5) 
37 (30.3) 
12 (9.8) 
 
 
 
 
0.001 
 
2 (2.2) 
17 (18.9) 
44 (48.9) 
27 (30.0) 
 
 
 
 
0.57 
 
 
 
 
<0.001 
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Median SF-36 quality of life score (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional  problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
85.0 (65.0-100.0) 
25.0 (0.0-100.0) 
100.0 (0.0-100.0) 
45.0 (26.3-53.8) 
68.0 (55.0-77.0) 
75.0 (50.0-87.5) 
55.0 (32.5-77.5) 
45.0 (25.0-60.0) 
 
90.0 (73.8-100.0) 
100.0 (50.0-100.0) 
100.0 (66.7-100.0) 
55.0 (40.0-70.0) 
76.0 (60.0-88.0) 
87.5 (56.3-100.0) 
77.5 (57.5-90.0) 
60.0 (40.0-75.0) 
 
0.03 
0.001 
0.004 
0.005 
0.006 
0.02 
<0.001 
0.001 
 
90.0 (65.0-100.0) 
75.0 (25.0-100.0) 
100.0 (33.3-100.0) 
50.0 (30.0-70.0) 
72.0 (56.0-88.0) 
87.5 (62.5-100.0) 
77.5 (49.4-90.0) 
55.0 (35.0-75.0) 
 
0.14 
0.005 
0.06 
0.06 
0.06 
0.03 
<0.001 
0.01 
 
75.0 (45.0-95.0) 
25.0 (0.0-100.0) 
66.7 (0.0-100.0) 
30.0 (15.0-45.0) 
64.0 (48.0-80.0) 
50.0 (25.0-75.0) 
53.8 (32.5-67.5) 
35.0 (20.0-50.0) 
 
0.07 
0.44 
0.68 
0.01 
0.43 
0.002 
0.60 
0.06 
 
<0.001 
<0.001 
<0.001 
<0.001 
0.001 
<0.001 
<0.001 
<0001 
Mean FC (SD) 46.9 (20.2) 50.9 (23.3) 0.27 738 (892) <0.001 941 (1070) <0.001 <0.001 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-parametric data, and χ2 for comparison of categorical data vs. IBD with 
IBS-type symptoms. 
†One way ANOVA for normally distributed continuous data, Kruskal-Wallis analysis of variance for non-parametric data, and χ2 for comparison of categorical data across all 
four groups. 
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4.4 Discussion 
 After utilising FC as an objective measure of IBD activity, this cross-sectional 
study has demonstrated an overall prevalence of IBS-type symptom-reporting in 
outpatients with IBD of 27.7% in CD and 19.8% in UC. Among both patients with CD 
and UC with IBS-type symptoms there was substantial psychological co-morbidity, 
with the prevalence and severity of anxiety, depression, and somatisation all higher than 
among patients with either quiescent disease or occult inflammation. In addition, the 
reduction in quality of life associated with the presence of these symptoms was 
consistently greater than that observed in patients with CD and UC with quiescent 
disease or occult inflammation, and was of a similar magnitude to those with active 
disease.  
Many of the strengths of this study, including the use of validated 
questionnaires, the generalisability of its findings, and the use of quantitative measures 
of intestinal inflammation are in keeping with those described in Chapter 3, and are not 
re-discussed here. Specific strengths of this study include its sample size of 378 
patients, which is larger than any previous study examining the prevalence of IBS-type 
symptom-reporting in IBD, and the fact that it was not restricted to the study of patients 
with UC alone (Keohane et al., 2010; Berrill et al., 2013; Jonefjall et al., 2016; 
Henriksen et al., 2018).  
 Given that this was a cross-sectional study, an obvious weakness is that causality 
cannot be implied by these results. Furthermore, one-in-three patients with CD had 
undergone intestinal resection previously and, given that BAM or SIBO may occur as a 
result of surgery (Gracie et al., 2012; Greco et al., 2015), and that there is overlap 
between the symptoms of these conditions and those of IBS (Ford et al., 2009a; Aziz et 
al., 2015), it is possible that the reported prevalence of IBS-type symptoms has been 
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overestimated. The reliance on FC as the sole determinant of inflammatory activity, 
rather than “gold-standard” endoscopic and radiological investigations, could also be 
considered a weakness for two reasons. Firstly, in CD, patients with occult fibrostenotic 
disease, who may report symptoms that are not related to intestinal inflammation, but 
who may not have IBS, could have been falsely categorised as reporting these 
symptoms. Secondly, occult inflammatory activity could have been missed. However, 
even when a FC cut off <100µg/g was used, 18% of those with CD, and 11% of those 
with UC still reported IBS-type symptoms. There were fewer statistically significant 
differences between groups when a FC cut off <100µg/g was used, but this was likely to 
be secondary to a reduction in the size of the groups of individuals with either IBS-type 
symptoms or quiescent disease. When analyses using this cut off were repeated for all 
patients with CD and UC combined, the differences in psychological co-morbidity and 
quality of life in those with IBS-type symptoms became statistically significant once 
more.  
Several studies have investigated the prevalence of IBS-type symptoms in 
patients with IBD, and their association with psychological co-morbidity. However, 
only four have utilised an objective measure of mucosal inflammation (Berrill et al., 
2013; Keohane et al., 2010; Henriksen et al., 2018; Jonefjall et al., 2016). Keohane et al. 
assessed the prevalence of IBS-type symptoms, and their impact on quality of life and 
depression scores in 106 patients with IBD, and found that 60% of CD and 39% of 
patients with UC in clinical remission met the Rome II criteria for IBS (Keohane et al., 
2010). Quality of life scores were lower, and depression scores higher in UC, but not in 
patients with CD with IBS-type symptoms versus those without. However, FC levels 
were significantly higher among patients meeting Rome II criteria, suggesting that the 
mechanism for these symptoms was occult inflammation, rather than genuine IBS. In 
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contrast, Berrill et al. recruited 169 patients with IBD, and reported that 32% of those in 
clinical remission reported IBS-type symptoms, again with higher anxiety and 
depression scores in the IBS group, with no differences in FC levels between those with 
and without IBS-type symptoms, but only 61 patients returned a stool sample (Berrill et 
al., 2013).  
Subsequent to these studies Jonefjäll et al. reported a prevalence of IBS-type 
symptom-reporting of 18% in patients with UC in deep remission, defined using a 
flexible sigmoidoscopy or FC <200µg/g of stool. No significant difference in median 
FC level between patients in deep remission with, and without, IBS-type symptoms was 
reported, yet IBS-type symptom-reporting was consistently associated with anxiety, 
depression, and poor quality of life (Jonefjall et al., 2016). Finally, Henriksen et al. 
reported a prevalence of IBS-type symptoms of between 27% and 29% in 260 patients 
with UC who underwent colonoscopy or FC testing, and that this figure was unaffected 
by the presence, or absence, of inflammatory activity (Henriksen et al., 2018). The 
authors made no comment on the association between these symptoms and 
psychological health or quality of life. Taken into context with the findings of the 
present study, where no difference in mean FC level was observed between patients 
reporting IBS-type symptoms, and those defined as having quiescent disease, these 
studies refute the assertion that occult inflammatory activity is the sole cause of IBS-
type symptom-reporting in patients with IBD. 
 The aetiology of functional symptoms in IBD remains uncertain and is likely to 
be multi-factorial, as was discussed earlier. The association between IBS-type 
symptom-reporting and psychological co-morbidity, but not inflammatory activity that 
is described in this and other studies (Berrill et al., 2013; Jonefjall et al., 2016; 
Henriksen et al., 2018), suggests that brain-gut interactions may contribute to the 
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development of these symptoms. Here, patients with IBS-type symptoms and those with 
active disease had higher levels of anxiety, depression, and somatisation compared with 
those with quiescent disease or occult inflammation. In the former group, this suggests a 
brain-gut direction of effect with psychological co-morbidity leading to the generation 
of functional GI symptoms, and in the latter group a gut-brain direction of effect with 
active inflammation leading to psychological symptoms. However, longitudinal studies 
examining the relationship between psychological health, inflammatory activity, and GI 
symptom-reporting are required before this hypothesis can be proven. This deficiency in 
understanding, in combination with the findings presented in Chapter 3, provides further 
rationale for conducting the longitudinal follow-up studies that are described in 
Chapters 5 and 6.  
 These findings have important implications for clinical practice. Firstly, IBS-
type symptoms are common and, with the increased use of biomarkers such as FC, to 
monitor disease activity, the emergence of a cohort of patients with IBS-type symptoms 
without evidence of mucosal inflammation is likely to occur. Secondly, although 
escalation of conventional immunosuppressant and biological therapies has been 
advocated previously in these patients (Vivinus-Nebot et al., 2014), current data does 
not support the efficacy of such drugs when objective evidence of disease activity is 
lacking (Colombel et al., 2010; Schreiber et al., 2005; Reinisch et al., 2012). In addition, 
this approach may be expensive and could expose patients to potential unnecessary risks 
associated with these therapies (Ford and Peyrin-Biroulet, 2013; Lichtenstein et al., 
2012). Despite this, there is a paucity of evidence for alternative approaches in this 
group of patients, which further supports the need for novel treatments options 
addressing psychological wellbeing in patients with IBD, and provides the rationale for 
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conducting the systematic review and meta-analysis of RCTs of psychological therapies 
in IBD described in Chapter 7. 
In summary, genuine IBS-type symptoms in IBD are common, and are 
associated with higher levels of anxiety, depression, and somatisation, and reduced 
quality of life. This study has identified a distinct group of patients with ongoing GI 
symptoms in the absence of objective evidence of disease activity. The presence of 
these symptoms is associated with impaired psychological wellbeing and quality of life, 
to a similar degree to that observed in patients with active disease. The cause of these 
symptoms is uncertain, as is their effect on the natural history of IBD, and further 
longitudinal studies examining the relationship between disease activity, IBS-type 
symptoms, and psychological co-morbidity are warranted.  
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CHAPTER 5: Assessing the direction of brain-gut 
interactions in patients with IBD 
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5.1  Introduction 
Mood disorders, such as anxiety or depression, are observed more commonly in 
patients with IBD than in healthy individuals (Panara et al., 2014; Graff et al., 2009; 
Fuller-Thomson and Sulman, 2006; Mittermaier et al., 2004; Goodhand et al., 2012b), 
and are associated with GI symptom-reporting as illustrated in Chapters 3 and 4. 
However, the direction of the relationship between the gut and brain in IBD is unclear. 
In people with FGIDs, longitudinal studies suggest that there is a higher risk of 
developing anxiety or depression in people without mood disorders who report GI 
symptoms at baseline, but also an increased likelihood of asymptomatic people who 
demonstrate anxiety or depression at baseline developing GI symptoms de novo 
(Koloski et al., 2012; Koloski et al., 2016). This raises the possibility that the 
relationship between brain and gut may also be bi-directional in IBD. Hence, co-existent 
anxiety or depression, if unrecognised or untreated, may have deleterious effects on the 
subsequent natural history and prognosis of IBD, while untreated or refractory disease 
activity may have implications for future psychological health.  
These are important issues because patients with quiescent IBD may be at a 
lower risk of relapse if co-existing mood disorders are identified and treated. This in 
turn may lead to a more benign disease course, with a reduced need for subsequent 
escalation of medical therapy, hospitalisation, or surgery. Conversely, patients with 
active IBD may be at risk of developing potentially treatable mood disorders, which are 
known to negatively affect quality of life, as described in Chapter 4. The aim of this 
longitudinal follow-up study, conducted over a minimum of 2 years, was to investigate 
the possibility that brain-gut interactions in IBD may be bi-directional. On the basis of 
previous research, where a bi-directional relationship between the brain and gut has 
been identified in FGIDs (Koloski et al., 2012; Koloski et al., 2016), the hypothesis was 
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that the same relationships would exist between anxiety and depression, and disease 
activity in IBD. Confirmation of a bi-directional relationship between mood and disease 
activity would reinforce the need for the integration of therapies targeting inflammatory 
activity with novel interventions aiming to improve psychological wellbeing in patients 
with IBD, including psychological therapies, addressed in Chapter 7. 
 
5.2  Methods 
 
5.2.1 Participants and setting 
Individuals recruited into the cross-sectional study described in Chapters 3 and 4 
were sent a postal invitation to participate in a longitudinal follow-up study, after a 
minimum interval of 2 years had elapsed. All patients had an established radiological, 
histological, or endoscopic diagnosis of CD or UC, and were aged ≥16 years at the time 
of baseline recruitment. Exclusion criteria were an inability to understand written 
English, a diagnosis of IBD-unclassified, and anyone with an end ileostomy or 
colostomy, due to the difficulties in assessing disease activity indices in these patients. 
The follow-up postal invitation included a written information sheet explaining the 
nature of the study, a consent form, and a questionnaire similar to that completed at 
baseline. If no response to the initial invitation to participate was received, a second 
questionnaire was sent. In order to maximise response rates, non-responders to the 
postal invitation into the study were also contacted at their scheduled outpatient clinic 
appointments during the study period. The longitudinal follow-up study was approved 
by the local research ethics committee in September 2014 (REC ref: 12/YH/0443), and 
data collection continued until June 2017. Study findings were reported in accordance 
with the STROBE guidelines for reporting observational studies (von Elm et al., 2008). 
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5.2.2 Data collection and synthesis 
Date of recruitment into the original cross-sectional survey, demographic data, 
type of IBD, medications, Rome III IBS symptom data (Longstreth et al., 2006), 
somatisation data, captured using the PHQ-15 (Kroenke et al., 2002), and FC 
(Immundiagnostik, Bensheim, Germany) were recorded at baseline, as described in 
Chapters 3 and 4. In total, 401 (50.2%) of 799 patients provided a stool sample for FC 
analysis at baseline. 
 
5.2.2.1 Longitudinal objective assessment of IBD activity 
This was performed both at baseline and follow-up using the HBI for CD 
(Harvey and Bradshaw, 1980), and SCCAI for UC (Walmsley et al., 1998), with a score 
≥5 used to define clinical disease activity for both, as previously recommended 
(Vermeire et al., 2010; Jowett et al., 2003). Objective assessment of disease activity 
during longitudinal follow-up was made by detailed case note review by a sole 
investigator (DJG), blinded to the baseline questionnaire data. The case notes of each 
patient included at baseline were assessed for the following clinical endpoints, with the 
date of each endpoint recorded, where applicable: glucorticosteroid prescription or flare 
of disease activity identified by physician’s global assessment, escalation of medical 
therapy due to uncontrolled disease activity, hospitalisation secondary to objectively 
confirmed IBD activity, and intestinal resection. Escalation of medical therapy in 
response to therapeutic drug monitoring, but in the absence of inflammatory activity, 
was not included as an endpoint, nor was surgical intervention for isolated perianal CD.  
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5.2.2.2 Definition of normal and abnormal anxiety and depression scores 
This was as described in Chapters 3 and 4, with the presence of either anxiety or 
depression again assessed using the HADS (Zigmond and Snaith, 1983), and severity 
categorised as previously described (Zigmond and Snaith, 1983). 
  
5.2.3 Statistical analysis 
 All baseline data between those who responded to the follow-up questionnaire 
and those who did not were compared using a χ2 test for categorical variables, and an 
independent samples t-test for continuous data. 
To assess for the presence of a gut-to-brain interaction during longitudinal 
follow-up, the proportion of patients with new-onset abnormal anxiety or depression 
scores (i.e. normal HADS scores at baseline, but above threshold HADS anxiety or 
depression scores at follow-up) was compared according to baseline IBD activity. HBI 
or SCCAI scores ≥5 were used to define active disease at baseline, but a sensitivity 
analysis was also performed in patients with biochemical evidence of IBD activity at 
baseline (FC ≥250µg/g). To assess for the presence of a brain-to-gut interaction during 
longitudinal follow-up, the proportion of patients with clinically quiescent disease at 
baseline (defined by HBI or SCCAI scores <5) who subsequently developed one of the 
objective measures of disease activity detailed above, was compared according to the 
presence of either abnormal HADS anxiety or depression scores  at baseline. 
Furthermore, the relationship between the presence of clinical disease activity at follow-
up (defined by HBI or SCCAI scores ≥5) and the presence of baseline psychological co-
morbidity was also assessed in patients with HBI or SCCAI scores <5 at baseline, 
dichotomised into those with and without abnormal HADS anxiety or depression scores 
at baseline. Again sensitivity analysis, where only those in clinical remission and with 
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no biochemical evidence of IBD activity at baseline (FC <250µg/g) were considered as 
having quiescent disease, were conducted for all these analyses. Proportions were 
compared using a χ2 test. A 2-tailed P value of 0.05 was considered to be statistically 
significant for all these analyses. 
Independent predictors of the development of abnormal anxiety or depression 
scores at the point of questionnaire follow-up in those with normal scores at baseline 
were determined by performing multivariate logistic regression analysis to control for 
baseline demographic characteristics, type of IBD, medications, presence or absence of 
Rome III IBS-type symptoms, and somatisation severity. Similarly, multivariate Cox 
regression analysis was performed to indentify independent predictors of any of the 
clinical disease activity endpoints of interest during longitudinal follow-up in those with 
quiescent disease at baseline. A 2-tailed P value of <0.05 was considered to be 
statistically significant, and the results were expressed as ORs or HRs with 95% CIs. 
All statistical analyses were performed using SPSS for Windows version 22.0 (SPSS 
Inc., Chicago, IL, USA). 
 
5.3 Results 
 In total, 405 (50.7%) of 799 patients included in the initial cross-sectional survey 
consented to participate and returned a follow-up questionnaire. Of these, 239 (59.0%) 
had CD and 166 (41.0%) UC. Participants who returned the follow-up questionnaire 
were older, more likely to be married or co-habiting, and were more likely to fulfil the 
Rome III criteria for IBS. There were no other differences in baseline characteristics, 
including disease activity, defined by either FC or clinical disease activity indices, or 
psychological co-morbidity, between responders and non-responders (Table 14). 
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Table 14: Baseline demographic, disease-related, and psychological characteristics 
of responders and non-responders to the follow-up questionnaire 
 Follow-up  
questionnaire  
responder  
(n = 405) 
Follow-up  
questionnaire  
non-responder 
(n = 394) 
P value* 
Mean age in years (SD) 46.8 (16.4) 41.0 (16.4) <0.001 
Female gender (%) 234 (57.8) 205 (52.0) 0.10 
Caucasian ethnicity (%) 386 (95.8) 359 (92.1) 0.03 
Married or co-habiting (%) 265 (65.6) 217 (55.9) 0.005 
University/postgraduate (%) 112 (28.0) 111 (28.7) 0.83 
Mean BMI (SD) 26.6 (5.5) 26.1 (5.5) 0.26 
Tobacco user (%) 65 (16.1) 71 (18.1) 0.46 
Alcohol user (%) 264 (65.5) 254 (64.6) 0.80 
Crohn's disease (%) 239 (59.0) 220 (55.8) 0.36 
5-ASA use (%) 189 (46.7) 185 (47.0) 0.94 
Immunomodulator use (%) 153 (37.8) 133 (33.8) 0.24 
Anti-TNFα use (%) 85 (21.0) 67 (17.0) 0.15 
Glucocorticosteroid use (%) 44 (10.9) 39 (9.9) 0.66 
Rome III IBS criteria fulfilled (%) 166 (41.5) 128 (33.3) 0.02 
HBI/SCCAI <5 (%) 229 (58.9) 214 (58.0) 0.81 
FC <250µg/g (%) 152 (62.8) 89 (56.0) 0.17 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
215 (53.6) 
82 (20.4) 
104 (25.9) 
 
207 (53.4) 
76 (19.6) 
105 (27.1) 
 
 
 
0.92 
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HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
306 (76.3) 
47 (11.7) 
48 (12.0) 
 
292 (74.7) 
52 (13.3) 
47 (12.0) 
 
 
 
0.79 
PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
52 (13.5) 
126 (32.7) 
132 (34.3) 
75 (19.5) 
 
66 (17.6) 
113 (30.2) 
119 (31.8) 
76 (20.3) 
 
 
 
 
0.41 
*Independent samples t-test for continuous data, and χ2 for categorical data. 
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5.3.1 Association between baseline disease activity and the development of 
abnormal anxiety scores during longitudinal follow-up 
 There were 192 patients with normal HADS anxiety and depression scores at 
baseline, and 22 (11.5%) of these developed abnormal anxiety scores at the point of 
follow-up. Of these 22, 11 (50.0%) had evidence of clinical disease activity at baseline, 
compared with 46 (27.1%) of the 170 patients who did not develop abnormal anxiety 
scores (P = 0.03; Table 15). Following multivariate logistic regression analysis, clinical 
disease activity remained significantly associated with the development of abnormal 
anxiety scores (OR = 5.17; 95% CI 1.35-19.8). In sensitivity analysis, when FC 
≥250µg/g was used to define baseline disease activity, there was no association between 
this and abnormal anxiety scores (P = 0.80; Table 15), and this was confirmed following 
logistic regression analysis (OR = 2.38; 95% CI 0.14-41.0).  
 
5.3.2 Association between baseline disease activity an development of abnormal 
depression scores during longitudinal follow-up 
Of the 192 patients with normal HADS anxiety and depression scores at 
baseline, only three (1.6%) developed abnormal depression scores during follow-up. 
There was no significant association between baseline disease activity and the 
development of abnormal depression scores (Table 15), and too few patients developing 
abnormal depression scores to perform logistic regression analysis. Sensitivity analysis 
for abnormal depression scores could not be performed, because none of the three 
patients provided FC at baseline. 
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Table 15: Relationship between the presence of IBD activity at baseline and 
subsequent development of abnormal anxiety or depression scores, among patients 
with normal anxiety and depression scores at baseline 
 Normal 
follow-up 
HADS 
anxiety score 
Abnormal 
follow-up 
HADS anxiety 
score 
P 
value 
Normal follow-
up  HADS  
depression 
score 
Abnormal 
follow-up 
HADS 
depression 
score 
P 
value 
HBI/SCCAI 
≥5 (%) 
46/170 
(27.1) 
11/22 
(50.0) 
0.03 56/189 
(29.6) 
1/3 
(33.3) 
0.89 
FC ≥250µg/g 
(%) 
45/112 
(40.2) 
4/9 
(44.4) 
0.80 49/121 
(40.5) 
0/0 
(0) 
N/A 
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5.3.3 Association between baseline abnormal anxiety scores and development of 
disease activity during longitudinal follow-up 
 
5.3.3.1 Glucorticosteroid prescription or flare of disease activity 
Of 388 patients with clinically quiescent disease at baseline, 128 (33.0%) 
required a prescription of glucocorticosteroids or developed a flare of disease activity 
over a mean length of follow-up of 838 days (SD ± 436 days). Of these 128, 35 (27.3%) 
had abnormal anxiety scores at baseline, compared with 38 (14.6%) of the 260 patients 
who did not (P = 0.003; Table 16). When only need for glucocorticosteroids was 
considered, there were 22 (30.6%) of 72 patients requiring a glucocorticosteroid 
prescription with abnormal anxiety scores at baseline, compared with 51 (16.1%) of 316 
not requiring a glucocorticosteroid prescription (P = 0.005). Following multivariate Cox 
regression analysis, baseline abnormal anxiety scores were associated with 
glucocorticosteroid prescription or a flare of disease activity (HR = 2.08; 95% CI 1.31-
3.30; Table 17 and Figure 5). In sensitivity analysis, abnormal baseline anxiety scores 
remained associated with need for glucocorticosteroid prescription or flare of disease 
activity (P = 0.02; Table 18), and this was also the case following Cox regression 
analysis (HR = 2.29; 95% CI 1.03-5.07).  
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Table 16: Relationship between the presence of abnormal anxiety or depression scores at baseline, and subsequent development of IBD 
activity, among patients with IBD in clinical remission at baseline 
 Glucorticosteroid 
prescription or flare of 
disease activity 
Escalation of medical 
therapy in response to 
uncontrolled disease activity 
Hospitalisation due to 
disease activity 
Intestinal resection Clinical disease activity 
No 
 
Yes P 
Value 
No 
 
Yes 
 
P 
value 
No 
 
Yes 
 
P 
Value 
No 
 
Yes P 
value 
No Yes P 
value 
Abnormal 
baseline 
anxiety 
score (%) 
38/260 
(14.6) 
35/128 
(27.3) 
0.003 37/255 
(14.5) 
38/148 
(25.7) 
0.005 59/365 
(16.2) 
17/58 
(29.3) 
0.02 69/401 
(17.2) 
7/22 
(31.8) 
0.08 32/179 
(17.9) 
11/47 
(23.4) 
0.39 
Abnormal 
baseline 
depression 
score (%) 
13/259 
(5.0) 
4/128 
(3.1) 
0.39 13/254 
(5.1) 
5/148 
(3.4) 
0.42 16/364 
(4.4) 
5/58 
(8.6) 
0.17 18/400 
(4.5) 
3/22 
(13.6) 
0.06 6/178 
(3.4) 
6/47 
(12.8) 
0.01 
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Table 17: Independent predictors of subsequent IBD activity following multivariate Cox regression analysis, among patients with IBD in 
clinical remission at baseline 
 Glucorticosteroid 
prescription or flare of 
disease activity 
Escalation of medical 
therapy in response to 
uncontrolled disease 
activity 
Hospitalisation due to 
disease activity 
Intestinal resection Clinical disease activity 
Hazard ratio  
(95% CI) 
P value Hazard ratio 
(95% CI) 
P value Hazard ratio  
(95% CI) 
P value Hazard ratio 
(95% CI) 
P value Hazard ratio 
(95% CI) 
P value 
Female sex 0.82 
(0.56-1.22) 
0.33 0.89 
(0.62-1.29) 
0.53 1.12 
(0.63-1.98) 
0.70 1.13 
(0.43-2.98) 
0.81 2.55 
(1.15-5.65) 
0.02 
Age (per year) 0.96 
(0.95-0.98) 
<0.001 0.97 
(0.96-0.98) 
<0.001 0.97 
(0.94-0.99) 
0.002 0.96 
(0.91-1.00) 
0.06 0.99 
(0.97-1.02) 
0.55 
Married or co-habiting 1.10 
(0.73-1.66) 
0.64 1.49 
(1.01-2.21) 
0.05 1.22 
(0.67-2.24) 
0.52 0.58 
(0.20-1.65) 
0.31 1.00 
(0.49-2.06) 
1.00 
Tobacco use 1.28 
(0.72-2.27) 
0.40 0.97 
(0.56-1.66) 
0.90 1.66 
(0.79-3.50) 
0.19 1.52 
(0.44-5.18) 
0.51 1.90 
(0.81-4.47) 
0.14 
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Alcohol use 0.60 
(0.40-0.91) 
0.02 0.74 
(0.51-1.08) 
0.12 0.45 
(0.25-0.81) 
0.008 1.14 
(0.38-3.46) 
0.82 0.74 
(0.36-1.52) 
0.41 
University/postgraduate 
education 
1.12 
(0.73-1.71) 
0.61 1.10 
(0.74-1.63) 
0.65 0.76 
(0.38-1.51) 
0.43 0.90 
(0.30-2.71) 
0.85 0.75 
(0.30-1.84) 
0.53 
BMI (per unit) 1.04 
(1.00-1.07) 
0.03 1.02 
(0.99-1.06) 
0.24 1.03 
(0.98-1.08) 
0.28 1.06 
(0.97-1.17) 
0.20 0.99 
(0.93-1.06) 
0.77 
Crohn’s disease 0.54 
(0.32-0.90) 
0.02 0.79 
(0.49-1.28) 
0.35 0.68 
(0.29-1.57) 
0.36 0.41 
(0.04-4.15) 
0.45 1.39 
(0.58-3.30) 
0.46 
5-ASA use at baseline 1.06 
(0.65-1.72) 
0.82 0.97 
(0.61-1.54) 
0.90 0.60 
(0.28-1.31) 
0.20 0.15 
(0.02-1.39) 
0.10 1.20 
(0.54-2.66) 
0.65 
Immunosuppressant use at 
baseline 
1.15 
(0.77-1.73) 
0.49 0.73 
(0.50-1.08) 
0.12 1.60 
(0.87-2.94) 
0.13 1.25 
(0.47-3.29) 
0.66 0.56 
(0.28-1.14) 
0.11 
Anti-TNFα use at baseline 0.90 
(0.52-1.54) 
0.70 1.33 
(0.83-2.14) 
0.24 1.36 
(0.66-2.80) 
0.40 1.31 
(0.48-3.55) 
0.60 0.79 
(0.32-1.90) 
0.59 
Glucorticosteroid use at 
baseline 
1.81 
(0.96-3.42) 
0.07 2.56 
(1.51-4.32) 
<0.001 2.91 
(1.46-5.78) 
0.002 1.09 
(0.26-4.60) 
0.91 1.48 
(0.46-4.83) 
0.51 
Presence of Rome III IBS-
type symptoms at baseline 
1.17 
(0.77-1.78) 
0.45 1.30 
(0.88-1.91) 
0.18 1.36 
(0.74-2.50) 
0.32 1.09 
(0.38-3.11) 
0.88 1.52 
(0.74-3.10) 
0.25 
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Abnormal anxiety scores at 
baseline 
2.08 
(1.31-3.30) 
0.002 1.82 
(1.19-2.80) 
0.006 1.59 
(0.77-3.31) 
0.21 1.62 
(0.50-5.26) 
0.42 0.88 
(0.35-2.16) 
0.77 
Abnormal depression 
scores at baseline 
0.72 
(0.24-2.10) 
0.54 0.86 
(0.33-2.27) 
0.77 0.79 
(0.22-2.84) 
0.72 0.68 
(0.07-7.06) 
0.75 0.82 
(0.22-3.13) 
0.78 
High level of somatisation 
at baseline 
0.63 
(0.30-1.30) 
0.21 0.72 
(0.36-1.44) 
0.36 1.07 
(0.44-2.59) 
0.88 2.04 
(0.49-8.42) 
0.33 1.01 
(0.34-3.03) 
0.98 
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Figure 5: Survival plot for glucocorticosteroid prescription or flare of disease 
activity between patients with and without anxiety at baseline 
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Table 18: Relationship between presence of abnormal anxiety or depression scores at baseline, and subsequent development of IBD 
activity, among patients with IBD in both clinical and biochemical remission at baseline 
 Glucocorticosteroid 
prescription or flare of 
disease activity 
Escalation of medical 
therapy in response to 
uncontrolled disease activity 
Hospitalisation due to 
disease activity 
Intestinal resection Clinical disease activity 
No 
 
Yes P  
Value 
No 
 
Yes  
 
P  
value 
No  
 
Yes 
 
P  
Value 
No 
 
Yes  P 
value 
No Yes P value 
Abnormal 
baseline 
anxiety 
score (%) 
 
14/97 
 (14.4) 
 
14/46 
 (30.4) 
 
0.02 
 
14/98 
(14.3) 
 
14/45 
(31.1) 
 
0.02 
 
23/130 
 (17.7) 
 
5/13 
 (38.5) 
 
0.07 
 
26/139 
(18.7) 
 
2/4 
 (50.0) 
 
0.12 
 
14/80 
 (17.5) 
 
8/16 
 (50.0) 
 
0.005 
Abnormal 
baseline 
depression 
score (%) 
 
4/97 
 (4.1) 
 
1/46 
 (2.2) 
 
0.55 
 
4/98 
 (4.1) 
 
1/45 
 (2.2) 
 
0.57 
 
5/130 
 (3.8) 
 
0/13 
 (0) 
 
0.47 
 
5/139 
(3.6) 
 
0/4 
 (0) 
 
0.70 
 
1/80 
 (1.3) 
 
4/16 
 (25.0) 
 
<0.001 
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5.3.3.2 Escalation of medical therapy due to uncontrolled disease activity 
Of 403 patients with clinically quiescent disease at baseline, 148 (36.7%) 
underwent escalation of medical therapy in response to uncontrolled IBD activity over a 
mean length of follow-up of 807 days (SD ± 454 days). Of these 148, 38 (25.7%) had 
abnormal anxiety scores at baseline compared with 37 (14.5%) of 255 patients who did 
not undergo escalation of medical therapy (P = 0.005; Table 16). Following multivariate 
Cox regression analysis, baseline abnormal anxiety scores were associated with 
escalation of medical therapy (HR = 1.82; 95% CI 1.19-2.80; Table 17 and Figure 6). In 
sensitivity analysis, abnormal baseline anxiety scores remained associated with 
escalation of medical therapy (P = 0.02; Table 18), and this persisted following Cox 
regression analysis (HR = 2.43; 95% CI 1.13-5.20). 
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Figure 6: Survival plot for escalation of medical therapy in response to 
uncontrolled IBD between patients with and without anxiety at baseline 
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5.3.3.3 Hospitalisation due to IBD activity 
Of 423 patients with clinically quiescent disease at baseline, 58 (13.7%) were 
hospitalised as a result of objectively quantified IBD activity over a mean length of 
follow-up of 979 days (SD ± 414 days). Of these 58, 17 (29.3%) patients had an 
abnormal baseline anxiety score, compared with 59 (16.2%) of 365 patients who were 
not hospitalised (P = 0.02; Table 16). Following multivariate Cox regression analysis, 
baseline abnormal anxiety score was no longer associated with hospitalisation (HR = 
1.59; 95% CI 0.77-3.31; Table 17). In sensitivity analysis, there was no association 
between baseline abnormal anxiety scores and hospitalisation (Table 18). 
 
5.3.3.4 Intestinal resection 
Of 423 patients with clinically quiescent disease at baseline, 22 (5.2%) 
underwent intestinal resection over a mean length of follow-up of 1032 days (SD ± 384 
days). Of these, seven (31.8%) had abnormal baseline anxiety scores compared with 69 
(17.2%) of 401 patients who did not undergo intestinal resection (P = 0.08; Table 16). 
Following multivariate Cox regression analysis, baseline abnormal anxiety scores were 
not associated with intestinal resection (HR = 1.62; 95% CI 0.50-5.26; Table 17). In 
sensitivity analysis, there remained no association between baseline abnormal anxiety 
scores and intestinal resection (Table 18). 
 
5.3.3.5 Clinical disease activity 
Of 226 patients with clinically quiescent disease at baseline (defined as baseline 
HBI or SCCAI score <5), 47 (20.8%) reported symptoms consistent with clinical 
disease activity (defined as HBI or SCCAI score ≥5) over a mean length of follow-up of 
935 days (SD ± 187 days). Of these, 11 (23.4%) had abnormal baseline anxiety scores, 
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compared with 32 (17.9%) of 179 who did not report symptoms consistent with clinical 
disease activity (P = 0.39; Table 16). Following Cox regression analysis, there remained 
no association between abnormal anxiety scores at baseline and the development of 
clinically active IBD (HR = 0.88; 95% CI 0.35-2.16, Table 17). In sensitivity analysis, 
when only patients in clinical remission with FC <250µg/g at baseline were included, 
abnormal baseline anxiety scores were associated with the development of clinically 
active IBD (P = 0.005; Table 18). There were too few patients to perform Cox 
regression analysis. 
 
5.3.4 Association between baseline abnormal depression scores and development 
of disease activity during longitudinal follow-up 
 
5.3.4.1 Glucocorticosteroid prescription or flare of disease activity 
Of the 128 patients requiring a prescription for glucocorticosteroids or 
developing a flare of disease activity, four (3.1%) had abnormal depression scores at 
baseline, compared with 13 (5.0%) of the 259 patients who did not (P = 0.39; Table 16). 
There remained no association following multivariate Cox regression analysis (HR = 
0.72; 95% CI 0.24-2.10; Table 17), or in sensitivity analysis (Table 18). 
 
5.3.4.2 Escalation of medical therapy due to uncontrolled disease activity 
Of 148 patients undergoing escalation of medical therapy, five (3.4%) had 
abnormal depression scores at baseline compared with 13 (5.1%) of 254 patients who 
did not undergo escalation (P = 0.42; Table 16). Following multivariate Cox regression 
analysis, there was no association between escalation of medical therapy and abnormal 
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depression scores at baseline (HR = 0.86; 95% CI 0.33-2.27; Table 17), and in 
sensitivity analysis (Table 18). 
 
5.3.4.3 Hospitalisation due to IBD activity 
Among the 58 patients hospitalised, five (8.6%) had abnormal baseline 
depression scores, compared with 16 (4.4%) of 364 patients who were not hospitalised 
(P = 0.17; Table 16). There was no association between abnormal depression scores at 
baseline and hospitalisation following multivariate Cox regression analysis (HR = 0.79; 
95% CI 0.22-2.84; Table 17), or in sensitivity analysis (Table 18). 
 
5.3.4.4 Intestinal resection 
Of 22 patients undergoing intestinal resection, three (13.6%) had abnormal 
baseline depression scores compared with 18 (4.5%) of 400 patients who did not 
undergo resection (P = 0.06; Table 16). Following Cox regression analysis, there was no 
association between baseline abnormal depression scores and intestinal resection (HR = 
0.68; 95% CI 0.07-7.06; Table 17), and this remained the case in sensitivity analysis 
(Table 18). 
 
5.3.4.5 Clinical disease activity 
Six (12.8%) of 47 patients reporting symptoms consistent with clinically active 
disease had abnormal baseline depression scores, compared with six (3.4%) of 178 who 
did not report symptoms (P = 0.01; Table 16). However, this association was lost 
following Cox regression analysis (HR = 0.82; 95% CI 0.22-3.13; Table 17). In 
sensitivity analysis, abnormal depression scores were associated with development of 
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clinically active IBD (P <0.001; Table 18). There were too few patients to perform Cox 
regression analysis. 
 
5.4  Discussion 
 Building on the data presented in Chapters 3 and 4, this longitudinal follow-up 
study has demonstrated that bi-directional brain-gut axis interactions appear to exist in 
patients with IBD. Evidence for a gut-to-brain interaction is provided by the 
development of new-onset abnormal anxiety scores in patients with clinically active 
IBD, but no psychological co-morbidity at baseline. A brain-to-gut interaction is 
highlighted by the relationship between antecedent psychological co-morbidity and the 
subsequent development of objective markers of disease activity both in patients in 
clinical remission and, in sensitivity analysis, asymptomatic patients without evidence 
of biochemical IBD activity at baseline. These findings are novel, as previous studies 
examining the temporal relationship between psychological co-morbidity and disease 
activity have addressed either gut-brain, or brain-gut interactions, alone rather than 
describing both simultaneously, as is presented here.  
 This data set comprising almost 800 patients with complete clinical data at 
baseline, over 400 of whom provided longitudinal follow-up questionnaire data, is 
larger than the only other study that has sought to describe these relationships in IBD 
(Sexton et al., 2017). Performing Cox regression analysis allowed the determination of 
independent baseline predictors of subsequent new-onset psychological co-morbidity, 
and new-onset disease activity, after adjusting for other variables, including total 
duration of follow-up in all patients. The definition of normal and abnormal anxiety and 
depression scores at baseline and follow-up used in this study is a further strength. Here, 
only the association between definitely abnormal HADS anxiety and depression scores 
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at baseline with longitudinal disease activity was assessed, rather than including those 
with borderline scores at baseline. Similarly, only patients with definitely normal HADS 
scores at baseline who subsequently developed definitely abnormal scores de novo in 
longitudinal follow-up were classified as developing the psychological endpoints of 
interest. Excluding patients with borderline abnormal HADS scores from these 
definitions ensured that the most conservative estimate of the bi-directional relationship 
between disease activity and psychological co-morbidity over time was reported. 
Additionally, sensitivity analyses, assessing the association between impaired mood and 
longitudinal disease outcomes in patients in clinical remission with no biochemical 
evidence of IBD activity at baseline, meant that the potential confounding effect of 
occult inflammation was controlled for.  
Limitations of this study include the inability to collect FC data on all patients 
included in the initial cross-sectional survey. This meant that, although a sensitivity 
analysis incorporating baseline inflammatory activity was performed, the principle gut-
to-brain findings were based on clinical indices, rather than objectively quantified 
inflammatory activity at baseline. As a result, these analyses were performed in smaller 
numbers of patients. This meant that for longitudinal outcomes, including abnormal 
depression scores, hospitalisation, and intestinal resection, there were too few cases with 
the outcome of interest to perform Cox regression, despite some of these outcomes 
trending towards significance in univariate analysis. In keeping with this theme, 
although longitudinal disease activity endpoints were collected on the basis of 
objectively defined criteria, there is the possibility that some of these endpoints, such as 
escalation of therapy, were reached based on symptoms, rather than true inflammatory 
activity. However, in this UK-based study population, where decisions to escalate to 
biologic therapy are made solely on definite evidence of inflammatory activity, in line 
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with National Institute for Health and Care Excellence guidelines (NICE, 2010; NICE, 
2015a), the impact of this potential confounding factor is likely to be limited. The lack 
of serial FC measurement may also be perceived as a weakness, but this was 
compensated for by using objective clinical markers of the natural history of IBD in the 
brain-to-gut analyses, rather than clinical disease activity indices alone. A further 
limitation was that longitudinal data collection was performed on only two occasions 
during the study period, with data analysed at a group level. Thus, given that the 
relationship between disease activity and psychological distress is likely to be complex, 
and that individualistic psychological factors other than those reported here may 
influence this relationship, these findings may be less robust than assumed. Supporting 
this, a recent within-subject study, using vector autoregressive modelling, with multiple 
time points for individual patients post-myocardial infarction has shown a range of 
different complex interactions between psyche and soma (Rosmalen et al., 2012). This 
kind of personalised response has yet to be delineated in IBD, but may underlie the 
aggregated data outcomes reported here. Finally, the use of HADS scores as a marker of 
anxiety or depression could be criticised as, although these are widely used, their 
psychometric properties have been challenged by some experts (Coyne and van 
Sonderen, 2012). In addition, the HADS does not collect data concerning somatic 
depressive symptoms, such as anhedonia, change in appetite, and irritability, which 
have been shown to be associated with biomarkers of inflammation (van Dooren et al., 
2016), and may also explain the relatively low prevalence of abnormal depression 
scores observed in this study.  
Several previous studies investigating the temporal relationship between disease 
activity and mood in IBD have used clinical indices as the sole determinant of 
longitudinal disease activity (Mittermaier et al., 2004; Persoons et al., 2005; Mikocka-
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Walus et al., 2016; Gaines et al., 2016; Mardini et al., 2004; Lix et al., 2008; Porcelli et 
al., 1996). In doing so, as illustrated by the findings of Chapter 3, the authors only 
provide evidence of a relationship between psychological co-morbidity and subjective 
symptom-reporting, which does not distinguish their findings from those previously 
described in patients with FGIDs (Koloski et al., 2012; Koloski et al., 2016). In this 
study population, a baseline abnormal anxiety score was significantly associated with 
the development of flare or glucocorticosteroid prescription, escalation of medical 
therapy, and hospitalisation. However, there was no consistent association between 
baseline anxiety scores and subsequent development of clinical disease activity, 
suggesting that the longitudinal objective disease activity endpoints used in this study 
are likely to reflect the presence of genuine inflammatory activity, rather than subjective 
symptom-reporting alone. This is further supported by the fact that there was no 
significant association between high levels of somatoform-type behaviour and the 
longitudinal disease activity endpoints used.  
The findings of Chapter 3 go some way to deconstructing the complex 
relationship between inflammatory activity, GI symptom-reporting, and psychological 
co-morbidity in IBD. Added to that, in Chapter 4, the identification of a well-
characterised group patients with IBD with co-existent IBS-type symptoms, who suffer 
from anxiety and depression to the same degree as patients with overt inflammatory 
activity, provided the rationale for conducting the longitudinal study that is presented 
here. Although this study helps delineate the temporal relationship between symptom-
reporting, psychological co-morbidity, and inflammatory activity by its identification of 
bi-directional brain-gut interactions, it fails to address the potential impact of co-existent 
IBS-type symptom-reporting on longitudinal disease activity outcomes, specifically. In 
this study, following multivariate Cox regression analysis, fulfilling the Rome III 
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criteria at baseline was not associated with any of the four objective outcomes used to 
assess longitudinal disease activity (Table 17), nor was it associated with the 
development of new-onset psychological co-morbidity (OR = 2.29; 95% CI 0.57-9.20). 
However, this study did not aim to address this issue specifically, as the methodology 
described in Chapter 4 that successfully identified IBS-type symptom-reporters, was not 
adopted. This lack in understanding of the impact of IBS-type symptom-reporting on 
longitudinal disease activity outcomes is important, as these symptoms affect one-in-
four patients with IBD, and treatment options for these patients are not evidence-based. 
The study described in Chapter 6 aims to resolve these uncertainties. 
To summarise the findings of this study, bi-directional brain-gut axis 
interactions appear to exist in patients with IBD. Patients with normal anxiety scores at 
baseline and clinically active disease had over five  times the odds of developing 
abnormal anxiety scores during follow-up, when compared with patients in clinical 
remission. Similarly, patients with quiescent disease activity at baseline, but abnormal 
anxiety scores, had two-fold higher rates of flare of disease activity or need for 
glucocorticosteroids, and escalation of therapy. An acceptance of the existence of brain-
gut axis activity in IBD, and its influence on disease course, has important implications 
for future management strategies. Evidence supporting the use of psychological 
therapies and antidepressants in IBD is poor (Macer et al., 2017; Timmer et al., 2011), 
and in the latter instance outdated. Thus, these findings underline the need for the 
development of a novel approaches towards IBD management, away from one that 
focuses solely on the management of inflammatory activity, to one that integrates this 
with the need for proactive management of psychological wellbeing. 
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CHAPTER 6: Describing the association between the 
reporting of IBS-type symptoms, and longitudinal disease 
activity, healthcare utilisation, psychological health, and 
quality of life in IBD 
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6.1 Introduction 
As described in Chapter 4, IBS-type symptom-reporting in IBD is common, and 
is associated with considerable psychological co-morbidity and reduced quality of life. 
Until now, the majority of studies that have drawn attention to the prevalence and 
impact of IBS-type symptoms in patients with IBD have been cross-sectional in nature 
(Berrill et al., 2013; Keohane et al., 2010; Jonefjall et al., 2016; Henriksen et al., 2018). 
Thus, the relationship between reporting these symptoms and the longer-term natural 
history and prognosis of IBD patients remains uncertain.  
The aim of this study was to address this issue in a longitudinal follow-up study 
of the patients who were recruited into the cross-sectional study described in Chapter 4. 
Specifically, the aims were to assess the relationship between reporting IBS-type 
symptoms at study entry and subsequent disease activity, healthcare utilisation, 
psychological well-being, and quality of life during a minimum follow-up period of 2 
years. The results described in Chapter 5 have shown that, following multivariate Cox 
regression analysis, in patients with quiescent disease at baseline, fulfilling the Rome III 
criteria for IBS was not associated with adverse longitudinal disease activity outcomes. 
This, in conjunction with the results of RCTs that have indirectly assessed the efficacy 
of biological therapy for the treatment of these patients, and found it to be poor 
(Schreiber et al., 2005; Colombel et al., 2010; Reinisch et al., 2012) helped to inform 
the hypothesis for this study, which was that these symptoms are not due to occult 
inflammatory activity, and that there would be no association between IBS-type 
symptom-reporting and adverse longitudinal disease activity outcomes.  
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6.2 Methods 
  
6.2.1 Participants and setting 
Individuals recruited into the cross-sectional study described in Chapter 4 were 
included in this longitudinal follow-up study. Participants were sent a follow-up postal 
invitation to participate as outlined in Chapter 5. The longitudinal follow-up study was 
approved by the local research ethics committee in September 2014 (REC ref: 
12/YH/0443), and data collection continued until June 2017. Study findings were 
reported in accordance with the STROBE guidelines for observational studies (von Elm 
et al., 2008). 
 
6.2.2 Data collection and synthesis 
Date of recruitment into the original cross-sectional survey, demographic data, 
type of IBD, medication use for IBD, Rome III IBS symptom data, anxiety and 
depression data, somatisation data, quality of life data, and FC (Immundiagnostik, 
Bensheim, Germany) were recorded at baseline, as described in Chapter 3. 
 
6.2.2.1 Definition of disease activity and presence of IBS-type symptoms 
 This was as described in Chapter 4. Sensitivity analysis, using a FC <100µg/g 
stool to define quiescent disease, was again performed. 
 
6.2.2.2 Definition of anxiety or depression 
This was as described in Chapters 3, 4, and 5, and for these reasons is not 
reported in detail here. The presence of either anxiety or depression was assessed using 
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the HADS (Zigmond and Snaith, 1983), with severity categorised as previously 
described (Zigmond and Snaith, 1983).  
 
6.2.2.3 Definition of somatisation severity 
This was as described in Chapters 3 and 4, with somatisation data collected 
using the PHQ-15 (Kroenke et al., 2002), and severity categorised into high (total PHQ-
15 ≥15), medium (10-14), low (5-9), and minimal (≤4) levels of somatisation severity 
(Kroenke et al., 2002). 
 
6.2.2.4 Assessment of quality of life 
 This was as described in Chapter 4. In brief, quality of life data were collected 
using the SF-36 health survey (McHorney et al., 1993). Patients were asked to complete 
the questionnaire giving responses to each question from zero to one hundred, from 
which a mean score for each health domain of the SF-36 was calculated, with higher 
scores indicating more favourable health-related quality of life. 
 
6.2.2.5 Longitudinal objective assessment of IBD activity 
As in Chapter 5, objective assessment of disease activity during longitudinal 
follow-up was made by detailed case note review by a sole investigator (DJG), blinded 
to baseline questionnaire data. The case notes of each patient included at baseline were 
assessed for the following clinical endpoints, with the date of each endpoint recorded, 
where applicable: glucorticosteroid prescription or flare of disease activity identified by 
physician’s global assessment, escalation of medical therapy due to uncontrolled disease 
activity, hospitalisation secondary to objectively confirmed IBD activity, and intestinal 
resection. Escalation of medical therapy in response to therapeutic drug monitoring, but 
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in the absence of inflammatory activity, was not included as an endpoint, nor was 
surgical intervention for isolated perianal CD. 
 
6.2.2.6 Longitudinal assessment of healthcare utilisation 
 Case note review was undertaken to determine the number of clinical encounters 
during follow-up. Specifically, the number of IBD-related clinic appointments, the 
number of IBD helpline telephone calls made in order to obtain IBD specialist nurse 
advice regarding disease management, and the number of radiological and endoscopic 
investigations performed for assessment of disease activity were recorded. Radiological 
investigations included computerised tomography imaging, magnetic resonance 
imaging, or small bowel meal. Imaging for the assessment of isolated perianal disease in 
CD was not included, due to the limited utility of FC as a marker of perianal disease 
activity. Endoscopic investigations performed for the assessment of IBD activity 
including flexible sigmoidoscopy, colonoscopy, or wireless capsule endoscopy were 
recorded. Planned therapeutic endoscopic procedures, and those requested as part of 
IBD-related colorectal cancer surveillance, were not included.  
 
6.2.2.7 Longitudinal assessment of psychological health and quality of life 
 Responses to the follow-up questionnaire, administered after a minimum of 2 
years, were used to assess for the presence of anxiety, depression, somatisation, and to 
measure quality of life, using the same instruments previously described. 
 
6.2.3 Statistical analysis 
Baseline demographic, disease-related, and psychological data for all patients 
with IBD included at baseline was compared between patients with CD and UC. After 
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classification of disease activity and IBS symptom status, baseline demographic 
characteristics, HADS scores, PHQ-15 scores, SF-36 scores, and presence or absence of 
anxiety, depression, or somatisation was compared between patients with IBD reporting 
IBS-type symptoms and the other three groups of patients individually (quiescent 
disease, occult inflammation, or active disease), using a χ2 test for categorical variables, 
and an independent samples t-test for continuous data. Comparisons across all four 
groups were performed using a χ2 test for categorical variables, and a one-way ANOVA 
for continuous data. Where continuous data were not normally distributed, equivalent 
non-parametric tests including the Mann-Whitney U test and Kruskal-Wallis analysis of 
variance were applied. The same comparisons were made between these groups for each 
of the four objective disease activity outcomes and the three measures of healthcare 
utilisation during longitudinal follow-up. Similarly, follow-up HADS scores, PHQ-15 
scores, SF-36 scores, and presence or absence of anxiety, depression, or somatisation at 
follow-up were compared between the four groups to determine the relationship 
between IBS-type symptom-reporting and psychological health and quality of life over 
time. Due to multiple comparisons in all these analyses, a 2-tailed P-value of <0.01 was 
considered statistically significant.  
Independent predictors of the occurrence of any of the objective disease activity 
outcomes of interest were determined by performing multivariate Cox regression 
analysis to control for all baseline demographic characteristics, baseline IBD activity 
category, medications, and the presence or absence of baseline abnormal anxiety or 
depression scores, or high somatisation scores. The results were expressed as HRs with 
99% CIs. Sensitivity analysis using a FC <100µg/g to define those who reported IBS-
type symptoms was also performed. All statistical analyses were performed using SPSS 
for Windows version 22.0 (SPSS Inc., Chicago, IL, USA).  
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6.3 Results 
  
6.3.1 Baseline demographic characteristics 
In total, 360 (95.2%) of 378 patients included in the initial cross-sectional survey 
had available follow-up disease activity data after case note review. Of these, 200 
(55.6%) had CD and 160 (44.4%) UC. At baseline, patients with CD were more likely 
to smoke, to use immunomodulator therapy and anti-TNFα drugs, but less likely to use 
5-ASAs, when compared with those with UC (P <0.001 for all) (Table 19). There was 
no difference in the proportion of patients who were defined as having IBS-type 
symptoms, quiescent disease, occult inflammation, or active disease, and no difference 
in levels of anxiety, depression, or somatisation between patients with CD and UC at 
baseline. Patients with CD had lower mean SF-36 quality of life scores at baseline for 
energy/fatigue (P = 0.005), pain (P = 0.002), and general health (P <0.001) than patients 
with UC. 
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Table 19: Baseline characteristics of patients with CD and UC 
 Crohn’s disease 
(n = 200) 
Ulcerative colitis 
(n = 160) 
P Value* 
Mean age in years (SD) 47.3 (16.7) 51.8 (16.5) 0.01 
Female gender (%) 124 (62.0) 89 (55.6) 0.22 
Married or co-habiting (%) 125 (62.8) 115 (71.9) 0.07 
University graduate/professional (%) 52 (26.1) 48 (30.6) 0.35 
Mean BMI (SD) 26.4 (5.6) 27.2 (5.7) 0.19 
Tobacco user (%) 43 (21.5) 8 (5.0) <0.001 
Alcohol user (%) 122 (61.3) 106 (66.3) 0.33 
5-ASA use (%) 56 (28.0) 130 (81.3) <0.001 
Immunomodulator use (%) 91 (45.5) 36 (22.5) <0.001 
Anti-TNFα use (%) 56 (28.0) 3 (1.9) <0.001 
Glucocorticosteroid use (%) 21 (10.5) 18 (11.3) 0.82 
Disease category (%) 
IBS-type symptoms 
Quiescent disease 
Occult inflammation 
Active disease 
 
54 (27.0) 
69 (34.5) 
47 (23.5) 
30 (15.0) 
 
31 (19.4) 
64 (40.0) 
31 (19.4) 
34 (21.3) 
 
 
 
 
0.14 
Mean HADS anxiety score (SD) 7.6 (4.7) 7.0 (4.9) 0.01 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
105 (52.5) 
39 (19.5) 
56 (28.0) 
 
92 (57.5) 
30 (18.8) 
38 (23.8) 
 
 
 
0.59 
Mean HADS depression score (SD) 5.2 (4.3) 4.6 (4.2) 0.19 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
142 (71.0) 
33 (16.5) 
25 (12.5) 
 
130 (81.8) 
10 (6.3) 
19 (11.9) 
 
 
 
0.01 
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Mean  PHQ-15 score (SD) 10.3 (4.7) 8.9 (5.1) 0.23 
PHQ-15 somatisation categories (%) 
Mild  
Low 
Medium 
High 
 
20 (10.6) 
63 (33.5) 
70 (37.2) 
35 (18.6) 
 
32 (20.8) 
46 (29.9) 
48 (31.2) 
28 (18.2) 
 
 
 
 
0.07 
Median SF-36 quality of life score (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional  problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
85.0 (51.3-95.0) 
50.0 (0.0-100.0) 
100.0 (33.3-100.0) 
40.0 (20.0-60.0) 
68.0 (52.0-84.0) 
75.0 (37.5-87.5) 
67.5 (32.5-80.0) 
40.0 (25.0-60.0) 
 
90.0 (70.0-100.0) 
75.0 (0.0-100.0) 
100.0 (33.3-100.0) 
50.0 (30.0-70.0) 
72.0 (60.0-88.0) 
75.0 (50.0-100.0) 
67.5 (45.0-90.0) 
55.0 (40.0-75.0) 
 
0.05 
0.05 
0.68 
0.005 
0.10 
0.05 
0.002 
<0.001 
Mean FC (SD) 482 (785) 574 (945) 0.31 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-
parametric data, and χ2 for comparison of categorical data. 
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6.3.2 Characteristics of patients with IBD with and without IBS-type symptoms 
 Based on FC results, Rome III IBS-type symptom status, and clinical disease 
activity indices at baseline, the 360 patients with IBD included in longitudinal follow-up 
were divided into four groups at study entry as follows: 85 (23.6%) had IBS-type 
symptoms, 133 (36.9%) had quiescent disease, 78 (21.7%) had occult inflammation, 
and 64 (17.8%) had active disease. Assessment of baseline demographic and disease 
characteristics, psychological data, and quality of life data across the four groups was 
unchanged from that previously reported in Chapter 4. In brief, patients reporting true 
IBS-type symptoms were more likely to be female and to smoke than patients with 
quiescent disease (P = 0.002 for both), but there were no other differences. Mean 
baseline anxiety, depression, and somatisation scores were significantly higher, and 
quality of life scores significantly lower, in patients with IBS-type symptoms when 
compared with patients with quiescent disease or occult inflammation, but were 
equivalent to those observed in patients with active disease. 
 
6.3.3 Association between reporting IBS-type symptoms at baseline and disease 
activity during longitudinal follow-up 
 During longitudinal follow-up, patients reporting IBS-type symptoms at baseline 
were no more likely to receive a glucocorticosteroid prescription or experience a flare of 
disease activity, require escalation of medical therapy in response to uncontrolled IBD 
activity, be hospitalised, or undergo intestinal resection than patients with quiescent 
disease or occult inflammation at baseline (Table 20). However, patients with active 
disease at baseline were more likely to receive a glucocorticosteroid prescription or 
experience a flare of disease activity, or require escalation of medical therapy in 
response to uncontrolled IBD activity, than patients reporting IBS-type symptoms at 
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baseline, and compared with all three of the other patient groups. There was also a non-
significant trend towards patients with active disease being more likely to require 
hospitalisation or intestinal resection, compared with the other three groups (P = 0.01 
and P = 0.02, respectively). Sensitivity analyses using a FC <100µg/g to define those 
who reported IBS-type symptoms as having IBD with IBS-type symptoms are provided 
in Table 21. The lack of any association between presence of IBS-type symptoms at 
baseline and subsequent disease activity remained consistent.  
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Table 20: Association between reporting IBS-type symptoms at baseline and objective markers of disease activity during longitudinal 
follow-up, after FC analysis using cut off <250µg/g 
 IBD with IBS-
type symptoms 
(n = 85) 
Quiescent 
IBD 
(n = 133) 
P 
value* 
IBD with occult 
inflammation 
(n = 78) 
P 
value* 
Active IBD 
(n = 64) 
P 
value* 
P 
value† 
Glucocorticosteroid prescription or flare of 
disease activity (%) 
36 (42.4) 43 (32.3) 0.13 29 (37.2) 0.50 45 (70.3) 0.001 <0.001 
Escalation of medical therapy in response to 
uncontrolled IBD activity (%) 
32 (37.6) 42 (31.6) 0.36 27 (34.6) 0.69 44 (68.8) <0.001 <0.001 
Hospitalisation due to disease activity (%) 10 (11.8) 11 (8.3) 0.39 9 (11.5) 0.96 16 (25.0) 0.04 0.01 
Intestinal resection (%) 5 (5.9) 4 (3.0) 0.30 3 (3.8) 0.55 9 (14.1) 0.09 0.02 
*χ2 for comparisons vs. IBD with IBS-type symptoms.  
†χ2 for comparison across all four groups. 
 
 
 
  
 
 
1
9
2
 
Table 21: Association between reporting IBS-type symptoms at baseline and objective markers of disease activity during longitudinal 
follow-up, after FC analysis using cut off <100µg/g 
 IBD with IBS-
type symptoms 
(n = 54) 
Quiescent 
IBD 
(n = 95) 
P 
value* 
IBD with occult 
inflammation 
(n = 122) 
P 
value* 
Active IBD 
(n = 89) 
P 
value* 
P 
value† 
Glucocorticosteroid prescription or flare of 
disease activity (%) 
23 (42.6) 28 (29.5) 0.11 45 (36.9) 0.47 57 (64.0) 0.01 <0.001 
Escalation of medical therapy in response to 
uncontrolled IBD activity (%) 
19 (35.2) 27 (28.4) 0.39 43 (35.2) 0.99 56 (62.9) 0.001 <0.001 
Hospitalisation due to disease activity (%) 3 (5.6) 6 (6.3) 0.85 16 (13.1) 0.14 21 (23.6) 0.005 0.001 
Intestinal resection (%) 1 (1.9) 1 (1.1) 0.68 7 (5.7) 0.25 12 (13.5) 0.02 0.002 
*χ2 for comparisons vs. IBD with IBS-type symptoms.  
†χ2 for comparison across all four groups. 
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Following multivariate Cox regression analysis, during a mean length of follow-
up of 754 days (SD ± 517), patients reporting IBS-type symptoms had a similar 
likelihood of requiring a glucocorticosteroid prescription or experiencing a flare of 
disease activity to those with quiescent disease (HR = 0.66; 99% CI 0.35-1.24) or occult 
inflammation (HR = 0.82; 99% CI 0.39-1.71) at baseline (Table 22 and Figure 7). 
However, this endpoint was significantly more likely in patients with active disease at 
baseline (HR = 3.16; 99% CI 1.65-6.07). Similarly, over a mean length of follow-up of 
773 days (SD ± 505), when compared with patients reporting IBS-type symptoms at 
baseline, need for escalation of medical therapy in response to uncontrolled IBD activity 
was significantly higher in patients with active disease at baseline (HR = 3.24; 99% CI 
1.70-6.20). However, the likelihood of this event was similar in patients with IBS-type 
symptoms and those with quiescent disease (HR = 0.80; 99% CI 0.41-1.55) or occult 
inflammation (HR = 0.87; 99% CI 0.39-1.91) (Table 22 and Figure 8). There were no 
differences in need for hospitalisation, over a mean length of follow-up of 1019 days 
(SD ± 430), or intestinal resection, over a mean length of follow-up of 1073 days (SD ± 
1117), when patients with IBS-type symptoms were compared with those with 
quiescent disease, occult inflammation, or active disease at baseline (Table 22 and 
Figures 9 and 10, respectively). Sensitivity analyses using a FC <100µg/g revealed 
similar findings (Table 23). 
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Table 22: Baseline independent predictors of objective markers of disease activity during longitudinal follow-up 
 Glucorticosteroid 
prescription or flare of 
disease activity 
Escalation of medical 
therapy in response to 
uncontrolled IBD activity 
Hospitalisation due to 
disease activity 
Intestinal resection 
Hazard ratio 
(99% CI) 
P value Hazard ratio 
(99% CI) 
P value Hazard ratio 
(99% CI) 
P value Hazard ratio 
(99% CI) 
P value 
Female sex 1.05 (0.64-1.72) 0.79 0.91 (0.54-1.54) 0.66 0.85 (0.34-2.08) 0.64 1.89 (0.36-9.80) 0.32 
Age (per year) 0.97 (0.96-0.99) <0.001 0.98 (0.96-0.99) <0.001 0.98 (0.95-1.01) 0.07 0.99 (0.94-1.04) 0.66 
Married or co-habiting 0.92 (0.57-1.48) 0.64 1.52 (0.88-2.63) 0.05 1.32 (0.51-3.40) 0.46 0.70 (0.18-2.83) 0.52 
Tobacco use 0.37 (0.15-0.94) 0.006 0.69 (0.32-1.48) 0.22 0.71 (0.18-2.86) 0.53 1.61 (0.31-8.25) 0.45 
Alcohol use 1.04 (0.63-1.71) 0.83 0.95 (0.57-1.60) 0.80 0.64 (0.26-1.58) 0.20 0.30 (0.07-1.30) 0.04 
University/postgraduate education 0.96 (0.57-1.59) 0.82 0.89 (0.52-1.54) 0.59 0.81 (0.28-2.35) 0.62 1.36 (0.25-7.54) 0.64 
Body mass index (per unit) 1.01 (0.98-1.06) 0.35 1.03 (0.99-1.07) 0.07 1.05 (0.98-1.12) 0.10 1.02 (0.91-1.14) 0.64 
Crohn’s disease 0.66 (0.37-1.76) 0.06 0.69 (0.38-1.26) 0.11 1.12 (0.37-3.42) 0.79 1.09 (0.17-7.06) 0.90 
5-ASA use 1.29 (0.72-2.31) 0.26 1.10 (0.60-1.99) 0.69 0.67 (0.23-2.01) 0.35 0.44 (0.07-2.58) 0.23 
Immunosuppressant use 0.85 (0.51-1.41) 0.40 0.56 (0.32-0.98) 0.007 1.30 (0.52-3.23) 0.46 1.04 (0.24-4.46) 0.94 
Anti-TNFα  use 0.81 (0.38-1.76) 0.49 1.05 (0.49-2.24) 0.86 1.49 (0.46-4.83) 0.39 7.41 (1.41-33.9) 0.002 
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Glucorticosteroid use 2.40 (1.30-4.42) <0.001 1.86 (0.97-3.57) 0.01 2.47 (0.89-6.87) 0.02 2.76 (0.38-20.31) 0.19 
Disease category 
IBS-type symptoms 
Quiescent disease 
Occult inflammation 
Active disease 
 
Reference 
0.66 (0.35-1.24) 
0.82 (0.39-1.71) 
3.16 (1.65-6.07) 
 
N/A 
0.09 
0.49 
<0.001 
 
Reference 
0.80 (0.41-1.55) 
0.87 (0.39-1.91) 
3.24 (1.70-6.20) 
 
N/A 
0.38 
0.64 
<0.001 
 
Reference 
0.57 (0.17-1.97) 
0.75 (0.19-3.05) 
2.03 (0.66-6.25) 
 
N/A 
0.24 
0.60 
0.11 
 
Reference 
0.63 (0.08-4.88) 
0.58 (0.05-6.73) 
2.82 (0.51-15.5) 
 
N/A 
0.56 
0.56 
0.12 
Abnormal anxiety score 1.12 (0.64-1.96) 0.61 1.30 (0.73-2.31) 0.24 1.73 (0.65-4.57) 0.15 2.13 (0.45-10.1) 0.21 
Abnormal depression score 1.46 (0.70-3.03) 0.19 1.60 (0.76-3.37) 0.11 1.73 (0.53-5.68) 0.24 1.19 (0.18-7.95) 0.82 
High somatisation score 0.73 (0.38-1.42) 0.22 0.94 (0.48-1.84) 0.82 0.73 (0.22-2.37) 0.49 1.21 (0.21-6.96) 0.78 
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Figure 7: Survival plot of the association between reporting IBS-type symptoms and flare of disease activity or glucocorticosteroid 
prescription  
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Figure 8: Survival plot of the association between reporting IBS-type symptoms and escalation of medical therapy in response to 
uncontrolled IBD 
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Figure 9: Survival plot of the association between reporting IBS-type symptoms and hospitalisation 
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Figure 10: Survival plot of the association between reporting IBS-type symptoms and intestinal resection 
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Table 23: Baseline IBS-type symptom status as a predictor of objective markers of disease activity during longitudinal follow-up, after 
FC analysis using a cut off <100µg/g 
 Glucorticosteroid 
prescription or flare of 
disease activity 
Escalation of medical 
therapy in response to 
uncontrolled IBD activity 
Hospitalisation due to 
disease activity 
Intestinal resection 
Hazard ratio 
(99% CI) 
P value Hazard ratio 
(99% CI) 
P value Hazard ratio 
(99% CI) 
P value Hazard ratio 
(99% CI) 
P value 
Disease category 
IBS-type symptoms 
Quiescent disease 
Occult inflammation 
Active disease 
 
Reference 
0.61 (0.28-1.33) 
0.77 (0.37-1.58) 
2.64 (1.30-5.36) 
 
N/A 
0.10 
0.34 
<0.001 
 
Reference 
0.81 (0.35-1.87) 
0.88 (0.40-1.95) 
3.03 (1.44-6.38) 
 
N/A 
0.51 
0.68 
<0.001 
 
Reference 
1.06 (0.15-7.33) 
1.99 (0.36-11.1) 
4.38 (0.83-23.1) 
 
N/A 
0.94 
0.30 
0.02 
 
Reference 
Unable to estimate 
3.40 (0.18-63.4) 
9.19 (0.51-166) 
 
N/A 
0.96 
0.28 
0.05 
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6.3.4 Association between reporting IBS-type symptoms and healthcare 
utilisation during longitudinal follow-up 
 When compared with patients reporting IBS-type symptoms at baseline during a 
mean length of follow-up of 1073 days (SD ± 1117), there was no difference in the 
median number of investigations performed or clinics attended when compared with 
patients with quiescent disease, occult inflammation, or active disease at baseline (Table 
24). Patients reporting IBS-type symptoms made fewer IBD helpline telephone calls 
than patients with active disease (P = 0.007; Table 24), but no difference was observed 
when IBS-type symptom reporters were compared with patients with quiescent disease 
or occult inflammation. When the same comparisons were made across all four groups, 
an overall difference in the number of investigations performed (P = 0.004; Table 24), 
clinic attendances (P = 0.002; Table 24), and helpline calls made (P <0.001; Table 24) 
was observed, which may have been related to increased healthcare utilisation in 
patients with active disease.   
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Table 24: Association between reporting IBS-type symptoms and healthcare utilisation during longitudinal follow-up 
 IBD with IBS-
type symptoms 
(n = 85) 
Quiescent IBD 
(n = 133) 
P 
value* 
IBD with occult 
inflammation 
(n = 78) 
P 
value* 
Active IBD 
(n = 64) 
P 
value* 
P 
value† 
Median number of investigations (IQR) 1.0 (0.0-2.0) 1.0 (0.0-1.0) 0.04 1.0 (0.0-1.3) 0.21 1.0 (1.0-2.0) 0.24 0.004 
 Median number of clinic appointments (IQR) 6.0 (3.5-10.0) 5.0 (3.0-7.5) 0.06 6.0 (3.0-8.0) 0.16 7.5 (5.0-11.0) 0.12 0.002 
Median number of helpline calls (IQR) 0.0 (0.0-2.0) 0.0 (0.0-1.0) 0.30 0.0 (0.0-2.0) 0.51 1.0 (0.0-3.0) 0.007 <0.001 
*Mann-Whitney U test for comparisons vs. IBD with IBS-type symptoms.  
†Kruskal-Wallis analysis of variance for comparison across all four groups.  
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6.3.5 Association between reporting IBS-type symptoms and psychological health 
and quality of life during longitudinal follow-up 
228 (63.3%) of 360 patients returned a follow-up questionnaire and therefore 
provided anxiety, depression, somatisation, and quality of life data after a minimum 
follow-up period of 2 years. There were no significant differences in baseline 
characteristics between patients with IBD who did, and did not, return a follow-up 
questionnaire (Table 25). During longitudinal follow-up (mean duration 928 days (SD ± 
198)), patients reporting IBS-type symptoms at baseline had significantly higher mean 
anxiety, depression, and somatisation scores when compared with patients with 
quiescent disease at baseline (Table 26). These were also generally higher than among 
patients with occult inflammation at baseline, although not statistically significant, but 
were similar to those in patients with active disease at baseline.  
Follow-up quality of life scores across all eight domains of the SF-36 were 
impaired among those reporting IBS-type symptoms at baseline, compared with those 
with either quiescent disease or occult inflammation, and in several instances these 
differences were statistically significant. The degree of impairment of quality of life 
during longitudinal follow-up was similar among patients reporting IBS-type symptoms 
and those with active disease at baseline. 
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Table 25: Baseline characteristics of patients with and without follow-up 
questionnaire data 
 No follow-up 
questionnaire 
returned 
(n = 132) 
Follow-up 
questionnaire 
returned 
(n = 228) 
P value* 
Mean age in years (SD) 47.0 (17.7) 50.7 (16.0) 0.04 
Female gender (%) 71 (53.8 ) 142 (62.3) 0.11 
Married or co-habiting (%) 84 (63.6) 156 (68.7) 0.32 
University graduate/professional (%) 34 (26.0) 66 (29.3) 0.49 
Mean BMI (SD) 26.6 (5.0) 26.8 (6.0) 0.83 
Tobacco user (%) 16 (12.1) 35 (15.4) 0.39 
Alcohol user (%) 79 (59.8) 149 (65.6) 0.27 
Crohn’s disease (%) 67 (50.8) 133 (58.3) 0.16 
Disease category (%) 
IBS-type symptoms 
Quiescent disease 
Occult inflammation 
Active disease 
 
21 (15.9) 
54 (40.9) 
28 (21.2) 
29 (22.0) 
 
64 (28.1) 
79 (34.6) 
50 (21.9) 
35 (15.4) 
 
 
 
 
0.04 
5-ASA use (%) 69 (52.3) 117 (51.3) 0.86 
Immunomodulator use (%) 43 (32.6) 84 (36.8) 0.41 
Anti-TNFα use (%) 15 (11.4) 44 (19.3) 0.05 
Glucocorticosteroid use (%) 17 (12.9) 22 (9.6) 0.34 
Mean HADS anxiety score (SD) 7.7 (5.1) 7.2 (4.6) 0.38 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
74 (56.1) 
23 (17.4) 
35 (26.5) 
 
123 (53.9) 
46 (20.2) 
59 (25.9) 
 
 
 
0.81 
Mean HADS depression score (SD) 5.3 (4.4) 4.7 (4.2) 0.25 
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HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
93 (70.5) 
22 (16.7) 
17 (12.9) 
 
179 (78.9) 
21 (9.3) 
27 (11.9) 
 
 
 
0.10 
Mean  PHQ-15 score (SD) 9.8 (4.9) 9.6 (5.0) 0.69 
PHQ-15 somatisation categories (%) 
Mild  
Low 
Medium 
High 
 
22 (17.3) 
32 (25.2) 
46 (36.2) 
27 (21.3) 
 
30 (14.0) 
77 (35.8) 
72 (33.5) 
36 (16.7) 
 
 
 
 
0.21 
Median SF-36 quality of life score (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional  problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
85.0 (55.0-100.0) 
50.0 (0.0-100.0) 
100.0 (0.0-100.0) 
42.5 (25.0-65.0) 
68.0 (52.0-84.0) 
62.5 (50.0-100.0) 
67.5 (45.0-90.0) 
45.0 (30.0-70.0) 
 
90.0 (65.0-100.0) 
75.0 (0.0-100.0) 
100.0 (33.3-100.0) 
45.0 (27.5-65.0) 
72.0 (56.0-84.0) 
75.0 (50.0-100.0) 
67.5 (45.0-90.0) 
50.0 (30.0-70.0) 
 
0.84 
0.05 
0.05 
0.57 
0.56 
0.23 
0.56 
0.81 
Mean FC (SD) 544 (893) 510 (841) 0.73 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-
parametric data, and χ2 for comparison of categorical data. 
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Table 26: Association between reporting IBS-type symptoms and psychological health and quality of life during longitudinal follow-up 
 IBD with IBS-
type symptoms 
(n = 64) 
Quiescent IBD 
(n = 79) 
P 
value* 
IBD with occult 
inflammation 
(n = 50) 
P 
value* 
Active IBD 
(n = 35) 
 
P 
value* 
P 
value† 
Mean HADS anxiety score (SD)  9.2 (4.8) 6.4 (5.1) 0.001 7.4 (5.0) 0.05 7.7 (4.2) 0.13 0.008 
HADS anxiety categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
23 (35.9) 
12 (18.8) 
29 (45.3) 
 
49 (62.8) 
11 (14.1) 
18 (23.1) 
 
 
 
0.005 
 
27 (54.0) 
12 (24.0) 
11 (22.0) 
 
 
 
0.03 
 
18 (51.4) 
9 (25.7) 
8 (22.9) 
 
 
 
0.09 
 
 
 
0.02 
Mean HADS depression score (SD) 6.8 (4.9) 4.2 (4.0) 0.001 4.8 (4.1) 0.02 6.2 (4.7) 0.57 0.003 
HADS depression categories (%) 
Normal 
Borderline abnormal 
Abnormal 
 
38 (59.4) 
14 (21.9) 
12 (18.8) 
 
61 (78.2) 
11 (14.1) 
6 (7.7) 
 
 
 
0.04 
 
37 (74.0) 
7 (14.0) 
6 (12.0) 
 
 
 
0.26 
 
21 (60.0) 
7 (20.0) 
7 (20.0) 
 
 
 
0.97 
 
 
 
0.20 
Mean  PHQ-15 score (SD) 12.4 (5.2) 8.0 (5.4) <0.001 9.8 (6.3) 0.02 10.8 (4.7) 0.14 <0.001 
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PHQ-15 somatisation categories (%) 
Mild 
Low 
Medium 
High 
 
4 (6.5) 
14 (22.6) 
26 (41.9) 
18 (29.0) 
 
21 (28.4) 
28 (37.8) 
16 (21.6) 
9 (12.2) 
 
 
 
 
<0.001 
 
10 (20.0) 
14 (28.0) 
17 (34.0) 
9 (18.0) 
 
 
 
 
0.10 
 
2 (6.3) 
11 (34.4) 
11 (34.4) 
8 (25.0) 
 
 
 
 
0.67 
 
 
 
 
0.003 
Median SF-36 score (IQR) 
Physical functioning 
Role limitations physical health 
Role limitations emotional problems 
Energy/fatigue 
Emotional well-being 
Social functioning 
Pain 
General health 
 
75.0 (50.0-90.0) 
37.5 (0.0-81.3) 
100.0 (0.0-100.0) 
35.0 (20.0-50.0) 
58.0 (48.0-72.0) 
62.5 (37.5-87.5) 
61.3 (32.5-67.5) 
30.0 (20.0-50.0) 
 
90.0 (70.0-100.0) 
100.0 (50.0-100.0) 
100.0 (66.7-100.0) 
55.0 (30.0-73.8) 
72.0 (57.0-92.0) 
87.5 (50.0-100.0) 
77.5 (56.9-90.0) 
50.0 (35.0-73.8) 
 
<0.001 
<0.001 
0.04 
<0.001 
<0.001 
<0.001 
0.001 
<0.001 
 
85.0 (57.5-95.0) 
75.0 (0.0-100.0) 
100.0 (33.3-100.0) 
40.0 (25.0-65.0) 
76.0 (58.0-84.0) 
75.0 (50.0-100.0) 
68.8 (55.6-87.5) 
50.0 (30.0-65.0) 
 
0.16 
0.26 
0.57 
0.16 
0.007 
0.02 
0.01 
0.01 
 
85.0 (47.5-95.0) 
75.0 (0.0-100.0) 
100.0 (33.3-100.0) 
35.0 (11.3-55.0) 
64.0 (56.0-84.0) 
75.0 (37.5-93.8) 
67.5 (42.5-80.0) 
32.5 (23.8-55.0) 
 
0.23 
0.11 
0.51 
1.00 
0.05 
0.32 
0.42 
0.60 
 
0.003 
<0.001 
0.22 
0.001 
0.001 
0.003 
0.005 
<0.001 
*Independent samples t-test for normally distributed continuous data, Mann-Whitney U test for non-parametric data, and χ2 for comparison of categorical data vs. IBD with 
IBS-type symptoms. 
†One way ANOVA for normally distributed continuous data, Kruskal-Wallis analysis of variance for non-parametric data, and χ2 for comparison of categorical data across all 
four groups. 
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6.4 Discussion 
 This longitudinal follow-up study has demonstrated that the reporting of IBS-
type symptoms in patients with objectively confirmed quiescent IBD is not associated 
with adverse disease activity outcomes, but is associated with a long-term to impairment 
of mood and quality of life. Although the reporting of these symptoms does not appear 
to affect longitudinal disease activity, suggesting that they are not related to occult 
inflammation, their association with impaired psychological well-being and quality of 
life highlights the importance of these findings.  
The association between the reporting of IBS-type symptoms and psychological 
co-morbidity and reduced quality of life has been described in previous studies, (Berrill 
et al., 2013; Jonefjall et al., 2016; Keohane et al., 2010) as well as in Chapter 4, but no 
study, to date, has attempted to address the impact of these symptoms on longitudinal 
outcomes in IBD. Specifically, this is the first study to examine the relationship between 
IBS-type symptom-reporting and subsequent IBD activity, using objective endpoints, 
and to provide data on healthcare utilisation in these patients, as well as the durability of 
the association between the reporting of these symptoms and psychological co-
morbidity and poor quality of life over time.  
Strengths of this study, including its large sample size, the generalisability of its 
findings, the use of validated questionnaires, and the use of Cox regression analysis to 
identify independent predictors of longitudinal disease activity, are in keeping with 
those reported in previous chapters. The stratification of patients into those with IBS-
type symptoms, quiescent disease, occult inflammation, and active disease is a further 
strength as it permitted independent assessment of the longitudinal association between 
baseline inflammatory activity and GI symptom-reporting, and objective measures of 
disease activity, healthcare use, psychological well-being, and quality of life over time. 
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Finally, objective longitudinal disease activity assessment data were collected blinded to 
baseline disease activity and psychological data, therefore eliminating researcher 
confirmation bias.  
 Limitations of this study include the sample size and length of follow-up. 
Following Cox regression analysis, there was no statistically significant difference in 
the need for hospitalisation or intestinal resection when patients reporting IBS-type 
symptoms were compared with those with active disease at baseline. Despite this, in 
univariate analysis, the absolute proportion of patients fulfilling these endpoints was 
higher in those defined as having active disease at baseline. This is likely to be 
secondary to the relatively low event rate for these variables and, if the sample size had 
been larger, or follow-up continued for a longer period of time, these comparisons may 
have become statistically significant. The contentious nature of a FC cut off of 
≥250µg/g used in these analyses has been addressed in previous chapters. For this 
reason, sensitivity analysis was performed using a threshold of ≥100µg/g to define 
mucosal inflammation, and the findings remained consistent.  
 The assessment of quality of life and psychological well-being in longitudinal 
follow-up was based on questionnaire responses at a single point in time after a 
minimum of 2 years. Because of this, no comment on the consistency of the association 
between baseline IBS-type symptom-reporting and psychological well-being and poor 
quality of life over multiple points of follow-up can be made. However, in sensitivity 
analysis, patients reporting IBS-type symptoms who had abnormal anxiety scores at 
baseline were more likely to continue to report abnormal anxiety scores at longitudinal 
follow-up than those who did not (16 (64.0%) of 25 vs. 13 (33.3%) of 39; P = 0.02). 
Similar findings were also true for those with IBS-type symptoms and abnormal 
baseline depression scores (9 (69.2%) of 13 vs. 3 (5.9%) of 51; P <0.001), and high 
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baseline somatisation scores (12 (54.5%) of 22 vs. 5 (13.5%) of 37; P = 0.001). This 
suggests that, in susceptible individuals, the association between IBS-type symptoms 
and psychological co-morbidity is likely to be durable. Finally, due to the low event rate 
for some of the longitudinal disease activity outcomes, and the attrition rate associated 
with administering postal follow-up questionnaires for longitudinal psychological and 
quality of life, data on patients with IBD dichotomised into those with UC and CD were 
not presented.  
 Only one other study has attempted to address the longitudinal impact of IBS-
type symptom-reporting in IBD (Jonefjall et al., 2013). This study reported data from an 
inception cohort of 94 patients with UC followed up annually over a 3-year period. In 
keeping with the findings from this study, the authors describe an association between 
IBS-type symptom-reporting in patients with objectively confirmed quiescent disease, 
and poor psychological well-being and quality of life over time. However, the impact of 
IBS-type symptom-reporting on longitudinal disease activity, or healthcare utilisation, 
was not addressed. In addition, the study population was relatively small, and excluded 
patients with CD. A relationship between IBS-type symptom-reporting and healthcare 
utilisation has been described in another study (Abdalla et al., 2017), but this was cross-
sectional in design, relied on patient recall of healthcare interactions over the preceding 
year, rather than accurate prospective data collection, and did not examine effects on 
investigation requesting. 
 The aetiology of IBS-type symptom-reporting in patients with IBD remains 
uncertain. The role of subclinical mucosal inflammation is debated, with some authors 
suggesting it is likely to be central to the development of these symptoms (Vivinus-
Nebot et al., 2014; Keohane et al., 2010), although the findings reported in Chapter 4 
and those of other investigators refute this (Jonefjall et al., 2013; Berrill et al., 2013; 
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Henriksen et al., 2018). Increased colonic mucosal pro-inflammatory cell infiltrates, and 
increased mucosal TNFα mRNA protein expression have been described in patients 
reporting IBS-type symptoms (Vivinus-Nebot et al., 2014). In keeping with this, raised 
serum levels of pro-inflammatory cytokines, including IL-1β, IL-6, IL-13, IL-10, and 
IL-8 have also been observed in patients reporting IBS-type symptoms (Jonefjall et al., 
2016). Despite this, in the same study, there was no difference in median FC levels 
between patients who did, and who did not, report IBS-type symptoms, although again 
an association between IBS-type symptom-reporting and psychological co-morbidity 
was observed. 
Studies identifying antecedent gastroenteritis as a risk factor for the subsequent 
development of IBS in non-IBD populations have led to the suggestion that post-
inflammatory dysmotility and visceral hypersensitivity may contribute to the 
development of chronic GI symptoms (Thabane et al., 2007). Whether this concept is 
transferrable to the IBD population is unclear, particularly as the extent and severity of 
inflammation at the time of first presentation does not appear to be associated with the 
subsequent development of IBS-type symptoms following mucosal healing in IBD 
(Jonefjall et al., 2015). These findings, in conjunction with the lack of association 
between objective longitudinal disease activity outcomes and IBS-type symptom-
reporting described here, cast further doubt on the role of subclinical inflammation in 
the aetiology of these symptoms.  
The description of a distinct subgroup of patients with occult GI inflammation 
who have objective evidence of inflammatory activity, but who do not report GI 
symptoms, further supports this. When compared with patients with occult 
inflammatory activity, the greater consistency with which psychological co-morbidity 
was associated with IBS-type symptom-reporting suggests that brain-gut axis activation, 
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rather than the presence of subclinical mucosal inflammation, could be central to the 
development of these symptoms. However, this hypothesis remains speculative, 
particularly as, despite the high prevalence of psychological co-morbidity associated 
with the reporting of these symptoms, and the potential existence of bi-directional brain-
gut interactions in IBD described in Chapter 5, no association between adverse 
longitudinal disease activity outcomes was observed in patients reporting IBS-type 
symptoms in this study. Reasons for this could include the fact that, although the 
prevalence of abnormal HADS anxiety (35 (43.8%) of 85) and depression scores (16 
(18.9%) of 85) in patients reporting IBS-type symptoms at baseline was high, 47 
(55.3%) of 85 patients reporting IBS-type symptoms had neither abnormal HADS 
anxiety nor abnormal HADS depression scores at baseline.  This suggests that 
implicating abnormal brain-gut interactions as the sole factor responsible for their 
development may be too simplistic.   
The findings of this study highlight a distinct group of patients with occult 
inflammation who display evidence of ongoing mucosal inflammation, yet do not report 
symptoms consistent with active disease. A surprising finding was that, in these cases, 
no deleterious effect on longitudinal disease activity was observed. The reason for this 
is uncertain, and is in conflict with previously published data (D'Inca et al., 2008; 
Naismith et al., 2014; Turvill, 2014). However, these studies used different levels of FC 
to define occult inflammation at baseline than that described here, and failed to exclude 
patients reporting IBS-type symptoms from their analyses, which may have confounded 
longitudinal disease activity assessment made on the basis of patient reported 
symptoms. 
 This study provides data on an emerging cohort of patients with IBD with 
distinct needs. The lack of association between IBS-type symptom-reporting and 
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objective longitudinal disease activity outcomes may explain the limited efficacy of 
traditional pharmacological therapies in these patients (Colombel et al., 2010; Schreiber 
et al., 2005; Reinisch et al., 2012). Evidence-based management strategies for the 
treatment of IBS exist (Ford et al., 2014c; Ford et al., 2014b; Ford et al., 2009b; Ford et 
al., 2008), but are of unproven benefit in IBD. Trials of alternative therapies, including 
psychological therapies (Timmer et al., 2011), probiotics (Derwa et al., 2017), and 
antidepressants (Mikocka-Walus et al., 2017; Macer et al., 2017) have been conducted 
in patients with IBD but the results have been disappointing, and as will be described in 
Chapter 7, few have addressed the treatment of IBS-type symptoms in IBD specifically. 
In the UK, there has been a recent call from the Health Technology Assessment 
Programme of the National Institute for Health Research for a trial of therapies for 
ongoing diarrhoea and abdominal pain in patients with stable UC, which may help to 
address this deficit in current knowledge. 
 This work highlights the existence of a distinct group of patients with IBD who 
report IBS-type symptoms in the absence of inflammatory activity, and that reporting 
these symptoms is associated with long-term psychological co-morbidity and poor 
quality of life, but not adverse inflammatory disease activity outcomes. The consistent 
association between psychological co-morbidity and IBS-type symptom-reporting over 
time, and the lack of any equivalent relationship with mucosal inflammation, suggests 
that activation of the brain-gut axis, rather than subclinical inflammatory activity, could 
be contributory to the development of these symptoms. Future trials of therapies 
targeting disordered brain-gut axis activity in this specific group of patients with IBD 
may therefore be helpful. 
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CHAPTER 7: Summarising the effect of psychological 
therapies on disease activity, psychological co-morbidity, and 
quality of life in IBD 
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7.1  Introduction 
 As illustrated in Chapter 4, psychological co-morbidity in IBD is associated with 
both symptom-reporting and inflammatory activity. The results described in Chapter 5 
highlight the potential role of bi-directional brain-gut interactions in the aetiology of 
disease activity in IBD. These brain-gut interactions have been studied in other chronic 
GI disorders, including IBS, where the relationship between GI symptom-reporting and 
psychological co-morbidity is well-established (Fond et al., 2014), and where the 
direction of effect may also be bi-directional (Koloski et al., 2012; Koloski et al., 2016).  
RCTs of psychological therapies, such as CBT or hypnotherapy, have been 
conducted in IBS and meta-analyses of these studies have demonstrated that they are 
effective treatments (Ford et al., 2009b; Ford et al., 2014b). However, whether these 
therapies are also effective in IBD is unclear. A systematic review and meta-analysis 
published in 2011 suggested that these interventions were possibly of benefit in 
adolescents with IBD, but not adults (Timmer et al., 2011). However, the authors 
included quasi-randomised and non-randomised studies in their analysis, and there have 
been numerous additional studies published in the intervening years (McCombie et al., 
2016; Mikocka-Walus et al., 2015; Keefer et al., 2012; Schoultz et al., 2015; Jedel et al., 
2014; Keefer et al., 2013; Berrill et al., 2014; Boye et al., 2011; Mizrahi et al., 2012; 
Vogelaar et al., 2011; Vogelaar et al., 2014). Therefore an updated systematic review 
and meta-analysis examining the efficacy of psychological therapies in IBD, with 
particular emphasis on their effects on disease activity indices, psychological wellbeing, 
including anxiety, depression, and perceived stress, and quality of life was conducted. 
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7.2 Methods 
 
7.2.1 Search strategy and study selection 
A literature search of MEDLINE, EMBASE, EMBASE Classic, PsychINFO, 
and the Cochrane central register of controlled trials (from 1947 to September 2016) 
was carried out to identify studies investigating the effects of psychological therapies in 
IBD. Eligible studies had to include patients (≥16 years of age) with an endoscopic, 
histological, or radiologically confirmed diagnosis of IBD, and report the effect of 
psychological therapy of any modality, when compared with control or treatment as 
usual, on outcomes including disease activity, depression, anxiety, perceived stress, or 
quality of life. Only RCTs were eligible for inclusion. The eligibility criteria, which 
were defined a priori, are summarised in Table 27. 
 
Table 27: Eligibility criteria for study inclusion 
 Randomised controlled trials. 
 Patients aged ≥16 years with a confirmed diagnosis of IBD, according to 
endoscopic, histological, or radiological criteria. 
 Compared psychological therapies with a control, including a physician’s “usual 
management”, symptom monitoring, or supportive therapy. 
 Reported a dichotomous assessment of failure of remission in active disease or 
relapse of disease activity in quiescent disease, or a continuous assessment of 
clinical disease activity, psychological co-morbidity*, or quality of life. 
* Eligible studies could assess psychological co-morbidity via measurement of anxiety 
(including state and trait anxiety), depression, or perceived stress. 
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The literature search was performed using the terms: cognitive therapy, 
psychotherapy, behaviour therapy, relaxation techniques, mindfulness, meditation, 
or hypnosis (both as medical subject headings and free text terms), and the following 
free text terms: behavioural therapy, relaxation therapy, mindfulness meditation, 
or hypnotherapy. These terms were combined using the Boolean set operator AND with 
studies identified using the terms: Crohn disease, inflammatory bowel 
disease, colitis, ileitis, or ulcerative colitis (both as medical subject headings and free 
text terms), and Crohn$ disease or regional enteritis (as free text terms). There were no 
language restrictions applied to the search and any foreign articles were translated. All 
titles and abstracts identified by the search were assessed for inclusion, and a recursive 
search of the bibliographies of selected articles was carried out. Two investigators 
judged eligibility on the selected articles independently, using pre-designed eligibility 
forms, and a third investigator resolved any disagreements. 
 
7.2.2 Outcome assessment 
 Dichotomous outcomes assessed were the efficacy of psychological therapies 
versus control in terms of failure to achieve remission in active IBD, or to prevent 
relapse of disease activity in quiescent IBD. Data were extracted for these endpoints at 
the final point of trial follow-up, in order to maximise the number of events in the 
analysis. Continuous outcomes assessed included the efficacy of psychological 
therapies versus control, in terms of effect on clinical disease activity indices, anxiety 
scores, depression scores, perceived stress scores, or quality of life scores. Trials were 
analysed separately according to whether they recruited patients with IBD with 
clinically active disease at the time of randomisation, or patients whose disease was 
quiescent. As the effect of psychological therapies on mood and quality of life may be 
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greatest immediately after completion of therapy, data were extracted for these 
endpoints both at completion of therapy, and at the final point of follow-up. Where 
studies did not report these types of data, but were otherwise eligible for inclusion in the 
meta-analysis, the original investigators were contacted in order to obtain 
supplementary dichotomous or continuous data. This was obtained in six of these trials 
(Vogelaar et al., 2011; Vogelaar et al., 2014; Berrill et al., 2014; McCombie et al., 2016; 
Keefer et al., 2012; Keefer et al., 2013). 
 
7.2.3 Data extraction 
Data extraction was carried out by two investigators independently, using a 
Microsoft excel spreadsheet (XP professional edition; Microsoft, Redmond, WA, US) 
as dichotomous outcomes (remission or failure of remission in active IBD, and relapse 
or no relapse of disease activity in quiescent IBD), or mean disease activity scores, 
mean psychological wellbeing scores, or mean quality of life scores, and SD. As most 
RCTs recruited patients with IBD, rather than only patients with CD, or only patients 
with UC, studies were pooled to examine the effect of psychological therapies in IBD 
overall, rather than according to disease type individually. For dichotomous outcomes, 
data were extracted as an intention-to-treat analysis, wherever trial reporting allowed 
this, with all drop-outs assumed to be treatment failures (i.e. failed to achieve remission 
in active IBD trials, or disease activity relapsed in quiescent IBD trials). However, due 
to high drop-out rates in some trials, a sensitivity analysis was performed using a per 
protocol analysis. For the secondary outcomes, mean scores and SD after psychological 
therapies or control were recorded only for those who provided complete data, in order 
not to overestimate the efficacy of psychological therapies in IBD.  
In addition, the following data were recorded for each trial: type of 
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psychological therapy used, country, setting (primary, secondary, or tertiary care-
based), number of centres, number of sessions of psychological therapy administered, 
duration of therapy, and duration of follow-up. Handling of the control arm in each trial 
was also recorded.  
 The evidence base for psychological interventions in the management of 
depression and anxiety is greatest for CBT (APS, 2010). A subgroup analysis was 
therefore conducted including only trials using CBT, to assess whether the effect was 
stronger for this treatment modality. 
 
7.2.4 Assessment of risk of bias 
This was conducted by two investigators in accordance with guidance published 
in the Cochrane handbook (Higgins and Green, 2011). Any disagreement was resolved 
by discussion. Risk of bias was assessed by recording the methods used to generate the 
randomisation schedule and conceal treatment allocation, whether blinding was 
implemented for participants, personnel, and outcomes assessment, what proportion of 
subjects completed follow-up, whether an intention-to-treat analysis was extractable, 
and whether there was evidence of selective reporting of outcomes. 
 
7.2.5 Data synthesis and statistical analysis 
The degree of agreement between the two investigators, in terms of judging 
study eligibility, was measured using a Kappa statistic. For dichotomous outcomes the 
impact of psychological therapies was expressed as a RR of failure to achieve 
remission, with 95% CIs, with intervention versus control in trials of therapy for active 
IBD, or RR of relapse of disease activity in trials of therapy for quiescent IBD. Where 
psychological therapies appeared more effective than control in IBD, the number 
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needed to treat, along with 95% CIs, using the formula number needed to treat = 1/ 
(control event rate x (1-RR)) was calculated. For continuous data, including effect on 
disease activity indices, psychological wellbeing scores, and quality of life scores, the 
impact of psychological therapies was summarised using a standardised mean difference 
(SMD) and 95% CIs.  
Heterogeneity between studies was assessed using the I
2 
statistic with a cut off 
of 50% (Higgins et al., 2003), and the χ2 test with a P value <0.10, as the threshold to 
define a statistically significant degree of heterogeneity. All data were pooled using a 
random effects model (DerSimonian and Laird, 1986), in order to give a more 
conservative estimate of the effect of psychological therapies on disease outcomes in 
IBD. Review Manager version 5.3 (RevMan for Windows 2014, the Nordic Cochrane 
Centre, Copenhagen, Denmark) was used to generate Forest plots of pooled RRs and 
SMDs with 95% CIs, as well as funnel plots. These were assessed, if there were a 
sufficient number (≥10) of studies included in the meta-analysis (Sterne et al., 2011), for 
evidence of asymmetry, and therefore possible publication bias or other small study 
effects, using the Egger test (Egger et al., 1997). 
 
7.3 Results 
 
7.3.1 Search outcomes 
 The literature search identified a total of 1,824 citations of which, after title and 
abstract review, 46 were deemed potentially relevant and were assessed further for 
eligibility (Figure 11). Of these, a further 32 were excluded for various reasons leaving 
14 studies eligible for data extraction (Smith et al., 2002; Langhorst et al., 2007; 
Jantschek et al., 1998; Boye et al., 2011; Mizrahi et al., 2012; Keefer et al., 2012; Berrill 
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et al., 2014; Jedel et al., 2014; Mikocka-Walus et al., 2015; McCombie et al., 2016; 
Schoultz et al., 2015; Keefer et al., 2013; Vogelaar et al., 2011; Vogelaar et al., 2014). 
Agreement between reviewers for eligibility assessment was excellent (Kappa statistic = 
0.91). Detailed study characteristics are provided in Table 28, and risk of bias across all 
studies is reported in Table 29. 
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Figure 11: Flow diagram of assessment of studies identified in the 
systematic review and meta-analysis 
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Table 28: Characteristics of included studies 
Study Participants and 
setting 
Active intervention Handling of the 
control arm 
Duration of 
follow-up 
Outcomes studied (% of patients 
providing complete data) 
Jantschek 1998  108 patients with CD 
from 4 tertiary care 
centres in Germany 
10 sessions of psychodynamic 
psychotherapy over 12 months 
Standardised drug 
therapy including 
tapered prednisolone 
and sulfasalazine 
24 months Relapse of disease activity: CDAI, 
but no threshold specified (100) 
Psychological wellbeing: Beck 
depression inventory and state-trait 
anxiety (75.0) 
Quality of life: IBD-Q (73.1) 
Smith 2002* 100 patients (50 with 
CD, 50 with UC) from 
1 tertiary care centre in 
the UK 
3 to 6-monthly sessions of stress 
management and attention control 
therapy over 12 months 
Routine clinical 
follow-up 
12 months Clinical disease activity indices: 
modified CDAI (100) 
Psychological wellbeing: HADS 
(100) 
  
 
 
2
2
4
 
Langhorst 2007  60 patients with UC 
recruited via public 
advertisement in 
Germany 
Weekly sessions of stress reduction, 
stress management, dietary 
recommendations, and mindfulness 
over 10 weeks 
Usual medical care 12 months Relapse of disease activity: 
Rachmilewitz clinical activity index 
>5 (100) 
Clinical disease activity indices: 
Rachmilewitz clinical activity index 
(93.3) 
Psychological wellbeing: brief 
symptom inventory for anxiety (93.3) 
Quality of life: IBD-Q (93.3) 
Boye 2011 114 patients with IBD 
from 4 tertiary care 
centres in Norway and 
Germany 
3 group sessions, followed by 
weekly individual sessions for 6 to 9 
weeks, and up to 3 booster sessions 
of psychoeducation and relaxation, 
with cognitive behavioural therapy-
based sessions, over 12 months 
Treatment as usual 18 months Remission of disease activity: HBI or 
Rachmilewitz clinical activity index 
<4 (100) 
Clinical disease activity indices: HBI 
or Rachmilewitz clinical activity 
index (100) 
Quality of life: IBD-Q (100) 
  
 
 
2
2
5
 
Vogelaar 2011† 40 patients with CD 
from 1 tertiary care 
centre in the 
Netherlands 
5 sessions of solution focused 
therapy, or 10 sessions of problem 
solving therapy, over 3 months 
Treatment as usual 6 months Clinical disease activity indices: 
CDAI (57.5) 
Psychological wellbeing: HADS 
(57.5) 
Quality of life: IBD-Q (57.5) 
Keefer 2012  28 patients with CD 
from 1 tertiary care 
centre in the USA 
Weekly sessions of project-
management, including cognitive 
behavioural therapy and social 
learning theory, over 6 weeks 
Treatment as usual 8 weeks Psychological wellbeing: perceived 
stress questionnaire (100) 
Quality of life: IBD-Q (100) 
Mizrahi 2012  56 patients with IBD 
from 1 tertiary care 
centre in Israel 
3 sessions of relaxation training and 
guided imagery over 5 weeks 
Waiting list control 5 weeks Psychological wellbeing: state-trait 
anxiety, and visual analogue scales 
for depression and stress (69.6) 
Quality of life: IBD-Q (69.6) 
  
 
 
2
2
6
 
Keefer 2013  54 patients with UC 
from 1 tertiary care 
centre in the USA 
Weekly sessions of gut-directed 
hypnotherapy over 7 weeks 
Attention control 12 months Relapse of disease activity: Self-
report, Mayo score >2, or escalation 
of therapy (100) 
Psychological wellbeing: perceived 
stress questionnaire (92.6) 
Quality of life: IBD-Q and short-
form-12 (92.6) 
Berrill 2014  66 patients with IBD 
from 2 tertiary care 
centres in the UK 
6 sessions of multi-convergent 
therapy, including mindfulness 
meditation and cognitive behavioural 
therapy,  over 16 weeks 
Standard medical 
therapy 
12 months Relapse of disease activity: HBI ≥5 
or SCCAI ≥3 (100) 
Psychological wellbeing: perceived 
stress questionnaire (77.3) 
Quality of life: IBD-Q (89.4) 
  
 
 
2
2
7
 
Jedel 2014  55 patients with UC 
from 1 tertiary care 
centre, and the greater 
Chicago area, in the 
USA 
Weekly sessions of mindfulness-
based stress reduction, including 
sitting meditation, body scans, yoga 
postures, and awareness of personal 
reactions to everyday events, over 8 
weeks 
Attention control 12 months Relapse of disease activity: ulcerative 
colitis disease activity index >2 (100) 
Clinical disease activity indices: 
ulcerative colitis disease activity 
index (92.7) 
Psychological wellbeing: Beck 
depression inventory, state-trait 
anxiety, and perceived stress 
questionnaire (92.7) 
Quality of life: IBD-Q (92.7) 
Vogelaar 2014 98 patients with IBD 
from 2 tertiary care 
centres in the 
Netherlands 
6 sessions of solution focused 
therapy over 3 months, with a 
booster session at month 6 
Treatment as usual 9 months Clinical disease activity indices: 
CDAI or Rachmilewitz clinical 
activity index (91.8) 
Psychological wellbeing: HADS 
(91.8) 
Quality of life: IBD-Q and SF-36 
(91.8) 
  
 
 
2
2
8
 
Mikocka-Walus 2015  174 patients with IBD 
from 2 tertiary care 
centres in Australia 
Weekly sessions of face-to-face or 
internet-delivered cognitive 
behavioural therapy over 10 weeks 
Standard care 12 months Relapse of disease activity: 
CDAI≥150 or SCCAI ≥3 (100) 
Clinical disease activity indices: 
CDAI or SCCAI (40.8) 
Psychological wellbeing: HADS, 
state-trait anxiety, and COPE 
questionnaire (60.9) 
Quality of life: SF-36 (60.9) 
Schoultz 2015  44 patients with IBD 
from outpatient 
gastroenterology clinics 
in two national health 
boards in Scotland, UK 
Weekly sessions of mindfulness-
based cognitive therapy, including 
body scan, sitting and walking 
meditation, mindful stretching, and 
cognitive behavioural exercises, over 
8 weeks 
Waiting list control 6 months Clinical disease activity indices: 
CDAI or SCCAI (52.3) 
Psychological wellbeing: Beck 
depression inventory and state-trait 
anxiety (54.5) 
Quality of life: IBD-Q (54.5) 
  
 
 
2
2
9
 
McCombie 2016  199 patients with IBD 
from secondary and 
tertiary care centres, as 
well as support groups, 
in New Zealand 
8 sessions of computerised cognitive 
behavioural therapy over 12 weeks 
Treatment as usual 6 months Clinical disease activity indices: HBI 
or SCCAI (55.3) 
Psychological wellbeing: HADS  and 
perceived stress questionnaire (58.8) 
Quality of life: IBD-Q and short-
form-12 (58.8) 
*Smith 2002 provided all outcomes data for those with CD (Smith 2002a) and those with UC (Smith 2002b) separately. 
†Vogelaar 2011 compared solution focused therapy (Vogelaar 2011a) and problem solving therapy (Vogelaar 2011b) with treatment as usual. 
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Table 29: Assessment of risk of bias of included studies 
 Method of 
randomisation 
Concealment of 
allocation 
Level of 
blinding 
Follow-up rate 
≥90% 
Intention-to-treat 
analysis extractable 
Evidence of selective 
reporting of outcomes 
Risk of bias 
 
Jantschek 1998  No Yes Investigator No Yes No High 
Smith 2002  No No Unblinded Yes Yes No High 
Langhorst 2007  No No Unblinded Yes Yes No High 
Boye 2011 Yes Yes Investigator No Yes No High 
Vogelaar 2011 Yes No Unblinded No Yes No High 
Keefer 2012 Yes No Unblinded No No No High 
Mizrahi 2012  No No Unblinded No Yes No High 
Keefer 2013 Yes Yes Investigator Yes Yes No High 
Berrill 2014  Yes No Unblinded No Yes No High 
Jedel 2014  Yes Yes Double No Yes No High 
Vogelaar 2014 Yes No Investigator Yes Yes No High 
Mikocka-Walus 2015  Yes No Unblinded No Yes No High 
Schoultz 2015  Yes No Unblinded No Yes No High 
McCombie 2016  Yes No Unblinded No Yes No High 
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7.3.2 Effect of psychological therapies on disease activity, psychological 
wellbeing, and quality of life in patients with active IBD 
 Only two of the 14 RCTs eligible for inclusion included patients with IBD with 
ongoing active disease (Mizrahi et al., 2012; Boye et al., 2011). Only one of these 
studies reported dichotomous data concerning the efficacy of psychological therapy in 
the induction of remission of active IBD (Boye et al., 2011). In total, 12 (21.1%) of 57 
patients undergoing psychological therapy entered clinical remission, compared with 2 
(3.5%) of 57 patients in the control group, after 18 months of follow-up.  
 In terms of effect on other outcomes, including change in clinical disease 
activity indices (Boye et al., 2011), depression (Mizrahi et al., 2012), anxiety (Mizrahi 
et al., 2012), and perceived stress scores (Mizrahi et al., 2012), each of these were only 
reported in one RCT, and therefore formal meta-analysis was not possible. 
Psychological therapy was not associated with an improvement in any of these 
outcomes, when compared with control, in patients with active IBD. Both studies 
assessed the effect of psychological therapies on quality of life in a total of 153 patients 
with IBD. Here, the SMD in quality of life score at the final point of follow-up was not 
significantly different (0.27; 95% CI -0.05 to 0.59). 
 
7.3.3 Effect of psychological therapies on disease activity, psychological 
wellbeing, and quality of life in patients with quiescent IBD 
 Twelve of the 14 eligible RCTs assessed these outcomes in patients with IBD 
who had quiescent disease at randomisation (Jantschek et al., 1998; Smith et al., 2002; 
Langhorst et al., 2007; Keefer et al., 2012; Keefer et al., 2013; Berrill et al., 2014; Jedel 
et al., 2014; Mikocka-Walus et al., 2015; Schoultz et al., 2015; McCombie et al., 2016; 
Vogelaar et al., 2011; Vogelaar et al., 2014). Four of these presented data in patients 
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with CD (Jantschek et al., 1998; Smith et al., 2002; Keefer et al., 2012; Vogelaar et al., 
2011), four in patients with UC (Smith et al., 2002; Langhorst et al., 2007; Keefer et al., 
2013; Jedel et al., 2014), and five in patients with IBD (Mikocka-Walus et al., 2015; 
McCombie et al., 2016; Schoultz et al., 2015; Berrill et al., 2014; Vogelaar et al., 2014). 
Results from all analyses in patients with quiescent IBD are summarised in Table 30.  
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Table 30: Effect of psychological therapies on disease activity, psychological wellbeing, and quality of life in patients with quiescent IBD 
 Number 
of trials 
Number of 
patients 
Summary statistic for effect of psychological 
therapies (95% CI) 
P value for the 
difference
 
I
2
 
(P value) 
Preventing relapse of IBD (RR) 6 518 0.98 (0.77 to 1.24) 0.87 50% (0.07) 
Clinical disease activity indices (SMD) 8 534 -0.03 (-0.20 to 0.14) 0.73 0% (0.87) 
Anxiety scores (SMD) 
At completion of therapy 
At final point of follow-up 
 
5 
5 
 
504 
437 
 
-0.14 (-0.33 to 0.04) 
-0.18 (-0.39 to 0.04) 
 
0.13 
0.10 
 
7% (0.37) 
17% (0.30) 
State anxiety scores (SMD) 
At completion of therapy 
At final point of follow-up 
 
3 
3 
 
217 
207 
 
-0.14 (-0.41 to 0.14) 
-0.04 (-0.32 to 0.24) 
 
0.33 
0.76 
 
0% (0.66) 
0% (0.62) 
Trait anxiety scores (SMD) 
At completion of therapy 
At final point of follow-up 
 
3 
3 
 
191 
181 
 
-0.16 (-0.44 to 0.13) 
0.05 (-0.25 to 0.34) 
 
0.28 
0.75 
 
0% (0.80) 
0% (0.48) 
Depression scores (SMD) 
At completion of therapy 
At final point of follow-up 
 
7 
8 
 
605 
593 
 
-0.17 (-0.33 to -0.01) 
-0.11 (-0.27 to 0.05) 
 
0.04 
0.17 
 
0% (0.76) 
0% (0.93) 
  
 
 
2
3
4
 
Perceived stress scores (SMD) 
At completion of therapy 
At final point of follow-up 
 
6 
6 
 
434 
401 
 
-0.07 (-0.31 to 0.18) 
-0.10 (-0.33 to 0.13) 
 
0.59 
0.40 
 
34% (0.18) 
22% (0.27) 
Quality of life scores (SMD) 
At completion of therapy 
At final point of follow-up 
 
9 
10 
 
578 
577 
 
0.30 (0.07 to 0.52) 
0.15 (-0.05 to 0.34) 
 
0.01 
0.14 
 
42% (0.09) 
22% (0.24) 
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7.3.3.1 Effect of psychological therapies in preventing relapse of quiescent IBD 
 In total, there were six RCTs reporting dichotomous data concerning the effect 
of psychological therapies on relapse rates in quiescent IBD. One study included 
patients with CD (Jantschek et al., 1998), three studies included patients with UC (Jedel 
et al., 2014; Keefer et al., 2013; Langhorst et al., 2007), and two included patients with 
IBD (Berrill et al., 2014; Mikocka-Walus et al., 2015). Overall, 159 (57.4%) of 277 
patients treated with psychological therapy experienced a relapse of disease activity, 
compared with 127 (52.7%) of 241 patients in the control group. Compared with 
control, the RR of relapse of disease activity in all patients with IBD treated with 
psychological therapies was 0.98 (95% CI 0.77 to 1.24) (Figure 12). There was 
significant heterogeneity between studies (I
2
 = 50%, P = 0.07), but too few studies to 
assess for publication bias. When the effect of psychological therapies on relapse of 
disease activity was studied according to whether trials recruited patients with CD, 
patients with UC, or patients with IBD there remained no effect of psychological 
therapies at final point of follow-up (Figure 12). Per protocol analysis did not reveal any 
beneficial effect of psychological therapies on disease relapse (RR = 0.86; 95% CI 0.71 
to 1.05), but there was no heterogeneity between studies (I
2
 = 0%, P = 0.46). 
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Figure 12: Forest plot of RCTs reporting the effect of psychological therapies vs. control in preventing relapse of quiescent IBD at the 
final point of follow-up 
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7.3.3.2 Effect of psychological therapies on clinical disease activity indices in IBD  
 Eight RCTs reported data on the effect of psychological therapies on disease 
activity indices in patients with IBD at the final point of follow-up. Six RCTs assessed 
impact on disease activity indices in CD (McCombie et al., 2016; Mikocka-Walus et al., 
2015; Schoultz et al., 2015; Smith et al., 2002; Vogelaar et al., 2011; Vogelaar et al., 
2014), and seven in UC (Langhorst et al., 2007; McCombie et al., 2016; Mikocka-
Walus et al., 2015; Schoultz et al., 2015; Smith et al., 2002; Jedel et al., 2014; Vogelaar 
et al., 2014). There was no significant difference in disease activity indices among those 
treated with psychological therapies, compared with those in the control group, at the 
final point of follow-up (SMD = -0.03; 95% CI -0.20 to 0.14) (Figure 13), with no 
evidence of heterogeneity between studies (I
2
 = 0%, P = 0.87). Again, there were too 
few studies to assess for publication bias. There was also no effect of psychological 
therapies on disease activity indices among only patients with CD, or only patients with 
UC (Figure 13).  
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Figure 13: Forest plot of RCTs reporting the effect of psychological therapies vs. control on disease activity indices in quiescent IBD at 
the final point of follow-up   
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7.3.3.3 Effect of psychological therapies on anxiety scores in IBD 
 Five studies provided data on the effect of psychological therapies on anxiety 
scores in IBD at the end of therapy (Smith et al., 2002; Langhorst et al., 2007; Vogelaar 
et al., 2014; Mikocka-Walus et al., 2015; McCombie et al., 2016), and five at the final 
point of follow-up (Mikocka-Walus et al., 2015; McCombie et al., 2016; Smith et al., 
2002; Vogelaar et al., 2011; Vogelaar et al., 2014). At completion of therapy, when data 
were pooled from a total of 504 patients, there was no effect of psychological therapies 
on anxiety scores (SMD = -0.14; 95% CI -0.33 to 0.04) (Figure 14). There was no 
heterogeneity between the included RCTs (I
2
 = 7%, P = 0.37), and too few studies to 
assess for publication bias. At the last point of follow-up, there was still no effect of 
psychological therapies on anxiety scores in 437 patients (SMD = -0.18; 95% CI = -0.39 
to 0.04) (Figure 15). There was also no effect of psychological therapies on state 
(Jantschek et al., 1998; Schoultz et al., 2015; Mikocka-Walus et al., 2016) or trait (Jedel 
et al., 2014; Schoultz et al., 2015; Mikocka-Walus et al., 2016) anxiety scores in three 
trials at either completion of therapy, or at final point of follow-up (Figures 16-19). 
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Figure 14: Forest plot of RCTs reporting the effect of psychological therapies vs. control on anxiety scores in quiescent IBD at the 
completion of therapy 
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Figure 15: Forest plot of RCTs reporting the effect of psychological therapies vs. control on anxiety scores in quiescent IBD at the final 
point of follow-up 
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Figure 16: Forest plot of RCTs reporting the effect of psychological therapies vs. control on state anxiety scores in quiescent IBD at 
completion of therapy 
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Figure 17: Forest Plot of RCTs reporting the effect of psychological therapies vs. control on state anxiety scores in quiescent IBD at the 
final point of follow-up 
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Figure 18: Forest plot of RCTs reporting the effect of psychological therapies vs. control on trait anxiety scores in quiescent IBD at 
completion of therapy 
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Figure 19: Forest plot of RCTs reporting the effect of psychological therapies vs. control on trait anxiety scores in quiescent IBD at the 
final point of follow-up 
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7.3.3.4 Effect of psychological therapies on depression scores in IBD 
 Seven studies examined the effect of psychological therapies on depression 
scores in IBD at end of therapy (Jantschek et al., 1998; Smith et al., 2002; Jedel et al., 
2014; Mikocka-Walus et al., 2015; McCombie et al., 2016; Schoultz et al., 2015; 
Vogelaar et al., 2014), and eight at the final point of follow-up (Vogelaar et al., 2011; 
Vogelaar et al., 2014; Jantschek et al., 1998; Smith et al., 2002; Jedel et al., 2014; 
Schoultz et al., 2015; Mikocka-Walus et al., 2015; McCombie et al., 2016). Data were 
available for 605 patients at completion of therapy, with a SMD in depression scores for 
those treated with psychological therapies compared with control of -0.17 (95% CI -
0.33 to -0.01, P = 0.04) (Figure 20), with no heterogeneity between studies (I
2 
= 0%, P = 
0.76). Again there were too few studies to assess for publication bias. This beneficial 
effect on depression scores was only seen in RCTs that recruited patients with IBD 
(Figure 20). At the final point of follow-up, when data were pooled from 593 patients, 
the effect on depression scores was no longer evident (SMD = -0.11; 95% CI -0.27 to 
0.05), with no heterogeneity (I
2
 = 0%, P = 0.93) (Figure 21). There were too few studies 
to assess for publication bias.  
  
 
 
2
4
7
 
Figure 20: Forest plot of RCTs reporting the effect of psychological therapies vs. control on depression scores in quiescent IBD at 
completion of therapy 
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Figure 21: Forest plot of RCTs reporting the effect of psychological therapies vs. control on depression scores in quiescent IBD at the 
final point of follow-up 
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7.3.3.5 Effect of psychological therapies on perceived stress scores in IBD 
 Six RCTs reported data on the effect of psychological therapies on perceived 
stress score in IBD, when compared with control (Keefer et al., 2012; Keefer et al., 
2013; Jedel et al., 2014; Berrill et al., 2014; Mikocka-Walus et al., 2015; McCombie et 
al., 2016). When data were pooled at the end of therapy, psychological therapies had no 
effect on perceived stress scores in 434 patients (SMD = -0.07; 95% CI -0.31 to 0.18) 
(Figure 22), with no heterogeneity between studies (I
2
 = 34%, P = 0.18). At the final 
point of follow-up, when data were available for 401 patients, there was still no 
beneficial effect of psychological therapies compared with control (SMD in perceived 
stress scores = -0.10; 95% CI -0.33 to 0.13) (Figure 23), again with no heterogeneity 
noted between included studies (I
2
 = 22%, P = 0.27). There were too few studies to 
assess for publication bias in both these analyses. Again, there were no effects noted 
according to whether studies recruited patients with CD only, patients with UC only, or 
patients with IBD.  
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Figure 22: Forest plot of RCTs reporting the effect of psychological therapies vs. control on perceived stress scores in quiescent IBD at 
completion of therapy 
 
  
 
2
5
1
 
Figure 23: Forest plot of RCTs reporting the effect of psychological therapies vs. control on perceived stress scores in quiescent IBD at 
the final point of follow-up 
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7.3.3.6 Effect of psychological therapies on quality of life in IBD 
  Eleven studies reported data on the effect of psychological therapies on quality 
of life in IBD (Jantschek et al., 1998; Keefer et al., 2012; Langhorst et al., 2007; Keefer 
et al., 2013; Jedel et al., 2014; Berrill et al., 2014; Vogelaar et al., 2014; Vogelaar et al., 
2011; Schoultz et al., 2015; McCombie et al., 2016; Mikocka-Walus et al., 2015). Nine 
of these RCTs assessed effects on IBD-specific quality of life at end of therapy 
(Jantschek et al., 1998; Langhorst et al., 2007; Keefer et al., 2012; Berrill et al., 2014; 
Keefer et al., 2013; Jedel et al., 2014; Schoultz et al., 2015; McCombie et al., 2016; 
Vogelaar et al., 2014), and 10 at the final point of follow-up (Vogelaar et al., 2011; 
Vogelaar et al., 2014; Jantschek et al., 1998; Keefer et al., 2012; Keefer et al., 2013; 
Langhorst et al., 2007; Jedel et al., 2014; Berrill et al., 2014; Schoultz et al., 2015; 
McCombie et al., 2016). In addition, four trials examined effect on physical quality of 
life or mental quality of life separately (Keefer et al., 2013; Mikocka-Walus et al., 2015; 
McCombie et al., 2016; Vogelaar et al., 2014), both at end of therapy and at the final 
point of follow-up. There was a significant improvement in IBD-specific quality of life 
at the end of therapy, when data were pooled from 578 patients (SMD 0.30; 95% CI = 
0.07 to 0.52, P = 0.01) (Figure 24). There was borderline heterogeneity observed 
between the included studies (I
2
 = 42%, P = 0.09), but too few studies to assess for 
publication bias. When the effect of psychological therapies on IBD-specific quality of 
life was studied according to whether trials recruited patients with CD, patients with 
UC, or patients with IBD there was only a benefit observed among patients with IBD at 
the end of therapy (SMD = 0.37; 95% CI 0.15 to 0.59, P = 0.001) (Figure 24). Any 
beneficial effect of psychological therapies on IBD-specific quality of life at completion 
of therapy was lost by the final point of follow-up. When data were pooled from 577 
patients there were no differences in IBD-specific quality of life (SMD = 0.15; 95% CI -
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0.05 to 0.34) (Figure 25). There was no heterogeneity between studies (I
2
 = 22%, P = 
0.24), and no evidence of publication bias (Egger test, P = 0.44). 
 When compared with control, psychological therapies had no effect on physical 
quality of life or mental quality of life at completion of therapy in 399 patients (SMD = 
0.17; 95% CI -0.03 to 0.37 and SMD = 0.15; 95% CI -0.05 to 0.34, respectively). There 
was no evidence of heterogeneity between studies in these analyses although with only 
four RCTs, power to detect this would be limited. At final point of follow-up in 363 
patients there was no difference in physical (SMD = 0.02; 95% CI = -0.19 to 0.23) or 
mental quality of life (SMD = 0.05; 95% CI = -0.22 to 0.32) when those receiving 
psychological therapies were compared with control, with no heterogeneity noted for 
either outcome. There were too few studies to assess for publication bias in all these 
analyses.   
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Figure 24: Forest plot of RCTs reporting the effect of psychological therapies vs. control on quality of life scores in quiescent IBD at the 
completion of therapy 
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Figure 25: Forest plot of RCTs reporting the effect of psychological therapies vs. control on quality of life scores in quiescent IBD at the 
final point of follow-up 
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7.3.3.7 Effect of CBT in preventing relapse of quiescent IBD, and effect on clinical 
disease activity indices, anxiety scores, depression scores, perceived stress scores, 
and quality of life in IBD 
 Five studies (Keefer et al., 2012; Berrill et al., 2014; Mikocka-Walus et al., 
2015; Schoultz et al., 2015; McCombie et al., 2016), including 511 patients with IBD, 
reported data on the effect of CBT on one or more of these endpoints. There was a 
significant improvement in quality of life at the end of therapy, when data were pooled 
from 254 patients (SMD = 0.37; 95% CI 0.02 to 0.72; Figure 26), although this 
beneficial effect was lost at the final point of follow-up. There was no other significant 
effect of CBT on disease activity indices, anxiety or depression scores, or perceived 
stress scores when compared with control therapy. 
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Figure 26: Forest plot of RCTs reporting the effect of CBT vs. control on quality of life scores in quiescent IBD at completion of therapy 
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7.4 Discussion 
 This systematic review and meta-analysis has demonstrated that psychological 
therapies may provide a limited, short-term improvement in depression scores and 
quality life in patients with clinically quiescent IBD, but that these effects appear to be 
lost over time. The beneficial effect on quality of life was greater when only RCTs that 
used CBT, which is thought to have the best evidence for efficacy in the management of 
anxiety and depression (APS, 2010), were included in the analysis. Otherwise, 
psychological therapies did not appear to improve either clinical disease indices or 
psychological outcomes in IBD. There did not appear to be any benefits of 
psychological therapies according to type of IBD. Furthermore, there was no significant 
effect on most measurements of mood, either at the point where psychological therapies 
had just been completed, or during extended follow-up. Part of this lack of benefit may 
have arisen from a lack of sensitivity or specificity of the instruments used to detect 
changes in mood, as well as failure by the majority of trials to recruit only patients who 
had abnormal levels of psychological health, when compared with the general IBD 
population.  
 Strengths of this study include the rigorous methodology adopted. Several of the 
RCTs included in the 2011 Cochrane review (Timmer et al., 2011) addressing this issue 
did not fulfil the inclusion criteria for various reasons. These included a lack of 
randomisation (Grootenhuis et al., 2009; Freyberger et al., 1985), recruitment of 
patients with both active and quiescent disease, with no reporting of data separately for 
these distinct groups of patients (Milne et al., 1986), being conducted in an adolescent 
population (Szigethy et al., 2007), redundant publication (Elsenbruch et al., 2005), or 
providing no extractable data (Garcia-Vega and Fernandez-Rodriguez, 2004). Every 
effort was made to contact the authors of potentially eligible studies, where 
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dichotomous or continuous data of interest were not available in the published 
manuscript. Data extraction was performed on the basis of intention-to-treat analysis, 
with all patients lost to follow-up assumed to be treatment failures, for dichotomous 
endpoints such as remission or relapse of disease activity, in order to avoid 
overestimation of the effect of the active intervention. Pooling of data was performed 
using a random effects model, in order to give a more conservative estimate of the effect 
of psychological therapies in IBD. A further strength of this study is the number of 
participants included. This systematic review and meta-analysis included a number of 
additional studies (Mikocka-Walus et al., 2015; McCombie et al., 2016; Berrill et al., 
2014; Boye et al., 2011; Keefer et al., 2013; Vogelaar et al., 2011; Vogelaar et al., 
2014), and almost three times more participants than were included in the Cochrane 
review published by Timmer et al. in 2011. Analyses according to the subtype of IBD 
was also conducted, in order to assess whether there was any benefit of psychological 
therapies in either CD or UC separately. Lastly, a subgroup analysis to investigate the 
effect of CBT alone was conducted, as this has the best evidence for use in anxiety and 
depression (APS, 2010). 
There are limitations to this meta-analysis, which arise mainly from the 
relatively small number of studies available for analysis, and their risk of bias. Although 
there was no significant heterogeneity seen in the majority of the endpoints studied, 
there was significant heterogeneity between RCTs reporting on the effect of 
psychological therapies on relapse of disease activity in quiescent IBD. In addition, all 
the identified trials were at high risk of bias, due to the lack of adequate blinding, with 
only one trial employing a double-blind design (Jedel et al., 2014). This is often a 
problem with studies of psychological therapies, although there is the potential to blind 
assessors to therapy. However, only four of the identified studies performed this 
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(Jantschek et al., 1998; Keefer et al., 2013; Boye et al., 2011; Vogelaar et al., 2014). 
The included studies employed various methods of handling the control arms, which 
may mean that pooling the data from them could be viewed as inappropriate. The fact 
that duration of follow-up was not uniform between eligible studies may also mean that 
a significant benefit of psychological therapies, which is perhaps time-dependent, has 
been overlooked. Individual trials also used differing types, formats, durations, and 
intensities of psychological therapy, which may have led to a lack of benefit when all 
studies were pooled together. However, when only the five RCTs that used CBT were 
considered in the analysis, there was still no effect on disease activity indices, anxiety or 
depression scores, or perceived stress scores. Finally, the eligible trials included in these 
analyses span an 18-year period, during which the management of IBD has been 
revolutionised by the advent of biological therapies. The fact that increasing use of these 
drugs in more recent studies may have had an impact on the findings of this meta-
analysis cannot, therefore, be excluded.  
 These findings are in keeping with those previously published in adult IBD 
populations (Timmer et al., 2011). Other than a significant improvement in depression 
and quality of life scores immediately following the cessation of therapy, no statistically 
significant benefit of these interventions in IBD was identified. Despite this, 
psychological therapies have been shown to be effective in the treatment of other 
chronic disorders, including IBS, functional dyspepsia, and non-cardiac chest pain (Ford 
et al., 2014b; Orive et al., 2015; Jones et al., 2006a). The majority of the RCTs included 
in this meta-analysis were conducted in patients in clinical remission. Only two studies 
examined the effect of psychological therapies in active disease (Mizrahi et al., 2012; 
Boye et al., 2011). However, as described in Chapters 4 and 6, often the greatest 
psychological burden is seen in patients with active disease, or those with IBS-type 
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symptoms, suggesting it is these subgroups of patients who may benefit most from these 
types of treatment. Only one RCT, which conducted a subgroup analysis assessing the 
effect of multi-convergent therapy on disease activity and quality of life in patients with 
IBD reporting IBS-type symptoms, has considered this issue (Berrill et al., 2014). In 
this study, quality of life scores in those receiving multi-convergent therapy were 
significantly improved, when compared with control after 4 months of follow-up, and 
remained higher during the entire 12 months of the study, although this difference was 
no longer statistically significant. Furthermore, disease activity scores were also 
generally lower among those assigned to psychological therapy throughout the entire 12 
months of the study. Finally, none of the included RCTs investigated the effect of 
psychological interventions in patients with IBD with pre-existing depression or 
anxiety, despite there being evidence for a benefit in this distinct group of patients, 
particularly in paediatric populations (Szigethy et al., 2007; Thompson et al., 2012; 
Szigethy et al., 2004). 
 In addition to the outcomes addressed in this systematic review and meta-
analysis, fatigue is now recognised as an increasing problem in people with IBD, and is 
more prevalent than in the general population, affecting up to 40% of patients 
(Romberg-Camps et al., 2010; Jelsness-Jorgensen et al., 2011b). Furthermore, fatigue 
may be associated with depression and reduced quality of life, independent of disease 
activity (Cohen et al., 2014; Jelsness-Jorgensen et al., 2011a). To date, only two of the 
studies identified sought to investigate the effect of psychological therapies in this 
particular subgroup of patients with IBD (Vogelaar et al., 2014; Vogelaar et al., 2011), 
randomising patients in clinical remission with raised fatigue scores to receive solution 
focused therapy, problem solving therapy, or treatment as usual. In the larger of these 
two studies (Vogelaar et al., 2014), significant improvements in fatigue scores and 
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quality of life were observed after 3 months of follow-up in the intervention group, 
suggesting psychological therapies may be beneficial in this particular population.  
 The findings of the observational studies that have been conducted in Chapters 3 
to 6 highlight a high prevalence of psychological co-morbidity in IBD. The relationship 
between psychological co-morbidity and poor quality of life that is described in 
Chapters 4 and 6, its longitudinal association with IBS-type symptom-reporting, 
combined with the deleterious impact that symptoms of anxiety may have on 
subsequent disease activity, reinforces the need for evidence-based management 
strategies that address mood disorders in IBD. This systematic review and meta-analysis 
suggests that psychological therapies, and CBT in particular, may be of limited short-
term benefit in terms of improvements in depression and quality of life in patients with 
IBD. However, despite the inclusion of several hundred patients in most of the analyses 
conducted, no beneficial effect of psychological therapies on disease activity, or other 
measures of psychological health, including anxiety or stress was identified.  
 Despite this, there remains a need for further investigation of the utility of these 
interventions, particularly in those patients who are more likely to suffer from co-
existent psychological distress or fatigue. In addition, with the increasing use of faecal 
biomarkers of intestinal inflammation, such as FC, as a means of assessing disease 
activity objectively, it is likely that increasing numbers of patients with IBD with no 
objective evidence of disease activity who report IBS-type symptoms will be identified. 
This distinct cohort of patients also have unmet needs, in terms of therapy, and are often 
difficult to manage. Trials assessing the effects of psychological therapies, which use an 
adequate number of therapy sessions, have a sufficient duration of follow-up, use 
blinded assessors for endpoint assessment, and focus on the efficacy of CBT in these 
patients would therefore also be welcome.  
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CHAPTER 8: Conclusions 
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The diagnosis and management of IBD has evolved significantly in recent 
decades. Observational studies assessing disease outcomes in IBD have demonstrated a 
decline in the incidence of surgery, presumably secondary to the development of novel 
therapeutic agents during this time (Frolkis et al., 2013; Frolkis et al., 2014). Despite 
this, the complex nature of IBD, characterised by its uncertain aetiology, highlights that 
current available treatments remain suboptimal in some groups of patients. The focus of 
contemporary medical intervention is almost exclusively centred upon the treatment of 
inflammatory activity, via management of disordered intestinal immunity, despite the 
myriad of proposed aetiological factors that are likely to contribute to the development 
of disease activity in IBD. 
 Psychological co-morbidity is acknowledged as a potential contributor to the 
development of IBD, and to the propagation of disease activity. To date, studies that 
have sought to describe the relationship between mood and disease activity in IBD have 
failed to account for the presence or absence of inflammatory activity because they have 
used clinical disease activity indices as their sole measure of disease burden. 
Deconstructing the complex relationships between symptom-reporting, inflammatory 
activity, psychological co-morbidity and co-existent IBS-type symptoms in IBD is 
important for several reasons. Firstly, in clinical practice, aside from their poor 
correlation with objectively quantified inflammation, reliance on patient-reported 
symptoms to define disease activity fails to account for potential co-existent FGIDs or 
somatoform behaviour, which may result in inappropriate investigation requesting, or 
escalation of medical therapy (Derwa et al., 2018). Secondly, in observational research 
studies addressing the relationship between disease activity and psychological co-
morbidity, and in trials of therapeutic interventions aimed at improving psychological 
and disease activity outcomes, the potential for confounding is considerable. Therefore, 
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before an accurate assessment of the influence of mood on disease activity can be made, 
clarification of these relationships is required. This thesis has attempted to address these 
shortcomings in understanding by presenting data from five distinct, but inter-related 
pieces of work. Broad themes running throughout include the relationship between 
mood, symptom-reporting, and inflammatory activity, the relationship between IBS-
type symptom-reporting, psychological co-morbidity, and quality of life, as well as a 
review of the current evidence base for the use of psychological therapies in IBD. 
 Previous researchers have highlighted limitations of the use of clinical disease 
activity indices in identifying inflammatory activity in IBD (af Bjorkesten et al., 2012; 
Sipponen et al., 2008; Targownik et al., 2015). However, none had sought to address the 
potential impact of anxiety, depression, or somatisation on these relationships. 
Therefore, a cross-sectional study, using FC as an objective marker of intestinal 
inflammation, was performed to clarify these uncertainties. This confirmed that clinical 
disease activity indices were poor predictors of mucosal inflammation, and that 
psychological co-morbidity was associated with symptom-reporting, but not 
inflammatory activity, in IBD. 
 The results of this study subsequently informed the design of the longitudinal 
follow-up study that was conducted to assess how the relationship between mood, 
symptom-reporting, and inflammatory activity evolved over time. Here, the successful 
identification of bi-directional brain-gut axis activity in IBD was novel. These findings 
provide a mandate for further research investigating the benefit of treatments targeting 
mood disorders in IBD, not only because these are independently associated with 
detrimental effects on quality of life (Maunder, 2005), but also because effectively 
addressing co-existent mood disorders in IBD may have beneficial effects on 
longitudinal inflammatory activity.  
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 The second theme presented concerns the identification of patients with IBD 
who report IBS-type symptoms, and their association with impaired psychological 
wellbeing and quality of life. In a cross-sectional study using novel methodology 
incorporating clinical disease activity indices, the Rome III criteria for IBS, and FC as 
an objective marker of inflammatory activity, patients with IBD were divided into four 
distinct groups: quiescent IBD, IBD with IBS-type symptom, occult inflammatory IBD, 
and active IBD. Here, a distinct group of patients who report persistent symptoms in the 
absence of objectively determined inflammatory activity was identified. Affecting one-
in-four patients with IBD, the prevalence of IBS-type symptom-reporting was lower 
than that previously described in a meta-analysis of observational studies (Halpin and 
Ford, 2012). Psychological co-morbidity and poor quality of life were both associated 
with IBS-type symptom-reporting, to a significantly greater degree than was observed 
in patients with quiescent disease or occult inflammation, but to an equivalent extent to 
patients with overt active IBD.  
 These findings highlight the need for evidence-based management strategies for 
these patients. Furthermore, given the potential role of the brain-gut axis in the 
generation of these symptoms, and the apparent influence of brain-gut axis activity on 
longitudinal disease outcomes in IBD described above, this study also emphasised the 
need for longitudinal assessment of the impact of IBS-type symptom-reporting on 
disease activity, psychological wellbeing, and quality of life. The findings of the study 
conducted to investigate these issues suggested that, although IBS-type symptom-
reporting was not associated with adverse disease activity outcomes, its association with 
psychological co-morbidity and poor quality of life was robust over extended follow up. 
 Each of the four observational studies were conducted in order to address an 
unmet need, in terms of effective therapeutic interventions for the management of mood 
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disorders and IBS-type symptoms in IBD. Given the identification of bi-directional 
brain-gut interactions in IBD, such interventions have the potential to positively impact 
the natural history of IBD, but also mediate the detrimental effect of mood disorders on 
quality of life. For this reason an updated systematic review and meta-analysis of RCTs 
assessing the efficacy of psychological therapies in IBD was conducted. Although 
limited beneficial effects of psychological therapies on quality of life and depression 
were reported, the most promising of which was seen with CBT, methodological 
weaknesses in the included studies limit the validity of these findings. On the basis of 
this review, psychological therapies had no impact on disease activity in IBD, but again 
clinical disease activity indices were the sole measure of disease activity outcomes in 
these trials. Furthermore, the inclusion of patients without anxiety or depression at 
baseline is likely to have limited the effect of these interventions. 
 The work undertaken in this thesis has also informed the generation of novel 
hypotheses, which may provide opportunities for future research. As described in the 
systematic review and meta-analysis of RCTs of psychological therapies in IBD, the 
results of these interventions are disappointing. However, a review of the efficacy of 
psychological therapies and antidepressants in IBD, in a selected group of patients who 
suffer from mood disorders, or who report IBS-type symptoms, may yield results that 
are more positive. The aetiology of IBS-type symptom-reporting in IBD is uncertain. In 
this study population, less than 50% of patients reporting these symptoms had abnormal 
HADS anxiety or depression scores, suggesting that factors other than psychological 
health are likely to have an impact on the reporting of these symptoms. Investigating the 
role of the intestinal microbiome in the generation of these symptoms, for example, may 
provide a biological target for trials of future therapeutic interventions. A criticism of 
the longitudinal study describing bi-directional brain-gut interactions in IBD was that 
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the collection of data, which was conducted at only two time points and at group, rather 
than individual, level was too simplistic. Personalised research identifying complex 
relationships between psyche and soma has been studied in patients following 
myocardial infarction (Rosmalen et al., 2012), but to date this has not been explored in 
IBD.  Finally, in addition to defining a specific group of patients who report IBS-type 
symptoms, a second group of hitherto poorly characterised patients with occult 
inflammatory activity was also identified. In longitudinal follow-up, these patients tend 
not to suffer adverse disease activity outcomes, despite having evidence of 
inflammatory activity equivalent to those with overt active symptomatic IBD at 
baseline. Although the efficacy of a treat-to-target approach to the management of IBD 
is not evidence-based (Sandborn et al., 2014c), further characterisation of this group of 
patients may still be worthwhile.  
 In summary, this thesis has addressed the relationship between GI symptom-
reporting, psychological co-morbidity, and inflammatory activity in a large secondary 
care cohort of patients with IBD. A well-characterised group of patients who report 
IBS-type symptoms has been identified, and a robust association between the reporting 
of these symptoms and impaired psychological health and quality of life has been 
described. The identification of potential bi-directional brain-gut interactions in IBD 
provides a therapeutic target for rigorous RCTs of treatments addressing mood disorders 
in these patients, which are, to date, lacking.  
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